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Background: Heavy menstrual bleeding (HMB) is a common problem that affects many British women.
When initial medical treatment is unsuccessful, the National Institute for Health and Care Excellence
recommends surgical options such as endometrial ablation (EA) or hysterectomy. Although clinically and
economically more effective than EA, total hysterectomy necessitates a longer hospital stay and is
associated with slower recovery and a higher risk of complications. Improvements in endoscopic equipment
and training have made laparoscopic supracervical hysterectomy (LASH) accessible to most gynaecologists.
This operation could preserve the advantages of total hysterectomy and reduce the risk of complications.
Objectives: To compare the clinical effectiveness and cost-effectiveness of LASH with second-generation
EA in women with HMB.
Design: A parallel-group, multicentre, randomised controlled trial. Allocation was by remote web-based
randomisation (1 : 1 ratio). Surgeons and participants were not blinded to the allocated procedure.
Setting: Thirty-one UK secondary and tertiary hospitals.
Participants: Women aged < 50 years with HMB. Exclusion criteria included plans to conceive; endometrial
atypia; abnormal cytology; uterine cavity size > 11 cm; any fibroids > 3 cm; contraindications to laparoscopic
surgery; previous EA; and inability to give informed consent or complete trial paperwork.
Interventions: LASH compared with second-generation EA.
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Main outcome measures: Co-primary clinical outcome measures were (1) patient satisfaction and
(2) Menorrhagia Multi-Attribute Quality-of-Life Scale (MMAS) score at 15 months post randomisation.
The primary economic outcome was incremental cost (NHS perspective) per quality-adjusted life-year
(QALY) gained.
Results: A total of 330 participants were randomised to each group (total n = 660). Women randomised to
LASH were more likely to be satisfied with their treatment than those randomised to EA (97.1% vs. 87.1%)
[adjusted difference in proportions 0.10, 95% confidence interval (CI) 0.05 to 0.15; adjusted odds ratio (OR)
from ordinal logistic regression (OLR) 2.53, 95% CI 1.83 to 3.48; p < 0.001]. Women randomised to LASH
were also more likely to have the best possible MMAS score of 100 (68.7% vs. 54.5%) (adjusted difference
in proportions 0.13, 95% CI 0.04 to 0.23; adjusted OR from OLR 1.87, 95% CI 1.31 to 2.67; p = 0.001).
Serious adverse event rates were low and similar in both groups (4.5% vs. 3.6%). There was a significant
difference in adjusted mean costs between LASH (£2886) and EA (£1282) at 15 months, but no significant
difference in QALYs. Based on an extrapolation of expected differences in cost and QALYs out to 10 years,
LASH cost an additional £1362 for an average QALY gain of 0.11, equating to an incremental cost-effectiveness
ratio of £12,314 per QALY. Probabilities of cost-effectiveness were 53%, 71% and 80% at cost-effectiveness
thresholds of £13,000, £20,000 and £30,000 per QALY gained, respectively.
Limitations: Follow-up data beyond 15 months post randomisation are not available to inform
cost-effectiveness.
Conclusion: LASH is superior to EA in terms of clinical effectiveness. EA is less costly in the short term,
but expected higher retreatment rates mean that LASH could be considered cost-effective by 10 years
post procedure.
Future work: Retreatment rates, satisfaction and quality-of-life scores at 10-year follow-up will help to
inform long-term cost-effectiveness.
TriaI registration: Current Controlled Trials ISRCTN49013893.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 53.
See the NIHR Journals Library website for further project information.
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Plain English summary
A lmost 1.5 million women in England and Wales suffer from heavy periods. Initial treatment involvestablets or a medicated coil inserted within the womb. Sometimes these treatments do not work and
many women need an operation, either endometrial ablation (EA) (removing the lining of the womb) or a
full hysterectomy (complete removal of the womb). Previous studies have shown that a full hysterectomy is
better at relieving symptoms, but the risk of complications during surgery is higher and patients take
longer to recover fully.
A newer operation, laparoscopic (keyhole) supracervical hysterectomy, or ‘LASH’, removes only the part of
the womb that causes periods and preserves the cervix or neck of the womb. Women who have LASH can
expect fewer complications, earlier discharge from hospital and quicker recovery time.
In this study, we compared EA with LASH by asking women who had either procedure how they felt about
it 1 year after their operation.
Regardless of which operation they had, most women were very satisfied and felt that their symptoms
were better. However, the results were much better for those who had the LASH operation, although
these women stayed in hospital for longer and took more time to recover. There was no difference in
complications from either surgery, although nearly 1 in 20 women who had an EA returned within 1 year to
have their wombs removed in a second operation.
Although LASH led to a greater improvement in symptoms and levels of satisfaction, it was more expensive
in terms of costs incurred by both the health service and society. Given that some women who had an EA
are likely to need a second operation in the future, LASH surgery may provide better value for money in
the long term.
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Scientific summary
Background
Heavy menstrual bleeding (HMB) is a common problem that has a major impact on women’s physical,
emotional, social and material quality of life. The condition is initially treated in primary care by either oral
medication or insertion of the levonorgestrel-releasing intrauterine system (Mirena®, Bayer, Whippany, NJ,
USA). If medical therapy fails or is deemed unsuitable, surgical treatment can be offered: either endometrial
ablation (EA), which destroys the lining of the uterine cavity (endometrium), or hysterectomy (removal of the
uterus). Neither medical treatment nor EA can guarantee complete resolution of symptoms and up to 59%
of women on oral drugs and 13.5% of those using the levonorgestrel-releasing intrauterine system (Mirena)
need surgery within 2 years. Following initial treatment with EA, 19% of women require hysterectomy for
relief of their symptoms.
Although clinically and economically more effective than EA, a conventional total hysterectomy is more
invasive, poses a higher risk of injury to surrounding organs, involves a longer hospital stay and requires a
longer postoperative recovery period. The advantages of total hysterectomy could be maintained, and the
risk of complications reduced, by undertaking a laparoscopic supracervical hysterectomy (LASH), in which
only the body of the uterus is removed and the cervix is preserved.
Objectives
To compare the clinical effectiveness and cost-effectiveness of LASH with second-generation EA in women
with HMB.
Methods
The Hysterectomy or Endometrial AbLation Trial for Heavy menstrual bleeding (HEALTH) was a parallel-group,
multicentre, randomised controlled trial involving 31 UK secondary and tertiary hospitals. Women aged
< 50 years with HMB who wanted surgical treatment, and had no plans to conceive, were invited to
participate. Women were excluded if they met any of the following exclusion criteria: endometrial atypia;
abnormal cytology; uterine cavity size > 11 cm; any fibroids > 3 cm; contraindications to laparoscopic surgery;
previous EA; and inability to give informed consent or complete trial paperwork.
Interventions and randomisation
Eligible and consenting women were randomised to one of the following two treatment arms in a 1 : 1
allocation ratio using a remote web-based randomisation service:
1. LASH (removal of the body of the uterus by means of keyhole surgery)
2. second-generation EA (destroying the endometrium by means of a silicone balloon containing hot fluid
or radiofrequency energy).
The minimisation algorithm was based on centre and age group (< 40 years vs. ≥ 40 years).
Outcome measures
The co-primary clinical outcome measures were (1) patient satisfaction at 15 months post randomisation and
(2) the Menorrhagia Multi-Attribute Quality-of-Life Scale (MMAS) score at 15 months post randomisation.
The primary economic outcome was incremental cost per quality-adjusted life-year (QALY) gained.
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Secondary outcome measures included pain score at days 1–14 and 6 weeks post surgery; acceptability of
treatment at 6 weeks post surgery; satisfaction with treatment and MMAS score at 6 months post surgery;
menstrual outcomes at 6 months post surgery and 15 months post randomisation; generic health-related
quality of life [Short Form questionnaire-12 items (SF-12) and EuroQol-5 Dimensions, three-level version
(EQ-5D-3L)] at 6 weeks and 6 months post surgery and 15 months post randomisation; perioperative
complications, including recovery details and need for additional gynaecological surgery; cost; and
cost-effectiveness.
Blinding
Surgeons and participants could not be blinded to the allocated procedure.
Delivery of the intervention
Randomised participants were placed on the waiting list for the allocated treatment with the anticipation
that treatment would occur within 12–18 weeks of randomisation, as per the Scottish and UK government
guidelines. Operative techniques were not modified for the purposes of the trial.
Data collection during follow-up
Participant-reported outcomes were assessed by self-completed questionnaires at baseline (before surgery),
6 weeks and 6 months post surgery, and 15 months post randomisation. A self-completed 14-day diary
was also collected.
Sample size
It was originally anticipated that 292 participants per group would provide 90% power to detect a
difference in satisfaction rates of 8%, and 95% power to detect a 10-point difference in MMAS score
[assuming a standard deviation (SD) of 33 units]. Based on an expected 10% drop-out rate, the
recruitment target was 648 participants in total (324 participants per group).
Statistical analysis
Stata® version 15 (StataCorp LP, College Station, TX, USA) was used to conduct analyses in accordance
with the intention-to-treat principle. Analyses used a two-sided 5% significance level with corresponding
95% confidence intervals (CIs) generated as appropriate. Analysis of the two co-primary outcomes (patient
satisfaction and MMAS score at 15 months post randomisation) was conducted in a hierarchy such that
MMAS score was considered only if the difference in patient satisfaction was shown to be statistically
significant. Secondary outcomes were compared by randomised groups. These analyses were regarded as
hypothesis-generating and no adjustment was made for multiple statistical testing.
Economic evaluation
The economic analysis consisted of a trial-based analysis of individual patient-level cost and effect (QALY)
data and a Markov modelling component to inform cost-effectiveness in the longer term. Given the
limitations of the follow-up period for economic evaluation, the model-based approach forms the primary
economic analysis. Costs and outcomes were assessed via the trial case report forms, patient diary of pain
symptoms post surgery and postal questionnaires. The EQ-5D-3L scores were used to estimate QALYs.
To estimate longer-term economic differences, a simple Markov decision-analytic model was developed to
extrapolate the estimated 15-month difference in utility and simulate the incidence of further gynaecological
surgery over time. The key objective of the analysis was to inform the long-term cost-effectiveness of LASH
compared with EA.
Management of the study
The study was supervised by the Project Management Group, which consisted of representatives from the
study office and grant holders. The study was further overseen by a Trial Steering Committee, which
comprised four independent members, and an independent Data Monitoring Committee.
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Results
Recruitment
Between May 2014 and March 2017, 2552 potentially eligible patients were screened; 1351 (52.9%)
were confirmed as eligible, of whom 664 (49.1%) gave their consent and were randomised. Following
randomisation, four women were considered ineligible and treated as post-randomisation exclusions.
Therefore, 660 women (330 in each group) were included in the main trial.
Clinical results
Women randomised to LASH or to EA were comparable at baseline in terms of mean age [42.2 (SD 4.89)
years vs. 42.1 (SD 4.96) years], body mass index [29.1 kg/m2 (SD 5.55 kg/m2) vs. 29.0 kg/m2 (SD 5.34 kg/m2)],
preoperative haemoglobin levels [131.0 g/l (SD 13.1 g/l) vs. 130.1 g/l (SD 12.6 g/l)] and duration of symptoms
[227 (69.4%) participants in the LASH group vs. 216 (66.1%) participants in the EA group for symptoms in
excess of 3 years].
There were also no differences between the LASH and EA groups at baseline in the mean values for the
MMAS total score [30.5 (SD 19.0) vs. 32.3 (SD 20.0)], EQ-5D-3L utility score [0.71 (SD 0.30) vs. 0.70
(SD 0.31)] and SF-12 physical component score [45.0 (SD 9.0) vs. 44.9 (SD 9.7)] or mental component score
[37.2 (SD 11.0) vs. 38.7 (SD 11.6)]. There were no clear differences between the randomised groups with
respect to any of the baseline outcomes, including mean bleeding score and mean pain score.
A total of 44 participants who were randomised to either LASH (21/330, 6.4%) or EA (23/330, 7.0%) did
not undergo an operation but were sent the final questionnaire at 15 months post randomisation.
The median number of days between randomisation and treatment was higher for those randomised to
LASH [84 days, interquartile range (IQR) 57–127 days] than for those randomised to EA (63 days, IQR
41–97 days).
Of those undergoing treatment, 291 out of 309 (94.2%) women randomised to LASH and 297 out of
307 (96.7%) women randomised to EA received the allocated procedure. Women undergoing LASH
were more likely to be operated on by a consultant [239 (77.3%) vs. 176 (57.3%)] and required more
postoperative opiate injections [94/309 (30.4%) vs. 46/307 (15.0%)]. More women in the LASH arm
stayed in hospital for over 24 hours post procedure [99/306 (32.4%) vs. 16/303 (5.3%)].
Primary outcomes at 15 months post randomisation
Based on responses from 278 out of 330 (84.2%) women randomised to the LASH group and 280 out of
330 (84.8%) women randomised to the EA group, women randomised to LASH were more likely to be
satisfied with their treatment than those randomised to EA (97.1% vs. 87.1%) [adjusted difference in
proportions 0.10, 95% CI 0.05 to 0.15; adjusted odds ratio (OR) from ordinal logistic regression (OLR)
2.53, 95% CI 1.83 to 3.48; p < 0.001].
Total MMAS scores, based on responses from 262 out of 330 (79.4%) women in the LASH group and
268 out of 330 (81.2%) women in the EA group, indicate that women randomised to receive LASH were
more likely to have the best possible MMAS score of 100 (68.7% vs. 54.5%) (adjusted difference in
proportions 0.13, 95% CI 0.04 to 0.23; adjusted OR from OLR 1.87, 95% CI 1.31 to 2.67; p = 0.001).
They had almost twice the odds of being in a more favourable MMAS category than those allocated to EA
(adjusted OR 1.87, 95% CI 1.31 to 2.67; p = 0.001).
Twenty-five women experienced a total of 26 serious adverse events (SAEs) (LASH, n = 15; EA, n = 11).
There were no statistically or clinically significant differences between the randomised groups in the
proportions having a SAE (adjusted OR 1.30, 95% CI 0.56 to 3.02; p = 0.54).
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A total of 32 women experienced a complication following surgery. These included voiding dysfunction
(LASH, n = 14; EA, n = 2), consultation for pain (LASH, n = 1; EA, n = 1), haematoma (LASH, n = 1; EA n = 1),
blood loss > 500 ml (LASH, n = 1; EA, n = 1), inactive/blunt uterine perforation (LASH, n = 1; EA, n = 3),
pyrexia requiring antibiotics (LASH, n = 3; EA, n = 2) and blood transfusion (LASH, n = 0; EA, n = 1).
Eighteen women randomised to EA and two women randomised to LASH received further treatment for
HMB during the follow-up period. The most common reason was that the index EA procedure produced
an unsatisfactory reduction in HMB (n = 12). A further seven women required unplanned further surgery
because the index EA procedure could not be completed on first admission; this included one woman who
was randomised to LASH but for whom an EA procedure was attempted. On five occasions, a hysterectomy
was performed on the second admission.
Postoperative recovery
In the first 14 days following surgery, those in the LASH group had pain scores that were almost 1 point
higher than those reported by the EA group (mean difference 0.92, 95% CI 0.59 to 1.24; p < 0.001).
By 6 weeks post surgery, over half of the women in both groups reported no pain on a 10-point scale.
Those in the LASH group had higher odds of pain at 6 weeks than those in the EA group (adjusted OR
1.43, 95% CI 1.05 to 1.96; p = 0.03).
Women in the EA group returned to paid work sooner than those randomised to LASH (median time
10 days vs. 42 days; adjusted hazard ratio 0.23, 95% CI 0.18 to 0.30; p < 0.001).
Menstrual outcomes
Fewer women continued to have periods after receiving LASH than after receiving EA [6 months: LASH,
39/253 (15.4%); EA, 111/246 (45.7%) (adjusted OR 0.22, 95% CI 0.15 to 0.32; p < 0.001); 15 months:
LASH, 52/277 (18.8%); EA, 117/278 (42.1%) (adjusted OR 0.32, 95% CI 0.21 to 0.48; p < 0.001)].
A higher proportion of all women (including those with no periods) experienced cyclical pain following EA
[6 months: LASH, 68/236 (28.8%); EA, 108/199 (54.3%); 15 months: LASH, 71/224 (31.7%); EA, 118/196
(60.2%)].
Quality of life
At 6 weeks post surgery, those in the EA group had higher EQ-5D-3L utility scores than those in the
LASH group (adjusted OR 0.66, 95% CI 0.48 to 0.90; p = 0.009). However, at 6 months post surgery and
15 months post randomisation, the point estimates favoured LASH, although the results were not statistically
significant (6 months: adjusted OR 1.15, 95% CI 0.84 to 1.57, p = 0.38; 15 months: adjusted OR 1.21,
95% CI 0.89 to 1.64, p = 0.23).
The results for the visual analogue scale of the EQ-5D-3L tended to favour the LASH group, and this
finding was statistically significant at 6 months post surgery and at 15 months post randomisation
(6 weeks: adjusted OR 1.12, 95% CI 0.80 to 1.58, p = 0.51; 6 months: adjusted OR 1.53, 95% CI
1.08 to 2.17, p = 0.02; 15 months: adjusted OR 1.50, 95% CI 1.12 to 1.99, p = 0.006).
Health economic results
The mean initial episode costs for LASH and EA were £2757 and £1071, respectively. LASH was more
costly than EA because surgical costs were higher, time spent in the anaesthetic room, theatre and in
recovery was longer (178 minutes vs. 90 minutes) and discharge from hospital occurred later (23 hours vs.
6 hours). Taking all relevant NHS resource use into account over 15 months, unadjusted mean health
service costs were £3004 for LASH compared with £1281 for EA.
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Societal costs were also increased following LASH because women who received LASH took longer to return
to paid and unpaid productive activities than than who received EA (£2586 vs. £990). Mean out-of-pocket
expenses (£9 vs. £7) and the cost of time lost to attend outpatient appointments (£26 and £22) were slightly
higher in the LASH group.
The mean EQ-5D-3L scores in the LASH group at baseline, 6 weeks and 6 months post surgery and
15 months post randomisation were 0.7065 (SD 0.30), 0.8279 (SD 0.22), 0.8315 (SD 0.27) and 0.8357
(SD 0.24), respectively. The corresponding mean scores in the EA group were 0.6983 (SD 0.31), 0.8282
(SD 0.28), 0.8269 (SD 0.25) and 0.8005 (SD 0.28), respectively. By 15 months, the EQ-5D-3L score was
higher in the LASH group than in the EA group (unadjusted difference = 0.035), although the difference
was not statistically significant. At 15 months post randomisation (12 months post surgery), the mean
adjusted QALY gain was 0.978 and 0.974, whereas the mean adjusted costs were £2886 and £1282 for
LASH and EA, respectively, producing adjusted differences of 0.004 QALYs and £1604. The incremental
cost-effectiveness ratio (ICER) for LASH compared with EA was £458,334 per QALY gained at 15 months
post randomisation.
Over a modelled 10-year time horizon, in comparison with EA, the intention to treat with LASH resulted in an
increased cost to the health service of £1362 per woman, for an expected QALY gain of 0.111 per woman.
The corresponding ICER was £12,314 per QALY gained for LASH compared with EA. The chance of LASH being
cost-effective ranged from 53% to 80% at cost-effectiveness thresholds of £13,000 and £30,000, respectively.
Extending the time horizon of the model from 1 to 10 years reduced the incremental cost of LASH by £242
(from £1604 to £1362), owing to incorporation of the expected costs of further gynaecological surgery.
Conclusion
Laparoscopic supracervical hysterectomy is superior to EA in terms of clinical effectiveness. As EA is quicker,
cheaper and associated with an earlier discharge, it is less costly in the short term, but its expected higher
failure rate means that LASH could be considered cost-effective by 10 years post procedure. Long-term
follow-up is required to verify retreatment rates and their impact on cost-effectiveness.
Trial registration
This trial is registered as ISRCTN49013893.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
C hapter 1 contains material reproduced from Cooper et al.1 This article is distributed under the terms ofthe Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you
give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
In 2014, the UK Government’s National Institute for Health Research Health Technology Assessment (HTA)
programme funded the Hysterectomy or Endometrial AbLation Trial for Heavy menstrual bleeding
(HEALTH). This report describes the research. HEALTH was a multicentre UK randomised controlled trial
(RCT) investigating the clinical effectiveness (including safety) and cost-effectiveness of laparoscopic
supracervical hysterectomy (LASH) compared with second-generation endometrial ablation (EA).
Background
Heavy menstrual bleeding (HMB) is a common problem, affecting approximately 1.5 million women in
England and Wales. It accounts for one-fifth of all gynaecology outpatient referrals and has a major impact
on women’s physical, emotional, social and material quality of life (QoL).2 The condition is initially treated
in primary care by either oral medication or insertion of the levonorgestrel-releasing intrauterine system
(Mirena®; Bayer AG, Whippany, NJ, USA). If medical therapy fails or is deemed unsuitable, surgical treatment
can be offered, either EA, which destroys the lining of the cavity of the uterus (endometrium), or hysterectomy
(removal of the uterus). Neither medical treatment nor EA can guarantee complete resolution of symptoms
and up to 59% of women on oral drugs3 and 13.5% of those using the levonorgestrel-releasing intrauterine
system (Mirena®)4 ultimately undergo surgical treatment within 2 years. Over one-third (38%) of women
referred to an English NHS hospital between April 2009 and March 2012 with HMB underwent a surgical
procedure, with about three-quarters of these being EAs.2 Of those treated with EA, 19% have required a
subsequent hysterectomy for relief of their symptoms.5
Scale of the problem in the UK and use of NHS resources
Hospital Episode Statistics data indicate that a total of 136,921 hysterectomies and 128,434 EAs were
performed in England and Wales for HMB between April 1997 and December 2009.6 Current types of EA
that are recommended by the National Institute for Health and Care Excellence (NICE) are second-generation
(non-hysteroscopic) procedures, including bipolar radiofrequency ablation (Novasure®; Hologic Inc.,
Marlborough, MA, USA) and thermal balloon EA.7
Evidence explaining why this research is needed
The NICE guideline on HMB recommends both EA as well as hysterectomy as options for women with HMB
resistant to medical treatment,7 but a significant minority of women treated with EA are likely to need repeat
EA or hysterectomy. A recent individual patient data meta-analysis8 of results from randomised trials has
shown that, despite the the greater invasiveness of conventional hysterectomy (removal of the uterus and
the cervix) and associated longer hospital stay and prolonged recovery, fewer women are dissatisfied with it
than with EA. Additionally, a health economic model based on these data showed that hysterectomy is more
cost-effective.9 The accompanying HTA monograph10 showed that a quarter of all women who undergo
EA will require subsequent gynaecological surgery, with just under one-fifth requiring hysterectomy.
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These findings, which are consistent with those of a relevant Cochrane review,11 suggest that the optimal
surgical treatment for HMB that is unresponsive to medical treatment may well be hysterectomy, but its
effectiveness needs to be balanced against its invasive nature and increased short- and long-term morbidity.5
Removal of the cervix as part of a conventional total hysterectomy can be technically challenging and result
in injury to surrounding blood vessels, ureters and the bladder. In contrast, LASH is the use of keyhole
surgery to remove the body or major part of the uterus, which is the part responsible for menstrual
bleeding, but conserves the cervix. This approach reduces operating time as well as surgical morbidity,
while conserving the uterosacral ligament support to the cervix and upper vagina. Routine cervical screening
is required for women undergoing LASH. The procedure is quick, minimally invasive, relatively easy to learn
and associated with a low risk of complications, short hospital stay (< 24 hours) and rapid recovery.12,13
Before this technique is incorporated into routine clinical practice, it is important that it is subjected to
robust evaluation. The authors of two small RCTs comparing LASH with a first-generation EA (endometrial
resection13 or second-generation EA) thermal balloon12 suggest that LASH could lead to a better QoL, but
emphasised the need for larger evaluative studies to confirm this.
The last decade has seen widespread use of laparoscopic techniques in gynaecology due to increased
familiarity with the procedures, more sophisticated instruments, better training and greater laparoscopic
surgical skill. As a result of this, LASH could be delivered by most general gynaecologists, with minimal
morbidity to women who are currently being treated with EA. Advances in perioperative care mean that,
unlike conventional hysterectomy, women treated by this procedure may not need to stay in hospital any
longer than those receiving EA.
HEALTH is a multicentre RCT comparing the clinical effectiveness and cost-effectiveness of LASH with
second-generation EA (the current first-line surgical treatment for HMB) in women with HMB seeking
surgery. The trial is relevant and timely, as rigorous evaluation of this new surgical option will provide
much needed high-quality evidence to underpin any decision to use it in routine NHS practice.
Description of the surgical procedures
Laparoscopic supracervical hysterectomy
Laparoscopic supracervical hysterectomy involves keyhole surgery to remove the upper part of the uterus
(the body). The uterine body contains the endometrial cavity lined with tissue that undergoes cyclic growth
and shedding each month, thus causing menstrual bleeding. Increased access to specialised laparoscopic
equipment and training means that LASH is quick and relatively easy to learn. It is associated with low
morbidity, short hospital stay (< 24 hours) and rapid recovery. Unlike conventional total hysterectomy, the
cervix is not removed, thus removing the need for extended surgery around the cervix, which can lead to
serious complications, such as injury to the bladder, ureters and blood vessels.14,15 As the cervix is retained,
cervical smears are still required and, although most women will cease to have periods after the procedure,
light menstrual loss or cyclical spotting can occur in 5–20% of cases.16,17
The body of the uterus is usually removed though a small 10- to 12-mm incision, often within the umbilicus
or suprapubically by means of a ‘power’ morcellator, which breaks up the uterine tissue into small strips.
Alternative options include removal of the uterine body through an internal incision at the top of the vagina
(culdotomy) or, alternatively, morcellation within an intraperitoneal bag to prevent spread of fragmented
tissue within the peritoneal cavity.
Second-generation endometrial ablation
Endometrial ablation aims to treat HMB by destroying the endometrium (lining of the womb), which
is responsible for heavy periods. Historically, a number of methods have been used to achieve this.
First-generation EA techniques use an operating hysteroscope under direct vision. Energy is deployed
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through an electric loop, laser fibre or rollerball to remove or destroy the endometrium. First-generation
techniques are more complicated, require a long learning curve, are slower to perform and have a higher risk
profile than second-generation techniques. They are, however, highly versatile and are the recommended
approach for distorted uterine cavities or repeat ablations, and are a sensible option when the patient has
had more than one caesarean section.
This century, ‘second-generation’ techniques have become the most commonly used endometrial ablative
procedures, as they are quicker to learn and undertake, and have lower associated risks. These are blind
global energy sources which again aim to destroy the endometrium and superficial myometrium to a depth
of 5 mm (to destroy the endometrial glands). Current second-generation procedures used in the UK include
two forms of thermal balloon EA and a device known as Novasure. Thermal balloon EA is undertaken by
means of a silicone balloon, which is introduced through the cervix into the uterine cavity. The balloon fills
and expands to conform to the inside of the uterine cavity, compressing the endometrium. Hot fluid
circulating within the balloon ensures endometrial destruction and the temperature and duration of
treatment are carefully controlled electronically by means of a computer attached to the device. Novasure
uses bipolar radiofrequency energy delivered through an intrauterine mesh electrode that expands on
insertion through the cervix to fit the shape of the uterine cavity. The energy required is calculated by the
device and treatment times are < 90 seconds. All three treatments significantly reduce menstrual loss and
result in complete cessation of bleeding in 40–50% of women.7 Second-generation EA can be performed
as a day-case procedure, under either general or local anaesthetic, at a NHS cost of £995 per treatment.18
It has also been widely used in the outpatient setting.19,20
Questions addressed by HEALTH
The aim of this study is to compare the clinical effectiveness and cost-effectiveness of LASH and
second-generation EA in women with HMB.
The primary objective is to compare (1) patient-reported satisfaction, measured on a six-point Likert scale
(from ‘totally satisfied’ to ‘totally dissatisfied’) and (2) condition-specific QoL, measured using the Menorrhagia
Multi-Attribute Quality-of-Life Scale (MMAS), at 15 months post randomisation. The corresponding economic
objective is to estimate the incremental cost per quality-adjusted life-year (QALY) gained for LASH compared
with EA at 15 months post randomisation.
The hypothesis being tested is that LASH is superior to second-generation EA for the treatment of HMB in
terms of patient satisfaction, QoL and costs.
DOI: 10.3310/hta23530 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 53
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3

Chapter 2 Methods and practical arrangements
Study design
HEALTH was a parallel-group, multicentre RCT designed to compare the clinical effectiveness and cost-
effectiveness of LASH with second-generation EA in women with HMB. Further details of the study design
have been described previously1 and are represented in Figure 1. All trial case report forms (CRFs) and
participant-completed questionnaires are available at URL: www.journalslibrary.nihr.ac.uk/programmes/hta/
123523/#/ (accessed 22 May 2019).
Study population
Women aged < 50 years with HMB who were eligible for EA and willing to be randomised between LASH
and EA.
Women were excluded from trial entry if any of the following criteria were met: they had plans to conceive;
endometrial atypia; abnormal cytology; uterine cavity size > 11 cm; any fibroids > 3 cm; contraindications to
laparoscopic surgery; previous EA; and inability to give informed consent or complete trial paperwork.
Recruitment
Investigations prior to consent
Pelvic ultrasound scanning was undertaken to identify uterine or endometrial abnormality, fibroid size and
number. An endometrial biopsy was taken to measure cavity length and exclude endometrial atypia.
Consent to participate
Women with HMB who fulfilled the inclusion criteria were identified at gynaecology outpatient and
pre-assessment clinics. They were supplied with the patient information leaflet and given the opportunity
to discuss the study with the local clinical team, family and friends, and their general practitioner (GP),
as appropriate. Women could make the decision to participate during their initial consultation, during a
subsequent hospital visit or after a follow-up telephone consultation at home. Written informed consent
was obtained from all participants prior to trial entry.
Health technologies being compared
Women were randomised to one of two surgical treatments for HMB:
1. LASH [removal of the uterine corpus (body) by means of keyhole surgery]
2. second-generation EA [destroying the endometrium (lining of the womb) by means of a silicone balloon
containing hot fluid or radiofrequency energy delivered through an intrauterine mesh electrode].
Treatment allocation
Eligible and consenting women were randomised to one of the two treatment arms in a 1 : 1 allocation
ratio, using the randomisation application at the trial office at the Centre for Healthcare and Randomised
Trials (CHaRT). The randomisation application was available as both an interactive voice-response
telephone system and as an internet-based application, and used a minimisation algorithm based on
centre and age group (< 40 vs. ≥ 40 years).21
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Exclusion criteria
• Plans to conceive
• Desires to retain the uterus
• Endometrial atypia
• Abnormal cytology
• Uterine cavity size > 11 cm
• Any fibroids > 3 cm
• Contraindications to
   general anaesthesia and
   laparoscopic surgery 
   (e.g. bowel adhesions 
   or a previous midline
   laparotomy)
• Previous EA
Women aged < 50 years with heavy
menstrual bleeding who are
eligible for endometrial ablation
Assessed for
eligibility
Not recruited
Not recruited
• Missed patient
• Declined
Informed consent
baseline assessements
Pre-randomisation
SF-12, EQ-5D-3L, MMAS
Randomised
LASH
(n = 324)
Any second-generation EA
(n = 324)
Perioperative assessment Perioperative assessment
Days 1–14 after surgery Days 1–14 after surgery
6 weeks after surgery 6 weeks after surgery
6 months after surgery 6 months after surgery
15 months after randomisation 15 months after randomisation
Duration of operation, perioperative
complications and time to discharge
Duration of operation, perioperative
complications and time to discharge
Pain (NRS), analgesia requirements,
symptom diary
Pain (NRS), analgesia requirements,
symptom diary
Pain (NRS), time to return to activities,
acceptability of procedure, SF-12, EQ-5D-3L
Pain (NRS), time to return to activities,
acceptability of procedure, SF-12, EQ-5D-3L
Patient-reported satisfaction, SF-12,
EQ-5D-3L, MMAS, health resource use
Patient-reported satisfaction, SF-12,
EQ-5D-3L, MMAS, health resource use
Patient-reported satisfaction, SF-12,
EQ-5D-3L, MMAS, health resource use,
participant costs
Patient-reported satisfaction, SF-12,
EQ-5D-3L, MMAS, health resource use,
participant costs
FIGURE 1 HEALTH flow diagram. EQ-5D-3L, EuroQol-5 Dimensions, three-level version; NRS, Numerical Rating Scale;
SF-12, Short Form questionnaire-12 items. Reproduced from Cooper et al.1 This article is distributed under the terms
of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were
made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
applies to the data made available in this article, unless otherwise stated.
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Blinding
Baseline data were reported by women before randomisation using self-completed questionnaires.
Surgeons and participants could not be blinded to the allocated procedure.
Delivery of the intervention
Following randomisation, participants were placed on the waiting list for the appropriate treatment. As per
Scottish and UK government guidelines, it was anticipated that treatment would occur within 12–18 weeks
of randomisation.22–24 Surgeons used their standard practice so that the technique they normally used
was not modified for the purposes of the trial. All other aspects of care were left to the discretion of the
responsible surgeon.
Data collection during follow-up
Participant-reported outcomes were assessed by self-completed questionnaires at baseline (before surgery),
6 weeks and 6 months after surgery, and 15 months following randomisation (Table 1). A self-completed
14-day diary was also collected. Up to two reminders were sent to participants by post, e-mail, telephone
or text message, taking into account any preferences they had for mode of communication.
TABLE 1 Measurement of outcomes (components and timing)
Outcome
Pre randomisation
(baseline) Surgery
Post surgery
Post randomisation
(15 months)Days 1–14 6 weeks 6 months
CRF ✗
Surgical details ✗
Pain NRS symptom diary ✗
Pain NRS ✗
Time to return to normal
activities
✗
Acceptability ✗
Satisfaction ✗ ✗
MMAS score ✗ ✗ ✗
Menstrual outcomes ✗ ✗ ✗
EQ-5D-3L and SF-12
scores
✗ ✗ ✗ ✗
Health-care utilisation ✗ ✗
Participant costs ✗
EQ-5D-3L, EuroQol-5 Dimensions, three-level version; NRS, Numerical Rating Scale; SF-12, Short Form questionnaire-12 items.
Reproduced from Cooper et al.1 This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Intraoperative and postoperative data were collected by the local research team at the time of the
randomised procedure. A short CRF was also completed for any related hospital readmissions during the
follow-up period.
Study outcome measures
The co-primary clinical outcome measures were:
l patient satisfaction, measured on a six-point scale (from ‘totally satisfied’ to ‘totally dissatisfied’),
at 15 months after randomisation
l MMAS score, a condition-specific QoL outcome,25 ranging from 0 (worst possible health state) to
100 (best possible health state), based on six items, measured at 15 months after randomisation.
The primary study objective was to compare the LASH and EA groups with respect to the two co-primary
outcomes. These outcomes were addressed in a hierarchy. First, the patient satisfaction outcome was
considered and, if this showed a statistically significant difference at a p-value of < 0.05, then the MMAS
score outcome was also considered. By specifying this hierarchy, it was not necessary to apply any
adjustment for multiple statistical testing, as the overall false-positive rate is controlled at 5%.
The 15-month follow-up post-randomisation time point was chosen to accommodate the 12- to 18-week
waiting time for treatment. The intention was that the primary outcome questionnaire (triggered at 15 months
post randomisation) would be completed at approximately 12 months post surgery, in order to facilitate
comparison with the most similar RCTs in the literature.
The primary economic outcome was the incremental cost (to the health service) per QALY gained (LASH vs. EA).
Secondary outcome measures
Other outcome measures included pain score at days 1–14 and at 6 weeks post surgery; acceptability of
treatment at 6 weeks post surgery; satisfaction with treatment at 6 months post surgery; MMAS score at
6 months post surgery; menstrual outcomes at 6 months post surgery and at 15 months post randomisation;
generic health-related quality of life (HRQoL) [Short Form questionnaire-12 items (SF-12) and EuroQol-5
Dimensions, three-level version (EQ-5D-3L), scores at 6 weeks and 6 months post surgery and at 15 months
post randomisation]; perioperative complications, including recovery details and need for additional
gynaecological surgery; cost; and cost-effectiveness.
Pathology results for all endometrial biopsies and uterine specimens were also checked.
Statistical analyses were used to compare secondary outcomes by randomised groups. These analyses,
however, were regarded as hypothesis-generating and no adjustment was made for multiple statistical testing.
Safety reporting
Adverse events (AEs) were either notified to the study office by the local research team or reported by the
women in their follow-up questionnaires. If an AE was suspected, it was verified by the local research
team, if possible. Unrelated AEs were not recorded.
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In HEALTH, ‘relatedness’ was defined as an event that occurred as a result of a procedure required by the
protocol, whether or not it was either (a) the specific intervention under investigation or (b) administered
outside the study as part of normal care.
The following events were also potentially expected: admission to a high-dependency unit/intensive care;
emergency hysterectomy; laparotomy; port site hernia; blood transfusion; wound infection; lower urinary
tract infection; endometritis; blood stained vaginal discharge; anaesthetic complications; low-grade pyrexia;
blood loss; haematoma; constipation; pelvic discomfort/pain; internal bleeding or injury; deep-vein
thrombosis; pulmonary embolism; injury to the wall of the uterus; bladder/bowel/ureteric injury; and
voiding dysfunction.
Any serious adverse events (SAEs) related to the participants’ HMB treatment that were not further
interventions (e.g. being admitted to hospital for an infection) were recorded on the SAE form. Hospital
visits that were associated with further interventions due to HMB (e.g. further surgery) were recorded as
an outcome measure. All deaths from any cause (related or otherwise) were recorded on the SAE form.
It was a requirement to report to the sponsor any SAEs that were deemed related and unexpected within
24 hours of receiving the signed SAE notification. Such SAEs would also be reported to the main Research
Ethics Committee within 15 days of the chief investigator becoming aware of the event. All related SAEs
were summarised and reported to the appropriate authorities within their regular progress reports.
Sample size
An individual participant data meta-analysis of abdominal hysterectomy compared with first-generation EA8
suggested a target difference of an odds ratio (OR) of 2.84 (95% vs. 87%) for patient satisfaction. Such an
OR also equates to a medium-sized standardised effect (Cohen’s d). It was calculated that 292 participants
per group would provide 90% power to detect a difference in total satisfaction rates of 8% (87% vs. 95%),
using a two-sided continuity-corrected chi-squared test. This would also allow > 90% power to detect a
10-point difference in MMAS scores [assuming a standard deviation (SD) of 33 units]. Based on an expected
10% drop-out rate, the recruitment target was 648 participants in total (324 participants per group).
Owing to changes to the analysis plan during the trial, the implications for these calculations were later
revisited (see Statistical analysis).
Data Monitoring Committee
The independent Data Monitoring Committee (DMC), which consisted of a methodologist, a clinician
and a statistician, met on four occasions during the trial and considered interim reports of trial data by
randomised groups (denoted as group 1 and group 2). On each occasion they agreed that the trial should
continue as planned. At the final meeting, which took place in September 2017, after recruitment had
ended, the DMC was shown the distributions of the primary outcomes using interim data.
Statistical analysis
Analyses were conducted using Stata® version 15 (StataCorp LP, College Station, TX, USA). Categorical
variables were described with the number and percentage in each category. Continuous variables were
described using mean and SD or median and interquartile range (IQR), depending on the distribution
of data.
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Analyses were based on the intention-to-treat principle, analysing women in the groups to which they
were randomised. Analyses used a two-sided 5% significance level, with corresponding 95% confidence
intervals (CIs) generated as appropriate [see URL: www.journalslibrary.nihr.ac.uk/programmes/hta/123523/#/
(accessed 22 May 2019)].
Analyses of the two co-primary outcomes (patient satisfaction and MMAS at 15 months after randomisation)
were conducted independently.
Patient satisfaction was collected on a six-point scale: ‘totally satisfied’, ‘generally satisfied’, ‘fairly satisfied’,
‘fairly dissatisfied’, ‘generally dissatisfied’ or ‘totally dissatisfied’. The original analysis plan specified that
patient satisfaction be treated as a binary variable, but after considering the distribution of interim data
(September 2017), and to make better use of the data collected, the DMC requested that this outcome be
treated as ordinal with four categories (‘totally satisfied’, ‘generally satisfied’, ‘fairly satisfied’, with the
remaining three categories combined into a single ‘dissatisfied’ category), and analysed using an ordinal
logistic regression (OLR) model with adjustment for minimisation factors: age (< 40 vs. ≥ 40 years) and
centre (treated as a random effect).
We originally intended the MMAS score to be treated as a continuous outcome and analysed using a
linear regression model, adjusted for baseline MMAS scores (treated as a continuous variable) and the
two minimisation factors (age and centre). However, interim data presented to the DMC were highly
skewed, with over half of all trial participants reporting a maximum MMAS score of 100 at 15 months post
randomisation. After discussion, the DMC recommended that the analysis of this outcome be changed to
an OLR model with four categories (0–50, 51–75, 76–99, 100).
The Project Management Group (PMG) accepted the recommended changes to the analysis of the primary
outcomes after viewing the distribution of these outcomes with both groups combined. The decision to
change the analysis method for both co-primary outcomes to an ordered categorical analysis had implications
for the power of the study. It seemed appropriate to continue to use a common OR of 2.84 in the revised
power calculations. Based on the formulae in a report by Whitehead,26 assuming a common OR of 2.84 and
using the expected proportions in each category from interim trial data with treatment groups combined,
a total of 292 participants per group would have > 90% power to detect statistically significant differences
between the randomised groups for patient satisfaction. There were no accurate data on which to base our
decisions regarding the MMAS outcome, so a pragmatic decision was made to use the same OR for this
outcome. Both outcomes had similar distributions after classification into four categories and were addressed
in a hierarchy (MMAS score was considered only if patient satisfaction showed a statistically significant
difference). Therefore, it was considered unnecessary to recruit additional participants to the trial.
The MMAS total score was calculated only if the six constituent items were completed. There does not
appear to be a precedent in the literature for imputing scores for MMAS items from other items as the
response category weighting varies by item. In addition, to account for the nature of the treatments being
offered (i.e. the vast majority of the women in the LASH arm and 40–50% of the women in the EA arm
would be expected to be amenorrhoeic following treatment), the instructions for completion of the MMAS
were altered slightly before the start of the study [see URL: www.journalslibrary.nihr.ac.uk/programmes/
hta/123523/#/ (accessed 22 May 2019)].
It was expected that a small number of women might have to wait longer than 12–18 weeks for their
operation and therefore would receive their 6 months post-surgery and 15 months post-randomisation
questionnaires simultaneously. It was therefore agreed that scores for the co-primary outcomes and the
main outcome used in the economic analysis (EQ-5D-3L utility score) could be used from the 6-month
post-surgery questionnaire in lieu of the 15-month data, provided these were provided within 3 months of
the due date of the latter.
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A sensitivity analysis using a multiple imputation approach was used to explore the impact of missing data
on the robustness of the results of the analyses of co-primary outcomes. Missing values for the outcome
and for one covariate (MMAS score at baseline) were imputed using multiple imputation by chained
equations using the mi package in Stata.27 Twenty imputed data sets were created. There were no missing
data for the other covariates (age group and centre), as these were required for the minimisation algorithm.
A further sensitivity analysis using the results of the original analysis method for MMAS score (i.e. a linear
regression model treating MMAS score as a continuous outcome) was also presented.
Exploratory subgroup analyses were performed for the following groups: uterine cavity length (≤ 8 cm vs.
> 8 cm), menstrual pain (dysmenorrhoea) at baseline (severe/crippling pain vs. other categories, determined
using a five-point Likert scale), patient age (< 40 years vs. ≥ 40 years) and presence or absence of fibroids.
These prespecified subgroup analyses were conducted by including a treatment by subgroup interaction
term in the corresponding OLR model for the co-primary outcomes (patient satisfaction and MMAS score
at 15 months post randomisation). The effect sizes from these subgroup analyses were displayed graphically
in a forest plot, along with results for each recruiting centre and whether or not the operator was a consultant.
Centres with fewer than 50 randomised participants were included in an ‘other centre’ category.
Secondary outcomes were analysed using generalised linear models (GLMs), adjusted for the minimisation
factors and, when appropriate, a baseline measure. Continuous outcomes were analysed using linear
regression, binary outcomes using logistic regression and ordered categorical outcomes using OLR. As
many continuous outcomes had an extreme skewed distribution, an ordered categorical analysis had to be
used instead. The category thresholds were decided by the PMG after viewing the distribution of the
outcome of both groups combined.
Time-to-event outcomes such as time until return to normal activities (e.g. paid work for those in
employment) were analysed using Cox proportional hazards regression models.
Pain data from the participant diaries (collected in the first 14 days after the operation) were analysed
using a repeated-measures model.
All AEs were described using the number and percentage within each randomised group. All expected
SAEs and other SAEs were recorded in detail and the number and percentage in each randomised group
reported.
Economic evaluation
The economic analysis consisted of a trial-based analysis of individual patient-level cost and effect (QALY),
and a decision modelling component to inform cost-effectiveness in the longer term. See Chapters 5 and 6
for a detailed description of the methods used.
Management of the study
The trial management team, based within CHaRT, University of Aberdeen, provided day-to-day support for
the recruiting centres led by a local principal investigator (PI). The PIs, supported by dedicated research
nurses, were responsible for all aspects of local organisation, including recruitment of participants, delivery
of the interventions and notification of any problems or unexpected developments during the study period.
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The study was supervised by the PMG, which consisted of representatives from the study office and grant
holders. The study was further overseen by a Trial Steering Committee (TSC), which comprised four
independent members and an independent DMC (see Data Monitoring Committee).
Patient and public involvement
Pre-funding application and design of the research
Prior to the initial funding application, we sought support from the Royal College of Obstetricians and
Gynaecologists (RCOG) Women’s Network (URL: www.rcog.org.uk/our-profession/community/committees/
rcog-womens-network, accessed 11 January 2013), a group of professional laywomen who work to advise
and support the RCOG on women’s perspectives on obstetrics and gynaecology. The proposal was
discussed at the Women’s Network meeting prior to the original application and the group fed back their
comments to the rest of the research team. In addition, the vice chairperson of the RCOG Women’s
Network was a co-applicant on the grant and gave input into the application and continued to advise the
study PMG until October 2016.
Oversight of the study
One of the independent members of the TSC was a patient representative. The TSC met throughout
the study and reviewed all study documentation, including patient-facing documents, newsletters and
questionnaires that were sent to potential and recruited participants in HEALTH. In addition to being an
integral part of the study oversight, she provided the following feedback on what she felt were the key
impacts and value of her recent contributions:
In my role as a patient representative I am a member of the HEALTH TSC and attend annual meetings
as scheduled. I maintain an interest in all of the various aspects of the HEALTH trial but with a
particular interest in patient-related issues and the drafting of patient information, etc. In 2017 a major
problem arose when the success of the trial was threatened by the low return rate of the 12-month
questionnaire. Three actions were then agreed. First, I was involved with drafting a new covering letter
to be sent out with the questionnaire, the main aim of which was to emphasise the importance of
returning the necessary information otherwise the trial would fail, and the main constraint of which
was to avoid pressurising the women. Second, approval would be sought to offer the women a
monetary incentive to return the questionnaire. Third, I drafted a supporting submission from the
patient perspective to the Ethics Committee seeking approval for the above two actions.
Report writing, academic paper preparation and dissemination
The patient and public involvement partner on the TSC has been actively involved in discussions of the trial
results with the TSC, and has been supportive of the study in report preparation and has contributed
towards the preparation of the Plain English summary. The partner will continue to be involved in
dissemination activities and preparation of results dissemination to participants and academic papers.
Challenges in patient and public involvement
At the end of the study the patient and public involvement partner reflected on their input and made
suggestions for possible improvements for future trials in this area:
One potential limitation might certainly be when there is only one PPI [patient and public involvement]
partner on a trial. Perhaps the more important issues are the PP [patient and public] representative(s)’s
(PPR’s) background, understanding and commitment, but having more than one view or interpretation
should offer a wider perspective of perceived patient need and possibly areas in which greater clarity
is needed to ensure patient understanding, as far as possible.
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My involvement in trials has been as a member of the Project Management Group or of the Trials Steering
Committee. As a member of the latter I have felt somewhat distanced from the projects because of the
time lapse between meetings, normally around 12 months, and the lack of information during that
interim period. I think I would have found it helpful to have had some continuity such as sight of, for
instance, a copy of the PMG minutes, proposed changes to the Protocol, new developments etc. As
patient representatives do not have a presence in the workplace, they obviously miss out on the various
pieces of information that are discussed and circulated.
A patient representative can be used as a ‘bridge’ between the trials team and the Ethics Committee,
when appropriate. For instance, my experience in some of the trials with which I have been involved
has included producing a statement or proposal to assist in gaining approval from the Ethics Committee,
an example of which is noted in the paragraph on ‘Oversight of the study’ above. I think this sort of
direct contact can be very useful in conveying the patients’ perspective to the Ethics Committee so as
to further inform the latter as to the appropriateness of certain actions required of patients to assist in,
say, the successful outcome of a trial which is the major aim.
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Chapter 3 Baseline results
This chapter describes how the women were identified from 31 UK hospitals (see Appendix 1, Table 26)and reports the baseline characteristics up to the point of study entry. The subsequent findings are
described in Chapters 4 and 5.
The flow of women through the study is shown in the Consolidated Standards of Reporting Trials
(CONSORT) flow diagram (Figure 2) in line with the CONSORT recommendations.28
Between May 2014 and March 2017, 2552 potentially eligible patients were screened; 1351 (52.9%) were
confirmed as eligible, of whom 664 (49.1%) gave their consent and were randomised, 331 to LASH and
333 to EA (see Figure 2).
After randomisation, four women were considered to be ineligible, regarded as post-randomisation
exclusions and not included in any trial analyses. Therefore, 660 women (330 in each group) were
included in the main trial analyses (see Figure 2).
Study recruitment
Study design and recruitment methodology have been described previously1 (see also Chapter 2). Women
with HMB who attended gynaecology outpatients and pre-assessment clinics, and who were eligible for EA,
were invited to participate in HEALTH. Women were asked if they would be willing to be randomised to
either LASH or second-generation EA. The centres that randomised women into HEALTH, including numbers
recruited by centre, are described in Appendix 1, Table 26. The recruitment rate is illustrated in Figure 3.
Screened
(n = 2552) Ineligible/declined
(n = 1888)
• Ineligible, n = 1201
• Patient declined, n = 589
• Clinical preference, n = 98
Randomised
(n = 664)
Randomised to EA
(n = 333)
Randomised to LASH
(n = 331)
Post-randomisation
exclusions
(n = 1)
(Fibroid > 3 cm)
Post-randomisation
exclusions
(n = 3)
(Fibroid > 3 cm, endometrial
atypia, pregnant)
Number included in analysis
(n = 330)
Number included in analysis
(n = 330)
FIGURE 2 Flow of participants to the point of randomisation.
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Non-recruited women
Of the 2552 women approached, 1888 (74.0%) did not participate in the trial because they were ineligible
(n = 1201, 47.1%) or declined participation (n = 589, 23.1%) or because their consultant later indicated a
preference for a particular treatment (n = 98, 3.8%) (see Figure 2 and Appendix 1, Table 27). The most
common reasons for women declining to take part in the study were a preference for a particular treatment
[preference for EA, n = 151 (25.6%); preference for hysterectomy, n = 126 (21.4%); preference for medical
management, n = 89 (15.1%)] and an unwillingness to accept randomisation (n = 54, 9.2%). Ninety-eight
women (16.6%) did not give a reason for declining to take part (see Appendix 1, Table 28).
Reasons for ineligibility included ‘fibroids > 3cm’ (n = 361, 30.1%), a preference to continue with medical
management (n = 244, 20.3%) and age > 50 years (n = 239, 19.9%). In addition, 98 women who were
deemed eligible for HEALTH were not included for other clinical reasons. In the majority of cases, this was
because a treatment pathway had already been decided prior to study entry [hysterectomy, n = 25
(25.5%); EA, n = 18 (18.4%); and ‘other’ treatment, n = 16 (16.3%)] (see Appendix 1, Table 28).
Randomised participants: baseline characteristics
The baseline characteristics of the 660 women who agreed to participate in HEALTH and who were truly
eligible to take part are described in Tables 2–4 and Appendix 1, Table 29.
Participant characteristics
The two randomised groups were comparable at baseline. On average, women were around 42 years of
age when considering surgical treatment for their HMB symptoms. There was no difference between the
randomised groups in terms of age, body mass index or preoperative haemoglobin levels (see Table 2).
Heavy menstrual bleeding symptoms at baseline
Of the women who participated in HEALTH, 67.7% (443/654) had experienced trouble with their periods
for > 3 years and the majority of the women (79.5%) described their periods as very heavy with clots and
flooding (see Table 3). Just under half of the women (46.6%) described heavy bleeding for ≥ 7 days and
50.6% had experienced severe/crippling pain during their periods. Almost 80% of the women hoped the
operation would stop their periods completely.
The randomised groups were comparable with respect to other characteristics, including mean bleeding
score and mean pain score (see Table 3).
Generic quality of life at baseline
There were no differences between the randomised groups in either the MMAS total score, EQ-5D-3L
utility score, EQ-5D-3L visual analogue scale (VAS), SF-12 physical component score (PCS) or SF-12 mental
component score (MCS) at baseline (see Table 4).
TABLE 2 Baseline characteristics
Baseline characteristic LASH (N= 330) EA (N= 330)
Age (years), mean (SD) [n] 42.2 (4.89) [330] 42.1 (4.96) [330]
BMI (kg/m2), mean (SD) [n] 29.1 (5.55) [309] 29.0 (5.34) [304]
Preoperative haemoglobin level (g/l), mean (SD) [n] 131.0 (13.1) [306] 130.1 (12.6) [282]
Number of vaginal deliveries, median (IQR) [n] 2 (1–3) [326] 2 (1–3) [330]
Number of caesareans, median (IQR) [n] 0 (0–1) [326] 0 (0–1) [327]
BMI, body mass index.
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TABLE 3 Menstrual outcomes at baseline
Menstrual outcome LASH (N= 330) EA (N= 330)
How long have you had trouble with your periods?, n (%)
< 1 year 16 (4.9) 18 (5.5)
1–3 years 84 (25.7) 93 (28.4)
> 3 years 227 (69.4) 216 (66.1)
Description of period, n (%)
Light 2 (0.6) 0
Moderate 6 (1.8) 7 (2.1)
Heavy with clots 58 (17.7) 61 (18.7)
Very heavy with clots and flooding 261 (79.8) 259 (79.2)
On average, for how many days is the bleeding heavy?, n (%)
Not heavy 3 (0.9) 2 (0.6)
1–3 days 50 (15.3) 51 (15.6)
4–6 days 118 (36.1) 125 (38.2)
≥ 7 days 156 (47.7) 149 (45.6)
At any time in the last 3 months have you needed to use more than one form of sanitary protection at a time?, n (%)
No 27 (8.3) 25 (7.7)
Tampon and pad 117 (35.9) 118 (36.3)
Two pads 88 (27.0) 84 (25.8)
Tampon and two pads 48 (14.7) 56 (17.2)
More than this (e.g. bath towel) 46 (14.1) 42 (12.9)
Are your periods usually painful?, n (%)
No 19 (5.8) 18 (5.5)
Mild pain 33 (10.1) 38 (11.7)
Moderate pain 104 (31.9) 110 (33.7)
Severe/crippling pain 170 (52.1) 160 (49.1)
Bleeding (mean score of up to 10 days of period, 0 = no bleeding,
5 = worst bleeding), mean (SD) [n]
3.59 (0.88) [322] 3.55 (0.78) [322]
Pain (mean score of up to 10 days of period, 0 = no pain, 5 = worst pain),
mean (SD) [n]
2.76 (1.27) [311] 2.70 (1.30) [313]
What do you want from the operation?, n (%)
No periods 265 (82.6) 253 (78.6)
Light periods 29 (9.0) 38 (11.8)
Normal periods 27 (8.4) 31 (9.6)
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TABLE 4 Quality-of-life scores at baseline
QoL score LASH (N= 330) EA (N= 330)
MMAS
Total score
Mean (SD) 30.5 (19.0) 32.3 (20.0)
Median (IQR) 28.6 (14.7–43.7) 29 (15.7–47.7)
n 323 321
EQ-5D-3L
Utility score
Mean (SD) 0.71 (0.30) 0.70 (0.31)
Median (IQR) 0.76 (0.66–1.00) 0.79 (0.69–1.00)
n 319 322
VAS
Mean (SD) 65.2 (24.2) 67.2 (23.5)
Median (IQR) 70 (50–85) 70 (52–85)
n 317 321
SF-12
PCS
Mean (SD) 45.0 (9.0) 44.9 (9.7)
Median (IQR) 45.8 (39.0–52.1) 46.5 (39.0–51.9)
n 318 321
MCS
Mean (SD) 37.2 (11.0) 38.7 (11.6)
Median (IQR) 36.6 (29.8–45.1) 29 (15.7–47.7)
n 318 321
MCS, mental component score; PCS, physical component score; VAS, visual analogue scale.
Notes
MMAS total score: 0 represents worst possible health and 100 represents best possible.
EQ-5D-3L utility score: –0.59 represents worst possible QoL and 1 represents best possible.
EQ-5D-3L VAS: 0 represents worst imaginable health state and 100 represents best possible.
SF-12 PCS and MCSs: 0 represents worst possible QoL and 100 represents best possible.
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Chapter 4 Clinical results
This chapter describes the main clinical findings of HEALTH. Details of the trial operations are presentedfirst. This is followed by the results for the two co-primary outcomes (patient satisfaction and MMAS score
at 15 months post randomisation). Finally, the results of the secondary outcomes are provided in chronological
order. All results are presented by allocated randomised group (i.e. according to intention to treat).
Flow of participants through the trial
The CONSORT flow diagram shows the number of participants providing data at each stage of the trial
(Figure 4). Response rates are based on the number receiving an operation (14-day diary, 6-week and
6-month questionnaire) or the number randomised (15-month questionnaire), after accounting for
withdrawals. Questionnaire completion rates ranged between 80% and 89% (exact return rates are
reported in the CONSORT flow diagram; see Figure 4).
Operation details and operative outcomes
Forty-four participants [21/330 (6.4%) randomised to LASH and 23/330 (7.0%) randomised to EA] did not
undergo an operation. These women were not asked to complete the patient diary or questionnaires at
6 weeks and 6 months post surgery, but were sent the final questionnaire at 15 months post randomisation.
Table 5 provides details for the 616 women who received an operation. The median number of days
between randomisation and treatment was higher in the LASH group [84 (IQR 57–127) days] than in the
EA group [63 (IQR 41–97) days] (see Appendix 2, Figure 16). Six women across both arms waited a year
or more for their operation and therefore received the 6 months post-surgery and the 15 months
post-randomisation questionnaires at around the same time.
Of those undergoing treatment, 291 out of 309 (94.2%) randomised to LASH and 297 out of 307 (96.7%)
randomised to EA received the allocated procedure. Twelve of those randomised to LASH actually received an
EA, five underwent a total hysterectomy and one had a hysteroscopy/polypectomy. One woman randomised
to EA received LASH, five had a total hysterectomy and four had a hysteroscopy/polypectomy (see Figure 4).
In total, nine of the EA operations could not be completed during the first admission (one in the LASH
group and eight in the EA group), three women were subsequently readmitted for LASH, two women were
readmitted for the total hysterectomy and two women were readmitted for EA.
Compared with the EA group, the LASH group included higher proportions of women who were operated
on by a consultant (77.3% vs. 57.3%), received thromboprophylaxis (98.4% vs. 69.2%) and received
parenteral postoperative opiates (30.4% vs. 15.0%). Fewer women in the LASH group than in the EA
group were noted to have a uterus free from fibroids during surgery (75.7% vs. 91.1%) and more (32.4%
vs. 5.3%) stayed in hospital for > 24 hours (see Table 5).
Results for the co-primary outcomes
Satisfaction at 15 months post randomisation
The single question regarding satisfaction was answered by 278 out of 330 (84.2%) women randomised
to the LASH group and 280 out of 330 (84.8%) women randomised to the EA group at 15 months post
randomisation. This included one woman whose 6-month data were imputed for the 15-month time point
(Table 6).
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Screened
(n = 2552)
Randomised
(n = 664)
Ineligible/declined
(n = 1888)
• Ineligible, n = 1201
• Patient declined, n = 589
• Clinical preference, n = 98
Randomised to LASH
(n = 331)
Randomised to EA
(n = 333)
Post-randomisation
exclusions
(n = 1)
Post-randomisation
exclusions
(n = 3)
Number included in analysis
(n = 330)
Number included in analysis
(n = 330)
• Completed baseline PQ, n = 327
   (99.1%)
• Completed baseline PQ, n = 328
   (99.4%)
Treatment received Treatment received
• Received allocated treatment, n = 291
• Did not receive allocated treatment,
   n = 18 (EA, n = 12; other, n = 6a)
• No operation, n = 19
• Withdrawn prior to time point, n = 2
• Received allocated treatment, n = 297
• Did not receive allocated treatment,
   n = 10 (LASH, n = 1; other, n = 9b)
• No operation, n = 19
• Withdrawn prior to time point, n = 4
14-day diary (post surgery) 14-day diary (post surgery)
6 weeks (post surgery) 6 weeks (post surgery)
6 months (post surgery) 6 months (post surgery)
15 months (post randomisation) 15 months (post randomisation)
Completed 14-day diary
(n = 267/309; 86.4%)
Completed 14-day diary
(n = 267/307; 84.7%)
Completed 6-week PQ
(n = 255/309; 82.5%)
Completed 6-week PQ
(n = 251/306; 82.0%)
Completed 6-month PQ
(n = 254/308; 82.5%)
Completed 6-month PQ
(n = 244/305; 80.0%)
Completed 12-month PQ
(n = 280/327; 85.6%)
Completed 12-month PQ
(n = 284/322; 88.2%)
• No operation, n = 19
• Withdrawn prior to time point, n = 2
• No operation, n = 19
• Withdrawn prior to time point, n = 4
• No operation, n = 19
• Withdrawn prior to time point, n = 2
• No operation, n = 19
• Withdrawn prior to time point, n = 5
• No operation, n = 19
• Withdrawn prior to time point, n = 6
• No operation, n = 19
• Withdrawn prior to time point, n = 3
• Withdrawn prior to time point, n = 3c • Withdrawn prior to time point, n = 8d
FIGURE 4 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. a, Other operations (LASH group):
total hysterectomy (n= 5), EA (n= 1), hysteroscopy/polypectomy (n= 1); b, other operations (EA group): total
hysterectomy (n= 5), hysterectomy/polypectomy (n= 4); c, reasons included: unwillingness to have surgery (n= 1),
private treatment (n= 1), no reason given (n= 1); and d, reasons included: unwillingness to have surgery (n= 2),
requested a different operation (n= 2), family illness (n= 1), moved abroad (n= 1), did not want to complete
questionnaires (n= 2). PQ, participant questionnaire. Reproduced from Cooper et al.29 © The Author(s). Published by
Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
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TABLE 5 Surgical details for first admission
Detail from surgical procedure LASH (maximum N= 309) EA (maximum N= 307)
Grade of surgeon, n (%)
Consultant 239 (77.3) 176 (57.3)
Specialty doctor 8 (2.6) 16 (5.2)
Nurse practitioner 0 10 (3.3)
Registrar/junior 62 (20.1) 105 (34.2)
Supervised by consultant (if surgeon not consultant), n (%)
Yes 66 (96) 100 (78.1)
No 3 (4) 28 (21.9)
Not known 1 3
Type of procedure performed, n (%)
LASH 291 (94.2) 1 (0.3)
EA 12 (3.9) 297 (96.7)
Total hysterectomy 5 (1.6) 5 (1.6)
Hysteroscopy/polypectomy 1 (0.3) 4 (1.3)
Was thromboprophylaxis used?, n/N (%)
Any of below 303/308 (98.4) 209/302 (69.2)
Injectable heparinoid 236/309 (76.4) 23/307 (7.5)
TED stockings 254/309 (82.2) 194/307 (63.2)
Pneumatic anti-thrombosis boots 69/309 (22.3) 21/307 (6.8)
Type of anaesthesia, n (%)
General 308 (100) 291 (94.8)
Local 0 12 (3.9)
Not known 1 4
Uterine cavity length (cm), mean (SD) [n] 8.38 (1.63) [259] 7.24 (1.97) [292]
Fibroids, n (%)a
Normal 224 (75.7) 275 (91.1)
Type 0/1 fibroids ≤ 3 cm 11 (3.7) 11 (3.7)
Type 2 fibroids ≤ 3 cm 9 (3.0) 6 (2.0)
Intramural/subserosal fibroids ≤ 3 cm 50 (16.9) 10 (3.3)
Not known 15 5
Time from randomisation to operation (days), median (IQR)
[range], n
84 (57–127) [0–579], 309 63 (41–97) [0–541], 307
Time from entry to anaesthetic room to exit from operating
room (minutes), mean (SD) [n]
113.9 (38.1) [306] 44.3 (23.3) [295]
Time from operating room exit to exit from recovery room
(minutes), mean (SD) [n]
75.8 (43.7) [305] 52.4 (33.1) [297]
continued
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TABLE 5 Surgical details for first admission (continued )
Detail from surgical procedure LASH (maximum N= 309) EA (maximum N= 307)
Postoperative analgesia, n/N (%)
Paracetamol/ibuprofen 269/309 (87.1) 226/307 (73.6)
Oral opiate 136/309 (44.0) 72/307 (23.4)
Opiate injection 94/309 (30.4) 46/307 (15.0)
Hours from operation to discharge, median (IQR) [n] 21.5 (17.0–26.1) [306] 3.2 (2.1–5.1) [303]
Total number of women who stayed > 24 hours, n/N (%) 99/306 (32.4) 16/303 (5.3)
Reason for stay (if stayed > 24 hours)
Pain 30 (42) 3 (27)
Nausea/vomiting 2 (3) 1 (9)
Social/geographical 13 (18) 2 (18)
Voiding problems 14 (19) 1 (9)
Other 13 (18) 4 (36)
Not known 27 5
TED, thromboembolic-deterrent.
a Fibroids detected at baseline scan and at hysteroscopy/LASH procedure.
TABLE 6 Results for satisfaction and MMAS at 15 months post randomisation
Outcome LASH (N= 330), n (%) EA (N= 330), n (%) Adjusted OR (95% CI), p-value
Satisfaction
Total number of women 278 280 2.53 (1.83 to 3.48), p < 0.001
Totally satisfied 211 (75.9) 158 (56.4)
Generally satisfied 40 (14.4) 57 (20.4)
Fairly satisfied 19 (6.8) 29 (10.4)
Fairly/generally/totally dissatisfied 8 (2.9) 36 (12.9)
Total MMAS score
Total number of women 262 268 1.87 (1.31 to 2.67), p = 0.001
0–50 15 (5.7) 29 (10.8)
51–75 17 (6.5) 34 (12.7)
76–99 50 (19.1) 59 (22.0)
100 180 (68.7) 146 (54.5)
Notes
Analyses used OLR adjusting for age group, centre and baseline score (if applicable). ORs > 1 favour the LASH group.
The results suggest that the odds of being in a more favourable satisfaction or MMAS category were, respectively, 2.53 and
1.87 times higher in the LASH group than in the EA group.
Interpretation of a proportional OR: given four categories, A (totally satisfied), B (generally satisfied), C (fairly satisfied) and
D (dissatisfied, fairly/generally/totally), the assumption of the proportional odds model is that the effect of randomised
treatment (the proportional OR) is the same when comparing A vs. BCD, AB vs. CD, and ABC vs. D.
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The proportion of women who described themselves as satisfied with their treatment was higher in
the LASH group [LASH = 97.1% (270/278); EA = 87.1% (244/280); OR 4.89 (95% CI 1.91 to 12.45)].
Women in the LASH group were also more likely to choose the ‘totally satisfied’ category [LASH = 75.9%
(211/278); EA = 56.4% (158/280)].
This result was statistically significant in favour of LASH. In the primary analysis, OLR adjusted for age
group and centres, the odds of being in a more favourable satisfaction category were two and a half times
greater for women randomised to LASH than for women randomised to EA (OR 2.53, 95% CI 1.83 to
3.48; p < 0.001). The corresponding unadjusted result was similar (OR 2.55, 95% CI 1.79 to 3.63;
p < 0.001) (see Appendix 2, Table 30).
The OLR method assumes that the same underlying OR would be obtained for all three splits of the 2 × 4
table (the proportional odds assumption). We investigated this by examining the ORs obtained using binary
logistic regression (adjusted for age and centre) for these three splits of the data (see Appendix 2, Table 30).
The result for two of these splits was very similar to the OLR result. The results for the satisfied versus
dissatisfied split used in the individual patient data meta-analysis8 had a wider CI because of the smaller cell
counts involved, but the CIs were broadly consistent with the main result (OR 4.89, 95% CI 1.91 to 12.45).
The Brant test was also not statistically significant (p = 0.32); therefore, there was no indication that the
ordinal model was inappropriate.
There was also no difference in interpretation when considering per-protocol results (i.e. comparing those
who actually received LASH with those who actually received EA), or when considering only those
operated on by a consultant (see Appendix 2, Table 30).
It can be noted that the proportions who were satisfied (97% vs. 87%) were similar to those anticipated in
the individual patient data meta-analysis8 (95% vs. 87%). This corresponded to an adjusted difference in
proportions of 0.10 (95% CI 0.05 to 0.15) (see Appendix 2, Table 30). Although the OR from the primary
analysis (2.53) was less than the 2.84 specified as an important effect size in the original calculation, it
nonetheless represents a difference in satisfaction that can be regarded as clinically important.
MMAS scores at 15 months post randomisation
Total MMAS scores were available for 262 out of 330 (79.4%) women in the LASH group and 268 out
of 330 (81.2%) women in the EA group at 15 months post randomisation. This included MMAS scores
for two women whose 6-month data were imputed for the 15-month time point. A further 29 women
completed at least one of the six items, but were excluded from the primary analysis because a total score
could not be derived.
The total MMAS score ranges from 0 (worst possible health) to 100 (best possible health). Both groups
reported a considerable improvement in MMAS scores after surgery. At baseline, median scores were 28.6
(IQR 14.7–43.7) in the LASH group and 29 (IQR 15.7–47.7) in the EA group, but by 15 months post
randomisation the majority of women in each group had the best possible score (MMAS score = 100)
(Figure 5 and Appendix 2, Table 31).
The results for the primary analysis, OLR adjusting for age, centre and baseline MMAS, are presented in
Table 6. An OR of 1.87 (95% CI 1.31 to 2.67) was obtained, suggesting that women randomised to
receive a LASH had almost twice the odds of being in a more favourable MMAS category than women
randomised to EA (p = 0.001). The corresponding unadjusted OR was 1.90 (95% CI 1.35 to 2.68;
p < 0.001) (see Appendix 2, Table 32).
The proportional odds assumption was investigated by examining binary logistic regression models using
three splits of the data. All approaches yielded similar ORs that were consistent with the main result and
the Brant test was not statistically significant (p = 0.07). There was also no change in interpretation using a
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FIGURE 5 Total MMAS scores at (a) baseline; (b) 6 months post surgery; and (c) 15 months post randomisation.
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per-protocol analysis, when restricting analyses to those operated on by a consultant or when treating the
MMAS score as a continuous outcome (see Appendix 2, Table 32).
The mean between-group difference in MMAS scores of 6.3 points was lower than the difference of
10 points specified in the original sample size calculation. However, as the distribution of scores was highly
skewed, the median is a more appropriate summary to use, and this was 100 in each group. The 95% CI
for the effect size for the primary analysis did not include the OR of 2.84 specified in the revised sample size
calculation, but an OR of 1.87 could still be considered to have a clinically important impact on patients.
Subgroup analyses
Exploratory subgroup analyses were conducted to determine if there was evidence of differential treatment
effects for the co-primary outcomes by four binary factors: cavity length (< 8 cm vs. ≥ 8 cm), menstrual
pain at baseline (severe/crippling period pain vs. other categories), age (< 40 years vs. ≥ 40 years) and
presence or absence of fibroids.
One statistically significant interaction effect was identified. This suggested that women with fibroids who
were randomised to the LASH operation had greater than expected levels of satisfaction (OR for interaction
7.27, 95% CI 2.32 to 41.8; p = 0.002). There was no evidence of any other interaction effects (see
Appendix 2, Table 33). For the two primary outcomes, separate OLR results for the eight subgroups are
also displayed graphically, along with results by recruiting centre and by whether or not the operator was a
consultant (see Appendix 2, Figure 17). Except for the results for fibroids, each subgroup had broadly
consistent results.
Sensitivity analyses
The primary analyses were limited to those with complete 15-month follow-up data. Multiple imputation
techniques using chained equations were used to investigate the robustness of these findings.
For satisfaction at 15 months post randomisation, an OR of 2.15 (95% CI 1.53 to 3.02; p < 0.001) was
obtained using an adjusted OLR model after combining the 20 imputed data sets (see Appendix 2, Table 30).
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FIGURE 5 Total MMAS scores at (a) baseline; (b) 6 months post surgery; and (c) 15 months post randomisation.
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For MMAS score at 15 months post randomisation, an OR of 1.68 (95% CI 1.16 to 2.45; p = 0.007) was
obtained (see Appendix 2, Table 32). There was therefore no change in interpretation for either outcome
compared with the primary analysis approach.
Results for the secondary outcomes
Serious adverse events and complications
Twenty-five women experienced a SAE. One woman randomised to LASH experienced two such events,
so there were a total of 26 SAEs (15 in the LASH group and 11 in the EA group) (Table 7). There was
no statistically or clinically significant difference between the randomised groups in the proportions
experiencing a SAE (adjusted OR 1.30, 95% CI 0.56 to 3.02; p = 0.54).
In the LASH group, five women had an infection, three women were catheterised for > 72 hours, three
women experienced considerable pain, one woman had a conversion to open hysterectomy, one woman
was readmitted for investigation of shortness of breath and one woman had a bladder injury. A single
participant, whose bowel serosa was grazed at surgery, underwent prolonged admission for observation,
but did not require any treatment. One of the women in the EA group had her operation converted to
hysterectomy, five women had an infection, one woman was catheterised for > 72 hours and four women
experienced considerable pain.
TABLE 7 Serious adverse events and complications
SAE/complication LASH (N= 309), n (%) EA (N= 307), n (%)
SAEs
Any SAEa 14 (4.5) 11 (3.6)
Infection 5 (1.6) 5 (1.6)
Pain 3 (1.0) 4 (1.3)
Catheterisation for > 72 hours 3 (1.0) 1 (0.3)
Conversion to hysterectomy 1 (0.3) 1 (0.3)
Readmitted for investigation of shortness of breath 1 (0.3) 0
Prolonged admission for observation only 1 (0.3) 0
Bladder injury 1 (0.3) 0
Other complications
Voiding dysfunction 14 (4.5) 2 (0.7)
Consultation for pain 1 (0.3) 1 (0.3)
Haematoma 1 (0.3) 1 (0.3)
Blood loss > 500ml 1 (0.3) 1 (0.3)
Uterine perforation, inactive/blunt 1 (0.3) 3 (1.0)
Pyrexia requiring antibiotics 3 (1.0) 2 (0.7)
Blood transfusion 0 1 (0.3)
a Numbers refer to participants, not events. One woman in the LASH group had two AEs (infection and catheterisation);
adjusted OR for any SAE 1.30 (95% CI 0.56 to 3.02); p = 0.54.
Notes
Complication data come from two sources (operation form and hospital readmission form).
Denominators for percentages are based on all those receiving an operation.
Reproduced from Cooper et al.29 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY-NC-ND 4.0 license.
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A list of other complications from either the index operation or on subsequent hospital readmissions
associated with further treatment for HMB are provided in Table 7. A total of 32 women experienced a
complication following surgery. These included voiding dysfunction (LASH, n = 14; EA, n = 2); consultation
for pain (LASH, n = 1; EA, n = 1); haematoma (LASH, n = 1; EA, n = 1); blood loss > 500 ml (LASH, n = 1;
EA, n = 1); inactive/blunt uterine perforation (LASH, n = 1; EA, n = 3); pyrexia requiring antibiotics (LASH,
n = 3; EA, n = 2); and blood transfusion (LASH, n = 0; EA, n = 1).
Further treatment for heavy menstrual bleeding
Eighteen women randomised to EA and two women randomised to LASH received further treatment for
HMB during the follow-up period (Table 8). The most common reason was that the index EA procedure
produced an unsatisfactory reduction in HMB (n = 12). A further seven women required unplanned further
surgery because the index EA procedure could not be completed on first admission; this included one
woman who was randomised to LASH but in whom an EA procedure was attempted. On five occasions,
a hysterectomy was performed on the second admission.
Patient diary (1–14 days)
Table 34 in Appendix 2 reports data for the patient diary, which was completed in the first 14 days
following surgery. In both groups there was a reduction in self-reported levels of pain (0 = no pain,
10 = worst imaginable pain) (Figure 6) and in the proportion of women taking paracetamol or other
painkillers over these 2 weeks. In addition, fewer women were using pads for vaginal bleeding or
discharge. By day 14, 177 out of 256 (69.1%) women in the EA group and 34 out of 267 (12.7%)
women in the LASH group were using pads.
Overall, those in the LASH group had pain scores that were almost 1 point higher than those in the EA
group (mean difference 0.92, 95% CI 0.59 to 1.24; p < 0.001; see Appendix 2, Table 34).
Pain and return to usual activities (6 weeks post surgery)
By 6 weeks after surgery, over half of the women in both groups reported no pain on a 10-point scale
from 0, no pain, to 10, the worst pain imaginable (Table 9). After adjusting for the minimisation factors
(age group and centre), an OR of 1.43 (95% CI 1.05 to 1.96; p = 0.03) was obtained, suggesting that
those in the EA group had lower levels of pain at 6 weeks than those in the LASH group.
TABLE 8 Further treatment for HMB
Further treatment LASH (N= 309), n EA (N= 307), n
Total hysterectomy for failed (unsatisfactory outcome) EA 0 10
Subtotal hysterectomy for failed (unsatisfactory outcome) EA 0 2
Removal of cervical stump for cyclical pain/bleeding 1 0
Readmitted to perform total hysterectomy as EA could not be performed
on first admission
0 2
Readmitted to perform subtotal hysterectomy as EA could not be performed
on first admission
1 2
Readmitted to perform allocated procedure which could not be performed
on first admission
0 2
Total HMB treatmentsa 2 18
a Adjusted OR for further treatment for HMB 0.11, 95% CI 0.04 to 0.28 (p < 0.001).
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Figure 7 shows the time to return to work by randomised group for the women in full- or part-time paid
employment. Those in the LASH group returned to work after a median of 42 days, whereas those in
the EA group returned after a median of 10 days (see Table 9). A Cox proportional hazards regression
model adjusted for age group and centre suggested a statistically significant difference in favour of EA
[adjusted hazard ratio (HR) 0.23, 95% CI 0.18 to 0.30; p < 0.001].
Those in the EA group returned more rapidly to both unpaid work (adjusted HR 0.64, 95% CI 0.57 to 0.73;
p < 0.001) and sporting or social activities (adjusted HR 0.48, 95% CI 0.42 to 0.56; p < 0.001) (see Table 9).
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FIGURE 6 Mean pain during the first 14 days post surgery (0= no pain, 10 =worst imaginable pain).
TABLE 9 Patient outcomes and return to normal activities 6 weeks post surgery
Outcome LASH (N= 309) EA (N= 307)
Adjusted ORa (95% CI),
p-value
Level of pain today (0 = no pain,
10 = worst imaginable),
median (IQR) [range], n
0 (0–1) [0–10], 241 0 (0–1) [0–10], 234 1.43 (1.05 to 1.96),b p = 0.03
Current employment, n (%)
Full time 104 (43.7) 99 (42.1)
Part time 82 (34.5) 82 (34.9)
Not working 52 (21.8) 54 (23.0)
Adjusted HRc (95% CI),
p-value
Days until return to paid work,
median (95% CI)d [n]
42 (37 to 42) [186] 10 (7 to 14) [181] 0.23 (0.18 to 0.30),b p < 0.001
Days until return to unpaid work,
median (95% CI)d [n]
21 (17 to 25) [255] 7 (5 to 7) [251] 0.64 (0.57 to 0.73),b p < 0.001
Days until return to sporting or social
activities, median (95% CI)d [n]
42 (34 to 42) [255] 14 (14 to 18) [250] 0.48 (0.42 to 0.56),b p < 0.001
HR, hazard ratio.
a OLR using categories 0, 1–5, 6–10.
b Favours EA (p < 0.05).
c Cox regression.
d Estimated median (95% CI) from Cox regression.
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FIGURE 7 Time to return to (a) paid work; (b) unpaid work; and (c) sporting or social activities.
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Menstrual outcomes (6 months post surgery and 15 months post randomisation)
The proportion of women who continued to have periods was lower in the LASH group than in the EA
group [6 months: LASH, 39/253 (15.4%), EA, 111/246 (45.7%), adjusted OR 0.22, 95% CI 0.15 to 0.32,
p < 0.001; 15 months: LASH, 52/277 (18.8%), EA, 117/278 (42.1%), adjusted OR 0.32, 95% CI 0.21 to
0.48, p < 0.001] (Table 10).
Those in the LASH group had lighter and less painful periods, fewer days with heavy bleeding and lower
median bleeding scores and were less likely to require sanitary protection (see Table 10 and Appendix 2,
Table 35).
TABLE 10 Patient outcomes at baseline, 6 weeks and 6 months post surgery and 15 months post randomisation
Participant outcome LASH (N= 330)a EA (N= 330)b Adjusted effect size (95% CI) p-value
Are you still having periods? (6 months),c n (%)
Yes 39 (15.4) 111 (45.7) 0.22 (0.15 to 0.32)d < 0.001
No 214 (84.6) 132 (54.3)
Are you still having periods? (15 months),c n (%)
Yes 52 (18.8) 117 (42.1) 0.32 (0.21 to 0.48)d < 0.001
No 225 (81.2) 161 (57.9)
MMAS total scoree
Baseline
Mean (SD) 30.5 (19.0) 32.3 (20.0)
Median (IQR) 28.6 (14.7–43.7) 29.0 (15.7–47.7)
n 323 321
6 months
Mean (SD) 91.3 (18.1) 86.3 (21.9) 1.48 (1.02 to 2.14)d 0.04
Median (IQR) 100 (91–100) 100 (78.2–100)
n 230 224
15 months
Mean (SD) 91.2 (19.0) 84.9 (23.5) 1.87 (1.31 to 2.67)d 0.001
Median (IQR) 100 (93.3–100) 100 (77.9–100)
n 262 268
EQ-5D-3L utility scoree
Baseline
Mean (SD) 0.71 (0.30) 0.70 (0.31)
Median (IQR) 0.76 (0.66–1.00) 0.79 (0.69–1.00)
n 319 322
6 weeks
Mean (SD) 0.83 (0.22) 0.83 (0.28) 0.66 (0.48 to 0.90)f 0.009
Median (IQR) 0.88 (0.74–1.00) 1.00 (0.76–1.00)
n 251 246
6 months
Mean (SD) 0.83 (0.27) 0.83 (0.25) 1.15 (0.84 to 1.57) 0.38
Median (IQR) 1.00 (0.80–1.00) 0.85 (0.76–1.00)
n 251 237
CLINICAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
TABLE 10 Patient outcomes at baseline, 6 weeks and 6 months post surgery and 15 months post randomisation
(continued )
Participant outcome LASH (N= 330)a EA (N= 330)b Adjusted effect size (95% CI) p-value
15 months
Mean (SD) 0.84 (0.24) 0.80 (0.28) 1.21 (0.89 to 1.64) 0.23
Median (IQR) 1.00 (0.73–1.00) 0.85 (0.72–1.00)
n 281 281
EQ-5D-3L VASe
Baseline
Mean (SD) 65.2 (24.2) 67.2 (23.5)
Median (IQR) 70 (50–85) 70 (52–85)
n 317 321
6 weeks
Mean (SD) 78.4 (18.6) 76.6 (20.7) 1.12 (0.80 to 1.58) 0.51
Median (IQR) 80 (70–90) 80 (70–90)
n 248 245
6 months
Mean (SD) 79.9 (19.2) 75.9 (20.5) 1.53 (1.08 to 2.17)d 0.02
Median (IQR) 85.5 (75–90) 80 (69–90)
n 246 235
15 months
Mean (SD) 80.1 (17.6) 76.9 (19.5) 1.50 (1.12 to 1.99)d 0.006
Median (IQR) 85 (70–90) 80 (65–90)
n 279 282
SF-12 PCSg
Baseline
Mean (SD) 45.0 (9.0) 44.9 (9.7)
Median (IQR) 45.8 (39.0–52.1) 46.5 (39.0–51.9)
n 318 321
6 weeks
Mean (SD) 44.9 (10.1) 49.5 (9.6) –4.97 (–6.31 to –3.63)f < 0.001
Median (IQR) 46.4 (38.3–52.9) 52.2 (45.2–56.1)
n 249 234
6 months
Mean (SD) 53.2 (8.7) 52.4 (9.6) 0.83 (–0.70 to 2.35) 0.28
Median (IQR) 56.1 (52.1–57.8) 55.1 (50.4–58.3)
n 223 226
15 months
Mean (SD) 53.5 (8.9) 52.4 (9.0) 1.08 (–0.65 to 2.81) 0.21
Median (IQR) 56.1 (52.7–57.8) 55.1 (48.8–57.8)
n 219 216
continued
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Following EA, a higher proportion of all women (including those with no periods) experienced cyclical pain
[6 months: LASH, 68/236 (28.8%), EA, 108/199 (54.3%); 15 months: LASH, 71/224 (31.7%), EA 118/196
(60.2%)] (see Appendix 2, Table 35). Women in the LASH group generally had less pain during intercourse.
Similar proportions of women in each group had bladder problems (see Appendix 2, Table 35).
Table 36 in Appendix 2 shows results for menstrual outcomes by actual treatment received (per-protocol
analysis). The results were generally similar to those of the intention-to-treat analysis.
Quality of life (6 weeks and 6 months post surgery, 15 months post randomisation)
The quality-of-life results are presented in Table 10. An alternative presentation using categories used in
the OLR models is provided in Appendix 2, Table 37.
The results for the MMAS total score at 15 months have been described previously (see MMAS scores at
15 months post randomisation). The results for MMAS scores at 6 months showed more favourable scores
for those in the LASH group (adjusted OR 1.48, 95% CI 1.02 to 2.14; p = 0.04).
TABLE 10 Patient outcomes at baseline, 6 weeks and 6 months post surgery and 15 months post randomisation
(continued )
Participant outcome LASH (N= 330)a EA (N= 330)b Adjusted effect size (95% CI) p-value
SF-12 MCSg
Baseline
Mean (SD) 37.2 (11.0) 38.7 (11.6)
Median (IQR) 36.6 (29.8–45.1) 29.0 (15.7–47.7)
n 318 321
6 weeks
Mean (SD) 48.0 (11.2) 46.9 (11.8) 1.33 (–0.78 to 3.44) 0.21
Median (IQR) 50.7 (41.2–57.2) 49.6 (40.7–56.0)
n 249 234
6 months
Mean (SD) 48.2 (12.0) 45.4 (12.0) 3.36 (1.69 to 5.03)d < 0.001
Median (IQR) 51.5 (40.2–57.2) 48.4 (37.8–56.0)
n 223 226
15 months
Mean (SD) 48.5 (11.2) 46.6 (11.1) 2.47 (1.07 to 3.87)d 0.001
Median (IQR) 50.7 (43.3–57.1) 48.8 (38.9–55.3)
n 219 216
a Maximum n = 330 for baseline, 15 months; maximum n = 309 for 6 weeks, 6 months.
b Maximum n = 330 for baseline, 15 months; maximum n = 307 for 6 weeks, 6 months.
c Analysis method (effect size) = OR (Log Reg).
d Favours LASH (p < 0.05).
e Analysis method (effect size) = OR (OLR).
f Favours EA (p < 0.05).
g Analysis method (effect size) =MD (Lin Reg).
Notes
MMAS total score: 0 represents worst possible health and 100 represents best possible health.
EQ-5D-3L utility score: –0.59 represents worst possible QoL and 1 represents best possible QoL.
EQ-5D-3L VAS: 0 represents worst imaginable health state and 100 represents best possible health state.
SF-12 PCS and MCS: 0 represents worst possible QoL and 100 represents best possible QoL.
Analyses used OLR adjusting for age group, centre and baseline score (if applicable).
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At 6 weeks post surgery, those in the EA group had higher EQ-5D-3L utility scores than those in the
LASH group (adjusted OR 0.66, 95% CI 0.48 to 0.90; p = 0.009). However, at 6 months post surgery
and 15 months post randomisation, the point estimates favoured LASH, although the results were not
statistically significant (6 months: adjusted OR 1.15, 95% CI 0.84 to 1.57, p = 0.38; 15 months: adjusted
OR 1.21, 95% CI 0.89 to 1.64, p = 0.23).
The results for the VAS score of the EQ-5D-3L tended to favour the LASH group, and this finding was
statistically significant at 6 months post surgery and 15 months post randomisation (6 weeks: adjusted
OR 1.12, 95% CI 0.80 to 1.58, p = 0.51; 6 months: adjusted OR 1.53, 95% CI 1.08 to 2.17, p = 0.02;
15 months: adjusted OR 1.50, 95% CI 1.12 to 1.99, p = 0.006).
In the case of the SF-12 PCS, the EA group was favoured at 6 weeks post surgery (adjusted mean
difference –4.97, 95% CI –6.31 to –3.63; p < 0.001), but there was no evidence of group differences at
6 months post surgery (adjusted mean difference 0.83, 95% CI –0.70 to 2.35; p = 0.28) or at 15 months
post randomisation (adjusted mean difference 1.08, 95% CI –0.65 to 2.81; p = 0.21). There was evidence
of improved SF-12 MCS in the LASH group at the final two time points only (6 weeks: adjusted mean
difference 1.33, 95% CI –0.78 to 3.44, p = 0.21; 6 months: adjusted mean difference 3.36, 95% CI
1.69 to 5.03, p < 0.001; 15 months: adjusted mean difference 2.47, 95% CI 1.07 to 3.87, p = 0.001).
Satisfaction and acceptability (6 weeks and 6 months post surgery, 15 months post
randomisation)
Women receiving treatment were asked questions about the acceptability of treatment (6 weeks post
surgery) and satisfaction with treatment (6 months post surgery) (Table 11). Both these results favoured
LASH (acceptability of treatment at 6 weeks: adjusted OR 4.73, 95% CI 2.86 to 7.81, p < 0.001;
satisfaction with treatment at 6 months: adjusted OR 2.91, 95% CI 2.04 to 4.16, p < 0.001).
Women were also asked at 6 months post surgery and 15 months post randomisation whether or not they
agreed that they would recommend their treatment to a friend. Over 85% of women in each group agreed
that they would, but at both time points there was strong evidence in favour of the LASH group (6 months:
adjusted OR 4.49, 95% CI 2.44 to 8.27, p < 0.001; 15 months: adjusted OR 4.52, 95% CI 2.14 to 9.53,
p < 0.001) (see Table 11).
Summary of the clinical effectiveness results
Table 38 in Appendix 2 provides a summary of the primary and secondary analyses, including both
adjusted and unadjusted effect sizes for all outcomes as follows: mean differences for continuous
outcomes; both ORs and risk differences for binary outcomes (i.e. both relative and absolute effect sizes);
ORs for ordered categorical outcomes and HRs for time-to-event outcomes. Adjusted analyses include
the minimisation factors, age group and centre (random effect), in the model, as well as a baseline score,
if this is available.
The results of the unadjusted analyses tended to be similar to those of the adjusted analyses.
Using a threshold of a p-value of < 0.05, there was evidence that those randomised to EA had lower levels
of pain in the first 6 weeks following treatment. In addition, those randomised to EA also had improved
EQ-5D-3L utility scores and SF-12 PCSs at 6 weeks, but there was no evidence of a difference between
groups at later time points. Women in the EA group also returned to work and usual activities sooner than
those in the LASH group.
Most self-reported outcomes at the 6 months post surgery and 15 months post-randomisation time points
tended to favour LASH. There was evidence that women in the LASH group had better QoL outcomes and
were more satisfied with their treatment than those in the EA group.
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The results of both co-primary outcomes (satisfaction and MMAS score at 15 months post randomisation),
both strongly favoured those in the LASH group. The results of the secondary outcomes should be treated
as exploratory because no adjustment was made for multiple statistical testing. There is, however, a
pattern suggesting greater short-term benefits for EA but longer-term improvements in patient-reported
outcomes for the LASH group. In particular, LASH was strongly favoured for all the questions concerning
acceptability, satisfaction and recommendation to a friend.
TABLE 11 Patient outcomes at 6 months post surgery and 15 months post randomisation
Participant outcome
Analysis method
(effect size)
LASH (N= 330),
n (%)a
EA (N= 330),
n (%)b
Adjusted effect
size (95% CI) p-value
Acceptability of treatment
Totally acceptable OR (OLR) 205 (84.4) 130 (54.9) 4.73 (2.86 to 7.81)c < 0.001
Generally acceptable 30 (12.3) 53 (22.4)
Fairly acceptable 6 (2.5) 37 (15.6)
Fairly unacceptable 2 (0.1) 7 (3.0)
Generally unacceptable 0 4 (1.7)
Totally unacceptable 0 6 (2.5)
Satisfaction with treatment (6 months)
Totally satisfied OR (OLR) 181 (73.9) 123 (51.3) 2.91 (2.04 to 4.16)c < 0.001
Generally satisfied 46 (18.8) 52 (21.7)
Fairly satisfied 9 (3.7) 33 (13.8)
Fairly unsatisfied 3 (1.2) 9 (3.8)
Generally unsatisfied 1 (0.4) 10 (4.2)
Totally unsatisfied 5 (2.0) 13 (5.4)
Satisfaction with treatment (15 months)
Totally satisfied OR (OLR) 211 (75.9) 158 (56.4) 2.53 (1.83 to 3.48)c < 0.001
Generally satisfied 40 (14.4) 57 (20.4)
Fairly satisfied 19 (6.8) 29 (10.4)
Fairly unsatisfied 2 (0.7) 9 (3.2)
Generally unsatisfied 1 (0.4) 15 (5.4)
Totally unsatisfied 5 (1.8) 12 (4.3)
Recommend treatment to friend? (6 months)
Yes OR (Log Reg) 245 (96.5) 208 (85.6) 4.49 (2.44 to 8.27)c < 0.001
No 9 (3.5) 35 (14.4)
Recommend treatment to friend? (15 months)
Yes OR (Log Reg) 263 (97.0) 246 (87.9) 4.52 (2.14 to 9.53)c < 0.001
No 8 (3.0) 34 (12.1)
Log Reg, logistic regression.
a Maximum n = 330 for baseline, 15 months; maximum n = 309 for 6 months.
b Maximum n = 330 for baseline, 15 months; maximum n = 307 for 6 months.
c Favours LASH (p < 0.05).
Note
Analyses used OLR, adjusting for age group, centre and baseline score (if applicable).
Co-primary outcome is highlighted in bold.
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Chapter 5 Economic evaluation: within-trial
analysis
Introduction
This chapter reports on the within-trial economic evaluation of LASH compared with second-generation
EA.1 The rationale for the economic evaluation in health care is to help inform the adoption of technologies
that provide good value for money in the context of constrained health service resources. The within-trial
economic analysis reported in this chapter considers the 15-month post-randomisation follow-up period
only. As the full impact of the alternative interventions on resource use and individuals’ HRQoL is likely to
accrue over a much longer time horizon, a Markov model was also developed to extrapolate the trial-based
findings. This model-based economic analysis is reported in Chapter 6 and constitutes the primary economic
analysis for HEALTH.
Objectives of the economic evaluation
The primary economic objective of the within-trial cost-effectiveness analysis was to estimate the
incremental cost per QALY gained for LASH compared with EA at 15 months post randomisation. Two of
the three secondary economic objectives are addressed in the current chapter: (1) to compare the costs
and consequences of LASH and EA at 15 months; and (2) to assess the wider societal costs associated
with changes in productivity. The third secondary economic objective of modelling the longer-term
cost-effectiveness of LASH compared with EA is addressed in Chapter 6.
Methods
Study design and participants
Details of the trial design are provided in the study protocol1 and in Chapter 2. The economic analysis was
based on all women randomised, with the exception of four post-randomisation exclusions, and follows
the same intention-to-treat principles as the statistical analysis.
Cost and outcome assessment
Costs and outcomes were assessed via the trial CRFs, patient diary of pain symptoms at days 1–14 post
surgery, and postal questionnaires at 6 weeks and 6 months post surgery and 15 months post randomisation
[see URL: www.journalslibrary.nihr.ac.uk/programmes/hta/123523/#/ (accessed 22 May 2019)]. Health-care
utilisation questions at 6 months post surgery and 15 months post randomisation were included for the
purpose of costing follow-up health-care resource use. The patient questionnaires also informed time taken
to return to normal activities and time off work due to ongoing/recurrent symptoms over the follow-up
period. The EQ-5D-3L and SF-12 were measured at baseline, 6 weeks and 6 months post surgery, and at
15 months post randomisation. These measures of HRQoL were used in the economic analysis for estimating
QALYs out to 15 months post randomisation.
Assessment of health service costs
As the economic evaluation seeks to inform the efficient allocation of the NHS budget, the base-case
analysis adopted a health service perspective. Nevertheless, the effect of incorporating patient productivity
costs was also considered as a secondary analysis.
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Cost of the primary interventions
The unit costs used for the valuation of health service resource use are reported in Table 12. The costs of
the initial HEALTH interventions were estimated from resource use data recorded in the HEALTH operation
form for each participant. In addition to the date and time of admission and operation, this CRF captured
the type of procedure carried out, time in theatre, grade of surgeon, time in recovery, postoperative
analgesic requirements, perioperative complications and time to discharge at the individual patient level
[see URL: www.journalslibrary.nihr.ac.uk/programmes/hta/123523/#/ (accessed 22 May 2019)].
TABLE 12 Unit costs (NHS perspective)
Resource How measured
Source of
measurement Unit cost (£) Source of valuation
Time in anaesthetic
room
Time in hours HEALTH operation
form
151 per hour Band 6 nurse
(£45) + consultant
anaesthetist (£106);
Unit Costs of Health
and Social Care 201730
Time in theatre Time in hours HEALTH operation
form
Surgeon time Unit Costs of Health
and Social Care 201730
Consultant 107 per hour
Associate specialist 101 per hour
Registrar 43 per hour
Foundation FY2 30 per hour
Foundation FY3 26 per hour
Nurse consultant 62 per hour
Anaesthetist time,
consultant
106 per hour Unit Costs of Health
and Social Care 201730
Theatre costs
(excluding medical
and nursing staff)
596 per hour Table R140; Information
Services Division31
Procedure consumables
LASH (morcellator
and loop package)
See Cost of the primary
interventions
Clinical advice Commercial-in-
confidence
information
Kebomed UK,
14 May 2018,
personal communication
LASH haemostatic
dissecting device
(e.g. Enseal™,
Ethicon, Johnson &
Johnson, Bridgewater,
NJ, USA; Ligasure™,
Medtronic plc, Dublin,
Ireland)
See Cost of the primary
interventions
Commercial-in-
confidence
information
Nicki Baxter, NHS
Grampian, 28 March
2018, personal
communication
EA (disposable
ablation kit)
See Cost of the primary
interventions
Clinical advice Commercial-in-
confidence
information
Alan Blair, Hologic,
28 March 2018,
personal communication
Perioperative
complication costs
See Costs of perioperative
complications and
readmissions
HEALTH operation
form
Various Based on recorded
reasons and procedures;
NHS Reference Costs
2016–201732
Readmissions See Costs of perioperative
complications and
readmissions
Additional hospital
admission CRFs;
patient questionnaire
Various Based on recorded
reasons and procedures;
NHS Reference Costs
2016–201732
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The primary costing approach assigned costs to these individual components of resource use to capture
patient-level variation in costs. Time in the anaesthetic room was costed using the cost per hour (incorporating
overheads) for a consultant anaesthetist and an anaesthetist nurse.30 For time in theatre, the unit costs of the
recorded grade of surgeon and a consultant anaesthetist were applied.30 Nursing staff were costed at the
requirement for gynaecology day surgery: one anaesthetic nurse, a scrub nurse and two further theatre nurses.
In addition, a published unit cost was applied for time in theatre to reflect the average cost of other staff,
supplies and consumables, and allocated capital charges and overheads.31 This detailed unit cost of theatre
time is available only for Scottish hospitals. However, the average cost per theatre hour in general hospitals
in Scotland (£1144 including medical and nursing staff) is comparable to a previously published estimate for
England (£1200 per hour).34 Therefore, the average Scottish estimate (£596 per hour, excluding medical and
nursing staff) was applied in the base-case analysis. In addition to this, we applied the unit costs of major
consumable items specific to the alternative procedures. For LASH, this includes a disposable morcellator
(LiNA Xcise™; LiNA Medical, Norcross, GA, USA), a disposable loop (LiNA Loop™; LiNA Medical, Norcross,
GA, USA) and a disposable haemostatic dissecting device. A survey of participating centres suggested that the
above consumables, or similar disposable items, were used for the majority of LASH procedures in HEALTH.
However, a small number of centres reported using a reusable morcellator and/or reusable dissecting/sealing
devices, so we also conducted a sensitivity analysis to assess the impact of removing the relevant consumable
costs from operations carried out at these centres. For EA, the cost of a disposable NovaSure™ (Hologic Inc.,
Santa Clara, CA, USA) radiofrequency ablation device was used for all procedures, as the alternative
Thermachoice thermal balloon (Ethicon, Inc., Johnson & Johnson, New Brunswick, NJ, USA) has been removed
from the market. The cost of the NovaSure™ controller has not been included as this is loaned free of charge.
With respect to preoperative care, we assumed that the procedures would have similar workup costs.
However, we did include the cost of preoperative overnight stays, which were more frequent in the
LASH arm. As histopathology is a requirement before EA and following LASH (not necessarily before
LASH) in routine practice, we assumed that these costs would balance out. We also assessed the impact
on cost-effectiveness of including an extra cost for pathology testing in the LASH arm of the model
TABLE 12 Unit costs (NHS perspective) (continued )
Resource How measured
Source of
measurement Unit cost (£) Source of valuation
Outpatient
appointments
See Costs of subsequent
health-care utilisation
Patient questionnaires
Non-admitted
face-to-face
attendance, first
appointment
155 per
attendance
NHS Reference Costs
2016–201732
Non-admitted
face-to-face
attendance,
follow-up
130 per
attendance
NHS Reference Costs
2016–201732
Primary care contacts See Costs of subsequent
health-care utilisation
Patient questionnaires
GP visits 37 per visit Unit Costs of Health
and Social Care 201730
GP home visits 45.98 per visit Unit Costs of Health
and Social Care 201730
GP phone
consultation
37 per visit Unit Costs of Health
and Social Care 201730
Medications See Costs of subsequent
health-care utilisation
Patient questionnaires Various British National
Formulary33
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presented in Chapter 6, to reflect the possibility that pathology costs following LASH may be higher than
they are prior to EA.
Time in recovery following surgery was costed using the unit cost of a grade 6 nurse (inclusive of
overheads), assuming one-to-one care. Time on the ward following recovery was costed using an estimate
of the cost per excess bed-day (transformed to an hourly rate) following EA or LASH.32
As an alternative approach to costing the initial HEALTH procedure episode, each patient record was
mapped to the appropriate Healthcare Resource Group (HRG) and costed using the relevant NHS reference
cost.32 The core HRG code for second-generation EA procedures is MA12 (Resection or Ablation Procedures
for Intra-Uterine Lesions). The core HRG code for LASH is MA08 (Major, Laparoscopic or Endoscopic, Upper
Genital Tract Procedures). The procedures were costed by applying either the day-case reference cost
(patient discharged same day) or the elective inpatient cost (stay ≥ 1 day), adjusted for length of stay using
the excess bed-day cost.
Costs of perioperative complications and readmissions
For perioperative complications leading to prolonged hospital stay, the clinical management costs were
based on the NHS reference cost for any additional procedures and adjustment for prolonged length of
stay. The information on the type of complications experienced and any procedures undertaken were
obtained from the HEALTH operation form and associated SAE forms.
Data on hospital readmissions were obtained from the ‘additional hospital admission form’ and associated
SAE forms [see URL: www.journalslibrary.nihr.ac.uk/programmes/hta/123523/#/ (accessed 22 May 2019)].
Descriptions of the reason for admission and clinical procedures conducted were used to assign a HRG-based
reference cost to each readmission.32 A hospital readmission form was triggered by patients reporting
readmissions in the questionnaire, but sites could also report these based on their own internal records.
Costs of subsequent health-care utilisation
Related primary and secondary outpatient care, incurred over the 15-month follow-up period, were obtained
from the patient questionnaires at 6 months post surgery and 15 months post randomisation. Medications
prescribed for any ongoing problems with pelvic pain, vaginal bleeding or discharge, pain at intercourse, or
any new urinary problems were also recorded in these questionnaires. All the primary care contacts were
costed using the Unit Costs of Health and Social Care 2017,30 and outpatient visits were costed using the
NHS reference cost for a gynaecology outpatient visit (see Table 12).32 For each participant, the number of
visits reported was multiplied by the appropriate unit cost. Relevant medications and quantities prescribed at
6 months post surgery and 15 months post randomisation were costed using prices recorded in the British
National Formulary.33
Indirect costs
Indirect costs, which account for time lost from productive activities, were estimated based on time taken to
return to normal activities (from the 6 weeks post-surgery questionnaire) combined with questions on work
productivity delivered at 6 months post surgery and 15 months post randomisation. The time taken away
from normal productive activities was estimated in hours and appropriate unit costs were used to estimate
the opportunity cost of time. Gross age- and sex-specific wage rates published by the Department of Work
and Pensions were used to cost time lost from paid employment.35 Time lost from unpaid work, such as
housework, was estimated using appropriate shadow prices reflecting the nature of the role. Forgone leisure
time, associated with travel to and from health-care appointments, was valued at the current value of travel
time savings available from the Department of Transport.36 The productivity questions at 6 months post
surgery and 15 months post randomisation related to the preceding 4 weeks.
In addition, the cost of any private health care falling on participants was estimated based on details
provided by participants in the 6 months post-surgery questionnaire and the 15 months post-
randomisation questionnaire.
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Outcome measures
Effectiveness for the economic evaluation was measured in terms of QALYs, estimated using the EQ-5D-3L
questionnaire, completed by participants at baseline and at 6 weeks and 6 months post surgery and 15 months
post randomisation. Participant responses were assigned a utility score based on the UK time trade-off tariff.37
For the base-case analysis, QALYs were estimated using the area under the curve approach, assuming a
baseline utility score up to the time of the index intervention and a linear change in utility between the
observed follow-up time points thereafter. The SF-12 provided an alternative source of health state utility
data via the Short Form questionnaire-6 Dimensions scoring algorithm.38 These values were used to calculate
QALYs in a sensitivity analysis.
Statistical analysis of trial economic data
Aggregating costs and effects
All cost and QoL elements were summed over the follow-up period (to 15 months post randomisation), to
estimate total costs and QALYs per participant. As the 6-month questionnaire was anchored on the date
of surgery, and the 15-month final questionnaire on randomisation date, there was a degree of overlap or
a gap between the 6-month recall periods of the questionnaires. We therefore adjusted the patient-
reported use of primary care and outpatient care to avoid double counting or undercounting, by applying
a multiplicative factor to the patient-reported resource use data at 15 months. The factor was equal to the
duration in months between the 15-month follow-up date and the 6 months post-surgery follow-up date,
divided by six. For example, if 8 months elapsed between the 15-month follow-up date and the 6 months
post-surgery follow-up date, the factor was equal to 1.333 (i.e. equal to 8/6), to account for the 2-month
gap between the recall periods. When < 6 months elapsed between the follow-up questionnaires, the
recall periods overlapped and the multiplicative factor was < 1. Cost were expressed in 2016–17 prices.
Missing data
Economic evaluations based on participant-level trial data are likely to encounter challenges with missing
data. The total estimated cost is the sum of numerous components over the observed follow-up period of
the trial. Furthermore, QALYs can be computed only when participants have responded to the relevant QoL
questionnaires at every follow-up point. Collected data allowed the estimation of total cost and total QALYs
for 57% (53% for EA, 60% for LASH) and 63% (65% for EA, 69% for LASH) of the study sample, respectively
(see Appendix 3). Reliance on complete-case data for cost-effectiveness analysis can introduce bias, unless the
data are missing completely at random. It was considered more likely that data were missing at random (i.e.
missing values can be predicted based on the observed data). Therefore, multiple imputation was implemented
as part of the within-trial analysis, using chained equations with predicted mean matching (kth-nearest
neighbour = 5) to generate 20 complete data sets with plausible fitted values assigned for missing cost and
utility elements. The imputation model for each variable included all the variables incorporated in the analysis
model, all the other cost and utility variables being imputed and one of the co-primary clinical outcome
measures (patient satisfaction) as a further auxiliary variable (see Appendix 3). Rubin’s rules were used to pool
estimates across the multiple imputation data sets.39 Missing cost data were imputed at the level of the main
cost categories at the different follow-up time points and EQ-5D data were imputed at the level of the index
score. Hospital readmission costs were assumed to be zero when no readmission form was completed. This
was done because these forms could be triggered by patient-reported readmission or by centres reporting
readmissions independently. Given the associated uncertainty with respect to rates of readmission for further
surgery in the year following surgery, the modelling reported in Chapter 6 explored the impact of applying
higher rates in year 1, derived from external sources.
Incremental cost-effectiveness analysis
The trial-based economic analysis estimated the joint difference in mean costs and QALYs between LASH
and EA (to 15 months post randomisation). GLMs with adjustment for minimisation factors (centre, age)
and baseline EQ-5D-3L score were used. A modified Park test was implemented to select an appropriate
family function. Moreover, Pearson’s correlation, Pregibon link and modified Hosmer–Lemeshow tests were
used to select the link function.40 Details of these test results are reported in Appendix 3. Based on the
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above, a Gaussian family with identity link function and a Poisson family with identity link were selected
for the cost data and QALY data, respectively. Recycled predictions were used to recover adjusted mean
values by treatment allocation group and the incremental differences between groups.40 The incremental
cost-effectiveness ratio (ICER) for LASH compared with EA was calculated as the difference in mean cost
divided by difference in mean QALYs. The variance surrounding the joint incremental costs and effects was
characterised using non-parametric bootstrapping (1000 iterations), with multiple imputation (m = 5)
nested within the bootstrap loops.41
Sensitivity analysis
Sensitivity analysis focused on the costing methodology for the initial interventions and the use of the
SF-12 as an alternative method for deriving QALYs. In addition, predefined subgroup analyses were
conducted according to uterine cavity length (≤ 8 cm vs. > 8 cm), severity of dysmenorrhoea at baseline
(severe vs. non-severe), age category at baseline (< 40 years vs. ≥ 40 years) and the presence of fibroids.
An indicator variable for the selected subgroup, and the interaction term between the selected subgroup
indicator and the treatment group indicator, were added to the base-case analysis regression model to
conduct these analyses.
Results
Resource use and costs
Table 13 summarises health service resource use and costs by intention to treat from an NHS perspective.
LASH required a substantially longer time in the anaesthetic room, theatre and recovery than EA. The
average time from entry into the anaesthetic room to arrival on the ward following recovery was almost
3 hours (178 minutes) for LASH, whereas the corresponding time for EA was approximately half of that
(90 minutes). Hospital stay on the ward following recovery was also longer for LASH (23 hours on average,
compared with 6 hours for EA). The consumed hospital resources translated into mean initial episode costs
of £2757 and £1071 for LASH and EA, respectively. The corresponding costs based on alternative HRG
costing methodology were £2774 and £1197 for LASH and EA, respectively.
In addition to the information on the initial procedure, follow-up data are reported in Table 13. Fourteen
participants had further hospital admissions in the LASH group within 15 months post randomisation,
compared with 24 participants in the EA group. Reasons for subsequent hospital admission included
abdominal pain, urinary tract infections, cervical stump removal following LASH (n = 1) and hysterectomy
following EA (n = 13). The duration of hospital readmissions was also slightly lower for LASH (1.07 days for
LASH vs. 1.13 days for EA). Average readmission costs were therefore lower for LASH than for EA (£53 vs.
£140). No major differences were observed on the average number of outpatient hospital visits or GP
contacts. The number of participants reporting prescribed medications related to the condition over the
follow-up period were low in both groups, but slightly lower in the LASH group than in the EA group
(5 women vs. 18 women).
The combined initial treatment and follow-up resource use translated into total average NHS costs of
£3004 for LASH compared with £1281 for EA, resulting in an unadjusted difference of £1722.
Utility scores and quality-adjusted life-years
Table 14 summarises the mean utility scores based on EQ-5D-3L and SF-12 responses at baseline, at
6 weeks and 6 months post surgery and at 15 months post randomisation. There was a small non-significant
difference in the EQ-5D-3L score at baseline in favour of LASH. The mean EQ-5D-3L data for LASH showed
an upwards trend from baseline until 15 months post randomisation, suggesting continued improvement in
QoL. For EA, the increase in the EQ-5D-3L from baseline was initially greater at 6 weeks compared with
LASH, but then stabilised before dropping by 15 months post randomisation. Notably, by 15 months, the
EQ-5D-3L score was higher in the LASH group than in the EA group (unadjusted difference = 0.035),
although not statistically significant.
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TABLE 13 Health service resource use and costs by treatment allocation
Variable Number of observations LASH (N= 330) EA (N= 330)
Resource use
Initial procedure, mean (SD)
Time in anaesthetic room (minutes) 643 16.4 (10.3) 10.8 (8.8)
Time in theatre (minutes) 651 90.5 (41.2) 30 (22.1)
Time in recovery (minutes) 646 70.9 (46.2) 48.6 (34.6)
Length of hospital stay on ward (hours) 647 22.9 (16.5) 6 (10)
Further follow-up
Hospital readmission, n (%) 660 14 (4.2) 24 (6.4)
Readmission length of stay (days), mean (SD) 38 1.07 (1.1) 1.13 (1.2)
Number of outpatient visits, mean (SD) 395 0.32 (1) 0.29 (0.9)
Number of GP contacts
Face-to-face visits, mean (SD) 391 0.89 (2.2) 0.87 (1.7)
Telephone consultations, mean (SD) 391 0.01 (0.1) 0.01 (0.1)
Home visits, mean (SD) 391 0.17 (0.6) 0.22 (0.7)
Medication prescribed, n (%) 391 5 (2.4) 18 (9.7)
Costs: initial surgical episode cost, mean (SD)
Primary analysis (microcosting) 639 2757 (1030) 1071 (617)
HRG-based estimates 660 2774 (906) 1197 (539)
Readmission costs for further treatment (£) 660 53 (309) 140 (662)
Outpatient costs (£) 393 33 (85) 30 (79)
Primary care costs (£) 391 40 (96) 40 (77)
Medication costs (£) 391 0.04 (0.3) 1.38 (7)
Total NHS cost (£) 374 3004 (725) 1281 (668)
TABLE 14 Health state utility scores by treatment allocation
Variable Number of observations LASH (N= 330) EA (N= 330)
EQ-5D-3L, mean (SD)
Baseline 641 0.7065 (0.30) 0.6983 (0.31)
6 weeks post surgery 497 0.8279 (0.22) 0.8282 (0.28)
6 months post surgery 488 0.8315 (0.27) 0.8269 (0.25)
15 months post randomisation 562 0.8357 (0.24) 0.8005 (0.28)
SF-12, mean (SD)
Baseline 568 0.6174 (0.12) 0.6249 (0.14)
6 weeks post surgery 345 0.6762 (0.14) 0.7506 (0.16)
6 months post surgery 412 0.8036 (0.14) 0.7757 (0.15)
15 months post randomisation 405 0.8094 (0.14) 0.7818 (0.14)
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Baseline utility scores obtained from the SF-12 were slightly higher for EA than for LASH. Data from
both study groups show a persistent improvement in utility scores from baseline until the end of follow-up.
However, the substantially lower response rate on this secondary economic outcome measure is notable.
Cost–utility analysis results
The incremental analysis was conducted using the multiple imputation data set and is presented in Table 15.
The adjusted mean costs per participant were £2886 and £1282 for LASH and EA, respectively, producing
an adjusted difference of £1604. The average cost difference resulting from the imputed data was slightly
narrower than the unadjusted difference based on complete data (see Table 13). The mean adjusted QALYs
per participant were 0.978 and 0.974 for LASH and EA, respectively, giving an adjusted QALY difference of
0.004 in favour of LASH.
Therefore, intention to treat with LASH resulted in significantly higher mean costs and a slight non-
significant QALY gain compared with EA at 15 months post randomisation. The ICER for LASH compared
with EA came to £458,334 per QALY gained over this relatively short time horizon. Although the EQ-5D-3L
health state utility was higher in the LASH group by 15 months post randomisation, the mean QALYs
accruing over 15 months remained very similar between groups owing to the earlier improvement in
HRQoL with EA than with LASH.
Figure 8 shows the scatterplot of the difference in mean costs and difference in mean QALYs based on the
1000 bootstrapped iterations of the regression analysis with nested multiple imputation. LASH was clearly
TABLE 15 Trial-based incremental cost-effectiveness analysis (base case; NHS perspective; 15 months post
randomisation)
Intervention Total cost (£) Incremental cost (£)a Total QALYs Incremental QALYsa
ICER
(£/QALY gained)
EA 1282 0.974
LASH 2886 1604 0.978 0.004 458,334
a Differences adjusted by study minimisation variables.
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FIGURE 8 Trial-based incremental cost-effectiveness scatterplot for LASH vs. EA (base case; imputed data;
1000 bootstrap iterations).
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more costly, on average, than EA, as all the iterations resulted in mean cost differences that were greater
than zero. However, the mean difference in QALYs was centred on 0.004 (favouring LASH), with a
substantial proportion of the bootstrapped iterations favouring EA. Although Figure 8 shows that ≈60%
of the bootstrapped iterations generated a QALY gain favouring LASH over EA, all these points lie above
accepted cost-effectiveness thresholds,42 suggesting that LASH had little chance of being considered
cost-effective based on its incremental cost-per-QALY ratio over a 15-month time horizon. This was to be
expected, given the relatively short duration of follow-up combined with the higher initial treatment costs
for LASH and the more delayed pattern of improvement in HRQoL described above.
Sensitivity, subgroup and secondary analyses
Further to the base-case analysis, several sensitivity analyses were conducted using alternative costing
methodology and QoL instruments to estimate QALYs (Table 16). In addition, the results of the prespecified
subgroup analyses are presented in Table 17 and indirect costs are reported in Table 18. Finally, the
differences in cost are summarised in relation to the main clinical findings (cost–consequences analysis).
Alternative costing and utility instrument
Table 16 summarises the results of the key sensitivity analyses. The analysis using HRG-based reference
costs for the index procedure generates a very similar incremental cost for LASH compared with EA, and
led to the same finding as the base case, with the ICER for LASH at 15 months post randomisation being
above accepted cost-effectiveness thresholds. The sensitivity analysis results, using the SF-12 instrument to
estimate QALYs, are also reported in Table 16. The adjusted difference in QALYs was similarly very small
and in favour of LASH.
TABLE 16 Trial-based sensitivity analysis
Intervention
Total
cost (£)
Incremental
cost (£)
Total
QALYs
Incremental
QALYs
ICERa
(£)
Probability cost-effective
£13,000 £20,000 £30,000
Base-case analysis
EA 1282 0.974 1.000 1.000 1.000
LASH 2886 1604 0.978 0.004 458,334 0.000 0.000 0.000
HRG-based reference costs to cost initial surgical episode
EA 1417 0.974 1.000 1.000 1.000
LASH 2905 1488 0.978 0.004 425,229 0.000 0.000 0.000
Removal of relevant LASH consumable costs from procedures carried out using reusable equipment
EA 1280 0.974 1.000 1.000 1.000
LASH 2815 1535 0.978 0.004 438,709 0.000 0.000 0.000
QALYs based on Short Form questionnaire-6 Dimensions
EA 1282 0.921 1.000 1.000 1.000
LASH 2886 1604 0.927 0.007 239,428 0.000 0.000 0.000
a £/QALY gained.
Note
Differences adjusted by study minimisation variables.
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Subgroup analyses
The results of the prespecified subgroup analyses are reported in Table 17. The ICER for LASH compared
with EA remained unfavourable against accepted cost-effectiveness thresholds applied in the UK NHS.
In several subgroups, the estimated QALY gain favoured EA, but this may be due to the small numbers
and should be treated with caution. Moreover, all the p-values for the interaction terms between the
corresponding subgroup and treatment effect variables were > 0.05 (i.e. none of the subgroup indicators
were found to have a statistically significant effect on incremental health service costs or incremental
QALYs) (see Appendix 3, Table 45).
TABLE 17 Trial-based incremental cost-effectiveness analysis by predefined subgroups
Intervention
Total
cost (£)
Incremental
cost (£)
Total
QALYs
Incremental
QALYs ICERa (£)
Probability cost-effective
£13,000 £20,000 £30,000
Base-case analysis (full cohort)
EA 1282 0.974 1.000 1.000 1.000
LASH 2886 1604 0.978 0.004 458,334 0.000 0.000 0.000
Uterine cavity length < 8 cm
EA 1333 0.969 1.000 0.993 0.937
LASH 2876 1543 0.984 0.015 102,877 0.000 0.007 0.063
Uterine cavity length ≥ 8 cm
EA 1465 1.005 1.000 1.000 1.000
LASH 3189 1724 0.998 –0.007 Dominatedb 0.000 0.000 0.000
Severe dysmenorrhoea at baseline
EA 1295 0.954 1.000 0.997 0.969
LASH 2848 1553 0.976 0.022 72,225 0.000 0.003 0.031
Non-severe dysmenorrhoea at baseline
EA 1289 0.995 1.000 1.000 1.000
LASH 2934 1645 0.982 –0.013 Dominatedb 0.000 0.000 0.000
Fibroids present
EA 1600 1.020 0.991 0.964 0.917
LASH 3208 1608 0.989 –0.031 Dominatedb 0.009 0.036 0.083
Fibroids absent
EA 1341 0.975 1.000 1.000 0.997
LASH 3056 1714 0.992 0.017 110,249 0.000 0.000 0.003
Age < 40 years
EA 1310 0.963 1.000 0.996 0.937
LASH 2919 1609 0.982 0.020 81,277 0.000 0.004 0.063
Age ≥ 40 years
EA 1270 0.979 1.000 1.000 0.996
LASH 2873 1603 0.978 –0.001 Dominatedb 0.000 0.000 0.004
a £/QALY gained.
b Dominated means that, on average, LASH is more costly and produces fewer expected QALYs than EA.
Note
Differences adjusted by study minimisation variables.
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Indirect costs
Table 18 shows the time to return to paid work, unpaid work and leisure or social activities, reported at
6 weeks post surgery. Women in the LASH group took longer to return to all of these activities. The
productivity costs associated with time away from paid and unpaid work in the LASH group came to
£2586, compared with £990 following EA. Women in the LASH and EA groups reported similar amounts
of time away from paid and unpaid employment and leisure activities at 6 months post surgery and
15 months post randomisation (see Appendix 3, Table 45).
Data were also collected on out-of-pocket expenses and time costs associated with travel to and from
health-care appointments. There were no notable between-group differences in mean out-of-pocket
expenses (£9 and £7 for the LASH and EA, respectively) or in the value of time lost to attend outpatient
appointments (£26 and £22 for the LASH and EA, respectively).
Summary of costs and consequences
The results of the cost-effectiveness analysis focused on the ICER using generic QALYs as the unit of
effectiveness, as prespecified in the HEALTH protocol. Although the trial-based cost-effectiveness analysis
did not show any significant difference in QALYs by 15 months post randomisation, LASH was superior on
both primary outcome measures for clinical effectiveness, as well as a range of secondary outcomes. To
summarise, although LASH conferred significantly higher direct costs on the health service (+£1604) and
indirect costs on society (+£1596) over 15 months of follow-up (post randomisation), it also provided
significantly greater benefits at 15 months in terms of satisfaction with treatment, MMAS score, EQ-5D-3L
VAS score, SF-12 MCS, acceptability of treatment and willingness to recommend treatment (see Tables 10
and 11 for effect sizes). These benefits were consistent with an emerging difference in the EQ-5D-3L score
favouring LASH at 15 months. Although the difference in the EQ-5D-3L score did not reach statistical
significance by 15 months, it pointed to the need to extrapolate over a longer time horizon to adequately
inform the cost-effectiveness of LASH compared with EA.
Discussion
The within-trial cost–utility analysis reported in this chapter indicated that, over a 15-month post-
randomisation follow-up period, intention to treat with LASH resulted in increased costs to the health
service (mean difference £1604). This was mainly driven by the cost of the initial procedure, with LASH
taking twice as long to perform and resulting in a longer hospital stay than EA. Costs to society were also
increased following LASH (£1596), because women treated with LASH took longer to return to paid and
unpaid productive activities than those treated with EA. There was very little difference in QALYs between
the treatment allocation groups, assessed over 15 months from randomisation, resulting in the ICER for
LASH being unfavourable at this time point. The 15-month ICER also remained unfavourable to LASH in
all the sensitivity analyses and subgroup analyses performed.
TABLE 18 Time to return to paid or unpaid work and productivity costs (6 weeks post surgery)
Variable Number of observations LASH (N= 330) EA (N= 330)
Time to return to usual activities (number of days)
Time to return to paid work, mean (SD) 368 33.2 (11.6) 13 (11)
Time to return to unpaid work, mean (SD) 408 18.9 (12.8) 7.3 (8.7)
Time to return to leisure/social activities, mean (SD) 438 30.2 (12.3) 16.5 (13.4)
Productivity costs (£)
Cost of time lost from paid work 367 1886 (919) 719 (677)
Cost of time lost from unpaid work 408 700 (475) 271 (321)
DOI: 10.3310/hta23530 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 53
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
Strengths of the trial-based economic analysis include the availability of randomised data on resource
use and HRQoL profiles collected prospectively as part of HEALTH. This enables accurate and unbiased
estimation of mean differences in costs and QALYs over the trial follow-up period. The pragmatic design
and intention-to-treat principles also enhance the generalisability of the findings to routine practice in the
UK NHS.
The key limitation of the trial-based economic analysis relates to the relatively short duration of follow-up.
Although there was no notable difference in QALYs between the groups by 15 months post randomisation,
this time horizon was insufficient for drawing any conclusions on cost-effectiveness. The follow-up data
indicate that there were more readmissions to hospital among those randomised to EA (n = 27) than there
were among those randomised to LASH (n = 15), including 13 hysterectomies following EA compared with
only one surgical episode related to menstrual bleeding post LASH. This trend for an increased incidence of
further gynaecological surgery following EA is likely to become more pronounced in the future,10 reducing the
incremental cost of LASH and resulting in QALY gains favouring it. Furthermore, the lack of difference in
QALYs by 15 months post randomisation belied the fact that the EQ-5D-3L health state utility curves crossed
during follow-up. Those randomised to EA experienced a shorter waiting time and quicker rise in health state
utility following surgery, but then a subsequent decline in their EQ-5D-3L score by 15 months. The LASH
group, on the other hand, experienced continued improvement in their EQ-5D-3L score out to 15 months post
randomisation, by which time the mean score was higher than the EA group. As QALYs were computed as the
area under the health state utility curve, terminating follow-up at 15 months has truncated the incremental
QALY gains that would be expected to accrue to LASH if the 15-month difference in health state utility was
maintained or increased over time. It is therefore necessary to extrapolate the trial results over a longer time
horizon to inform cost-effectiveness. This is the focus of Chapter 6.
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Chapter 6 Economic modelling
Introduction
The purpose of this chapter is to report on the details of further modelling conducted to extrapolate the
trial-based cost-effectiveness findings beyond 15 months post randomisation. Although the within-trial
analysis is useful for informing differences in costs and outcomes over a relatively short time horizon, it
does not capture expected differences over the medium (2–5 years) to long term (5–10 years). Eventually
20–25% of women assigned to EA are expected to require further surgical treatment,5,9,10 resulting in
downstream QALY losses and higher readmission costs than with LASH. These anticipated costs and
consequences should be accounted for in a full economic evaluation.43 Furthermore, although there was
no significant between-group difference in QALYs observed by 15 months post randomisation in HEALTH,
the mean health state utility scores appeared to be diverging by this time point (see Chapter 5, Table 14).
Although the difference was not statistically significant, the direction of the effect in favour of LASH is
consistent with the reported superiority of LASH on the primary clinical outcomes and with the expectation
of higher repeat surgery rates in the EA group.
To estimate longer-term economic differences, a simple Markov model was developed to extrapolate the
estimated 15-month difference in utility and simulate the incidence of further gynaecological surgery over
time. The key objective of the analysis was to inform the long-term cost-effectiveness of LASH compared
with EA.1 This analysis forms the primary economic analysis of HEALTH.
Methods
Model structure
The Markov model was constructed in TreeAge Pro software (TreeAge Software, Inc., Williamstown, MA,
USA) and was informed by reviewing decision models identified in a recent systematic review that was
undertaken to inform the NICE clinical guidelines on the assessment and management of HMB.43 A
structure similar to that of other models was developed to assess the cost-effectiveness of treatments for
HMB in the UK NHS was chosen.9,10,43 The state occupancy and estimated pay-offs are updated on a
constant monthly Markov cycle.
A cohort of women with HMB enter the model in the ‘HMB’ health state and are assigned to treatment
with either EA or LASH. Women are modelled to receive treatment as observed in HEALTH by intention
to treat. However, for simplicity, index procedures are modelled to occur in the first cycle of the model,
with the waiting time factored out.
Following the index treatment in the EA arm (Figure 9), women move to either the ‘post EA’ or ‘complication
post EA’ health state. The complication health state is designed to capture the cost and utility impact of
postoperative complications resulting in readmission to hospital. These events are assumed to be transitory
and so the health state utility impact is modelled to last for one cycle (1 month). Following this, women
transit to the ‘post EA’ health state for the subsequent model cycle unless they progress to further surgery.
The transition to further surgery from the ‘post EA’ health state is modelled on a monthly basis. Although the
model has the capability to include first-generation EA (rollerball) as a second-line surgical treatment,
the base case assumes that hysterectomy is the treatment of choice for women who require further surgery
following failed second-generation EA. Repeat EA is not explicitly recommended as a treatment option in
the recently updated NICE clinical guidelines for HMB.43 For women who transition to ‘hysterectomy post
EA’, the surgical intervention occurs in the first model cycle following the transition. Following this, women
either enter a temporary health state representing severe postoperative complications, or they move to
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‘convalescence post total hysterectomy’. The convalescence period is modelled to last for 3 months, after
which all women transition to the ‘well post total hysterectomy’ health state. Finally, ‘death’ is included as an
absorbing state in the model, which can be entered from any other state based on age-specific mortality
rates reported for females in UK life tables.44
The structure of the model in the LASH arm is similar to that in the EA arm (Figure 10). However, following
index treatment women either enter a temporary health state to capture postoperative complications or
they transition to ‘convalescence post LASH’. The complication state serves the same purpose as it does
in the EA arm. The convalesce state is included to capture the longer time to full recovery observed for
LASH than for EA in HEALTH. From the post-LASH health states, a monthly probability of requiring further
related gynaecological surgery is also applied. This includes further surgery related to ongoing bleeding or
pain following LASH, specifically removal of the cervical stump, laparoscopy to investigate/treat pain and
laparoscopic bilateral salpingo-oophorectomy (BSO). Following further surgery post LASH, women enter a
post-surgical state dependent on the type of surgery received. For women who undergo cervical stump
removal, a probability of severe post-surgical complications is applied and a convalescence period of
3 months is also assumed. Following convalescence, women are assumed to be well for the remainder of
the modelled time horizon. For women who require laparoscopy for pain or laparoscopic BSO, no further
postoperative complications or convalescence period are modelled, but women attract lower health state
utility in the cycle leading up to surgery. After surgery they are also assumed to be well for the remaining
time horizon.
Well post total hysterectomy
Complication post total hysterectomy
Convalescence post total hysterectomy
Complication post repeat EA
Post repeat EA
Hysterectomy post EA
Repeat ablation (rollerball)
Complication post EA
Post EA
HMB – EA
Death
10
11
9
8
7
6
5
4
3
2
1
FIGURE 9 Simplified schematic for the EA arm of the Markov model. The transition from ‘Post EA’ to ‘Well post
total hysterectomy’ is included as a one off transition at month 12 to account for the small proportion of patients
who had a total hysterectomy instead of EA for their index treatment.
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Population
The model analysis was conducted for a cohort of women with characteristics matching those of the
HEALTH cohort (mean age equals 42 years at baseline). The estimation of input parameters for the
economic model was based on the same intention-to-treat principles applied in the HEALTH analysis. Thus,
the model reflects the fact that a number of women do not receive their intended treatment. A scenario
analysis was also conducted to assess cost-effectiveness based on the restricted cohort that received their
allocated treatment (per-protocol analysis).
Time horizon and discounting
In line with a previous UK HTA conducted by Bhattacharya et al.,10 a long-term, 10-year time horizon
was applied in the model base case. This is consistent with the average age at onset of menopause in
the UK, and observational data which shows that the incidence of subsequent hysterectomy following EA
continues to rise out to 10 years post surgery.5 The impact of adopting a medium-term time horizon of
5 years was assessed in a sensitivity analysis. Costs and QALYs accruing beyond year 1 in the model are
discounted using an annual discount rate of 3.5%.42,45
Clinical input parameters
The key clinical input parameters in the model are tabulated in Table 19. The rates of post-surgical
complications following EA and LASH were based on HEALTH data, as were the rates of subsequent
gynaecological surgery for HMB out to 1 year following index surgery. Figure 11 shows the Kaplan–Meier
(KM) plots for further gynaecological surgery by treatment arm in HEALTH (conditioned on receipt of
index surgery); the estimated 12-month probabilities were 3% in the EA arm and 0.7% in the LASH arm.
These probabilities were transformed into monthly probabilities for application over the first 12 cycles in
the model.
Well post subsequent surgery
8
Death
9
Complication post trachelectomy
7
Convalescence post trachelectomy
6
Further surgery post LASH
5
Well post LASH
4
Complication post LASH
3
Convalescence post LASH
2
HMB – LASH
1
FIGURE 10 Simplified schematic for the LASH arm of the Markov model.
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TABLE 19 Clinical input parameters applied in the model
Variable
Point
estimate
Standard
error
Distributional
form Source
Probability of readmission for
complications post EA
0.033 0.01 Beta HEALTH
OR for postoperative complications
(LASH vs. EA)
1.107 0.420 Lognormal HEALTH
Probability of hysterectomy post EA
(by 12 months)a
0.03 0.0098 Beta HEALTH
Probability of further surgery for
bleeding post LASH (by 12 months)a
0.0069 0.0049 Beta HEALTH
Probability of hysterectomy post EA
(beyond 12 months up to 10 years)
Applied and
tested
deterministically
Weibull rate parameter (λ) 0.119 Cooper et al.5
Weibull shape parameter (γ) 0.397 Cooper et al.5
Log HR for hysterectomy (second- vs.
first-generation techniques)b
–0.274 0.0532 Lognormal Bansi-Matharu et al.46
Inferred log HR for further surgery
post LASH vs. EAc
–0.4886 0.122 Lognormal Calibrated to Lieng et al.,
200817; see Extrapolation
of subsequent surgery
following laparoscopic
supracervical hysterectomy
Probability of severe complications
post hysterectomy
0.0102 0.001 Beta Maresh et al.47;
Bhattacharya et al.10
Probability of severe complications
post trachelectomy
0.0102 0.001 Beta Assumption
a Observed further surgery included hysterectomy following EA and trachelectomy following LASH.
b Applied in sensitivity analysis to adjust down the incidence of hysterectomy following EA.
c Further surgery beyond 12 months post LASH includes laparoscopic surgery to remove the cervical stump, laparoscopy to
investigate/treat pain and laparoscopic BSO.
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FIGURE 11 Kaplan–Meier plot of time from index operation to further related surgery by treatment allocation.
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Extrapolation of subsequent hysterectomy following endometrial ablation
Given what is known about the probability of hysterectomy following EA, it is anticipated that the KM
curves for time to further surgery will continue to diverge over time. In addition, as the follow-up of
HEALTH is currently truncated at 15 months post randomisation and waiting times for the index surgery
were 3–4 months on average, only 69% of women in the EA group and 56% in the LASH group were
observed to 12 months post surgery at the time of writing. Coupled with the current waiting times for
subsequent surgery among those who need it, HEALTH data do not currently give an accurate picture of
further surgery rates by treatment allocation group.
Given these limitations, external data were used to inform rates of subsequent surgery beyond 12 months
in the model. A focused search of MEDLINE was conducted to identify randomised trials comparing EA
and LASH using the Ovid interface (see Appendix 4). This identified one small RCT which included
long-term follow-up of patients. Zupi et al.48 reported that, after a mean follow-up of 14.4 years, 20 out
of 71 patients (28.1%) required a reoperation for menstrual bleeding in the EA arm of the trial, compared
with none in the LASH arm (out of 82 available for analysis). They did report that 6 out of 82 women
(7.3%) required further surgery in the LASH arm for indications other than menstrual bleeding (five requiring
a laparoscopy to investigate pain). Although this RCT provides evidence in favour of a lower rate of
subsequent related surgery following LASH, it is a small, single-centre study. Given this limitation, a further
focused literature search was undertaken to identify cohort studies reporting rates of hysterectomy following
EA or rates of cervical stump removal, laparoscopy and BSO following LASH (see Appendix 4). Priority was
placed on identifying large population-based cohort studies reporting long-term rates. This yielded three5,46,49
population-based cohort studies reporting rates of hysterectomy following EA and eight17,50–56 smaller
observational studies reporting rates of further surgery following LASH (see Appendix 4 for details).
For the probability of hysterectomy following EA, we used data from a large observational study carried
out using routine Scottish health service data. Based on linked health episode data, Cooper et al.5 reported
on 14,078 women identified as having received primary EA for HMB between 1989 and 2006 in Scotland.
Over a median duration of 6.8 years follow-up, 2779 (19.7%) women were observed to receive a
subsequent hysterectomy. Data were extracted from the published KM curve using digitising software
(WebPlotDigitizer, V4.1, 2018; URL: https://automeris.io/WebPlotDigitizer/) and regression methods were
then used to fit a Weibull distribution to the observed time-to-event data (see Appendix 5 for details).
A limitation of the study by Cooper et al.5 was an inability to discriminate between EAs carried out using
second- and first-generation techniques, and a number of studies have suggested that some second-
generation techniques may incur a lower risk of post-ablation hysterectomy.46,57 However, a very similar
rate of post-ablation hysterectomy has been reported following second-generation procedures carried out
between 1997 and 2007 in a Finnish registry study (1086/5484, 19.8%).49 The Weibull distribution fitted
to the Scottish data was therefore used in the model to derive time-dependent probabilities of transition to
hysterectomy in the EA arm (see Appendix 5 for details regarding the derivation of transition probabilities).
Sensitivity analysis was used to explore the impact of adjusting the hazard rate downwards using a HR for
radiofrequency ablation (HR 0.76, 95% CI 0.69 to 0.85), reported by Bansi-Matharu et al.46 and based on
a large English population-based cohort study. Further sensitivity analysis was also conducted to explore
the impact of using time-dependent transition probabilities for hysterectomy following EA, derived directly
from the KM curve reported by Cooper et al.5 The model projections of post-ablation hysterectomy were
compared against the 5-year rates reported by Bansi-Matharu et al.46 as means of external validation
(see Model validation).
Extrapolation of subsequent surgery following laparoscopic supracervical hysterectomy
Several studies of variable size and quality were identified to inform the risk of further surgery following
LASH (see Appendix 4). The reported incidence of post-LASH cervical stump removal ranged from 0.9% to
23%.17,50–53,58 Based on length of follow-up, consistency with the observed 12-month rate in HEALTH, and
a similar rate of post-LASH menstrual bleeding (24% vs. 19%), a Norwegian cohort reported by Lieng
et al.17 was considered the most useful for informing longer-term rates in the model (see Appendix 4 for
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details). Lieng et al.17 reported that, of 308 women undergoing LASH at a university hospital in Oslo during
2004 and 2005, six (1.9%) subsequently underwent laparoscopic adhesiolysis, seven (2.3%) underwent
laparoscopic cervical stump removal, one (0.3%) underwent BSO and eight underwent other procedures in
the 12–36 months of follow-up after LASH. The other reported procedures included laparoscopic drainage
of postoperative abscess (n = 1), laparoscopy with bowel resection for postoperative peritonitis (n = 1), scar
correction (n = 3), umbilical hernia repair (n = 1) and tension-free vaginal tape procedures (n = 2). These
procedures were not included in the model as they were considered to be either short-term postoperative
complications (included in the model based on HEALTH data) or of uncertain association with the LASH
procedure. The model was therefore calibrated to yield the combined cumulative incidence of laparoscopic
adhesiolysis, laparoscopic cervical stump removal and BSO (4.5%), reported by Lieng et al.17 by month 36.
This was done by applying a HR to the rate parameter of the Weibull distribution used to model time to
hysterectomy following EA. Thus, it is assumed that the hazard for further surgery post LASH is proportional
to the hazard of hysterectomy post EA. This approach yields a cumulative incidence of further surgery of
≈11% by 10 years post LASH in the model.
Postoperative complications following hysterectomy and removal of the cervical stump
For those women modelled to go on to receive a hysterectomy following EA, or cervical stump removal
following LASH, an associated postoperative complication rate is applied. This probability is taken from the
previous HTA study conducted by Bhattacharya et al.,10 originally sourced from Maresh et al.47 As no data
were available to inform the risk of severe postoperative complications following cervical stump removal,
the same probability of complications was applied to this procedure.
Health state utilities
The health state utilities applied in the model were derived primarily from the EQ-5D-3L data from HEALTH
(Table 20). For the first 12 months in the model, adjusted utility estimates are applied by treatment arm.
Beyond 12 months, extrapolation assumptions are applied.
Post-endometrial ablation and post-laparoscopic supracervical hysterectomy health state
utility (to 12 months)
The baseline utility estimate for women entering the model was taken as the mean baseline EQ-5D-3L
index score observed across treatment groups. Following treatment in the first cycle of the model, the
cohort is distributed between the relevant post-treatment states. In cycle 2, the cohort is dichotomised by
whether or not early postoperative complications occur. Health state utility values were therefore estimated
TABLE 20 EuroQol-5 Dimensions, three-level version-based health state utilities applied to the post-EA and
post-LASH health states
Variable EA (mean) LASH (mean) Mean difference (95% CI)
Distributional
form Source
Baseline 0.702 0.702 – Beta HEALTH
6 weeks post surgery
(no complications)
0.829 0.820 –0.009 (–0.05 to 0.032) Beta + normal
for (increment)
HEALTH
6 weeks post surgery
(postoperative
complications)
0.786 0.739 –0.047 (–0.275 to 0.182) Beta + normal
for (increment)
HEALTH
6 months post surgery
(from cycle 3)a
0.815 0.817 0.0019 (–0.041 to 0.044) Beta + normal
for (increment)
HEALTH
12 months post surgery
(from cycle 9)a
0.787 0.825 0.038 (–0.013 to 0.090) Beta + normal
for (increment)
HEALTH
a Note, utility values are reported for those remaining in the post-EA and post-LASH states, free from subsequent surgery.
All values are adjusted for baseline utility and minimisation factors using lineal regression, with adjustment for clustering
within centres.
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by treatment allocation group and the occurrence of postoperative complications resulting in readmission
to hospital. This was done by regressing the 6-week utility data on indicators for treatment allocation,
readmission for complications (yes/no) and the interaction between treatment allocation and readmission.
The regression also adjusted for baseline utility and age (< 40 years vs. ≥ 40 years) as a minimisation factor
used in the randomisation process. Ordinary least squares regression was used for the analysis of the utility
data, given the moderately large sample size, but with cluster robust standard errors.59 The method of
recycled predictions was used to recover the adjusted mean value in the base group, and the estimated
incremental effects and robust standard errors from the regression models were used to define the
distributions on effect differences in the Markov model. The analyses to inform the model utility inputs
were based on available complete data for the relevant variables.
Beyond cycle 2 in the model, those remaining in the post-EA or post-LASH health states were assigned the
corresponding treatment arm-specific 6-month utility values derived from HEALTH data. Those remaining
in the post-EA or post-LASH treatment states were then modelled to receive the relevant treatment
arm-specific 15-month utility value from cycle 9 (month 9) post surgery. This assumes that, on average,
the 15-month post-randomisation utility estimate from HEALTH corresponds to 12-month postoperative
utility, and that the change in health state utility between 6 months and 12 months post surgery is linear.
For those modelled to incur a hysterectomy following EA, or subsequent surgery post LASH, further health
state utility assumptions were applied as described below under Extrapolations of post-endometrial
ablation and post-laparoscopic supracervical hysterectomy health state utility.
Extrapolations of post-endometrial ablation and post-laparoscopic supracervical
hysterectomy health state utility
Table 20 shows that health state utility was slightly increased following EA, relative to LASH, in the short
term (6 weeks), but, by 15 months post randomisation (≈12 months post surgery), there was an emerging
difference that favoured LASH. Although this difference was not significant (p = 0.14), the direction of
effect is consistent with superior satisfaction and MMAS scores observed in the LASH group at 15 months
(see Tables 10 and 11). A lower utility value among those remaining in the post-EA health state at 12
months is also consistent with the expected higher incidence of further surgery (hysterectomy) beyond
12 months. It may reflect an increased number of women experiencing treatment failure or recurrence by
12 months post EA, who are yet to return for further surgery.
Therefore, the model extrapolated the estimated 12-month (post-surgery) between-group difference in
health state utility over an extended time horizon (Figure 12). However, it is anticipated that it will be those
women who have a poorer outcome at 12 months following EA who return in the future for a hysterectomy.
Thus, the average utility score among those remaining in the post-EA state would be expected to rise over
time. Conversely, it is possible that the recurrence of symptoms following EA has yet to peak and that the
utility curves will continue to diverge further beyond 12 months before beginning to converge. It is also
uncertain to what extent the post-EA and post-LASH utility curves may converge, and how quickly. In our
base-case analysis, we adopted a conservative approach (in favour of EA) and assumed that the mean
difference in utility between the post-EA and post-LASH health states would diminish over time in proportion
to the total expected number of post-EA hysterectomies completed. For example, from a baseline of 12 months
post surgery, 50% of the further post-EA hysterectomies will have been completed after a further 3 years, by
which time the extrapolated utility difference is approximately half of that observed at 12 months. By 10 years
in the model, the utility difference is assumed to have diminished to zero. We explored the impact of applying
alternative extrapolation assumptions in sensitivity analysis, including retention of the full 12 months
post-surgery utility difference over the entire duration of the model and allowing it to diminish over a
shorter time.
Health state utilities associated with further surgery
Regarding the heath state utility of those transitioning to hysterectomy following EA, similar assumptions
to those used in the HTA by Bhattacharya et al.10 were applied. Women were assigned the baseline utility
value of 0.702 in the cycle preceding hysterectomy. Following that, a utility value appropriate to the
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post-hysterectomy state was applied. For severe postoperative complications following hysterectomy,
a utility value of 0.49 was sourced from Bhattacharya et al.,10 originally from Clegg et al.,60 and applied for
a single cycle. For the convalescence period following hysterectomy (3 months), a utility value of 0.74 was
applied.10,61 Finally, it was assumed that health state utility in the ‘well post hysterectomy’ health state is
equivalent to that in the ‘well post LASH’ health state. Table 21 provides a summary of health state utility
inputs applied for the further surgery states.
For women requiring cervical stump removal following LASH, the same utility assumptions pertaining to
total hysterectomy were applied. For post-LASH laparoscopy or BSO, we applied baseline utility in the cycle
preceding treatment and the cycle of treatment, but then assumed a return to the ‘well post LASH’ state.
Thus, overall, the model base case assumes that, after 10 years, women ultimately end up at the same
level of health state utility, although the pathway to that outcome varies.
Health service resource use and costs
Health service costs applied in the model were informed by the analysis of HEALTH data to 12 months post
surgery. As with the analysis of health state utility data, the individual cost inputs in the economic model
were informed, where possible, by ordinary least squares regression of the relevant complete trial cost
variables in the first 12 cycles. Costs were regressed on indicators for treatment allocation and age group,
with adjustment for clustering by centre. The method of recycled predictions was used to recover the
mean adjusted costs in the base treatment group, and the estimated incremental effects and cluster robust
standard errors from the regressions were used to define distributions for the cost differences applied in
the model. The mean initial treatment cost was estimated by intention to treat and applied in the first cycle
of the model. A two-part regression model was used to estimate the probability of further admission for
postoperative complications by treatment arm and the cost of treating these complications, conditional on
readmission. The first part utilised logistic regression and the second part OLS, to estimate adjusted mean
readmission costs by treatment allocation, conditional on readmission. These postoperative complication
costs were applied in the second cycle of the model following the initial treatment episode. Subsequent
hysterectomies following EA, and cervical stump removal and further laparoscopic surgery following LASH,
were costed using the appropriate HRG-based reference costs (Table 22).32
Finally, HEALTH follow-up data were used to estimate other costs (outpatient appointments, medications
and primary care use) to the health service post LASH and post EA. These were transformed into monthly
costs for application as health state costs in the model. The post EA costs were applied to the post-EA
states, and the post-LASH costs were applied to the post-LASH and post-hysterectomy health states. These
costs were stripped of outpatient costs during the extrapolation phase of the model and a separate
outpatient referral cost was applied on transition to further surgery for those requiring it.
Values based on the analysis of HEALTH data are adjusted for baseline utility and minimisation factors
using lineal regression, with adjustment for clustering within centres.
TABLE 21 Health state utility values applied for further surgery states
Variable Mean SEM Distributional form Source
Symptomatic requiring further surgery 0.702 0.012 Beta HEALTH
Severe postoperative complication following
hysterectomy or removal of cervical stump
0.49 0.049 Beta Clegg et al.60
Convalescence post hysterectomy or removal
of cervical stump
0.74 0.05 Beta Sculpher61
Well post hysterectomy 0.827 Beta Assumption (see Health
state utilities associated
with further surgery)
SEM, standard error of the mean.
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Model validation
To assess the internal validity of the model we compared the 12-month model-based cost and QALY estimates
with the 15-month trial-based estimates. These data are provided in Table 23. Although the expected QALYs
were lower in both arms in the model, the estimated incremental difference was similarly very small. The
lower average QALY estimates are accounted for by the simplifying assumption of omitting the pre-treatment
waiting period and running the model for 12 months rather than 15 months. The mean treatment arm costs
were also very similar between the model and trial-based analyses, as was the incremental cost. The small
differences are attributable to the fact that the model was populated using the available complete data for
each input parameter, rather than the multiple imputation data set used in the trial-based analysis.
To assess the validity of projected rates of further surgery beyond 12 months, the modelled cumulative
incidence following EA and LASH was plotted over the 10-year time horizon (Figure 13). The model
TABLE 22 Health service costs applied in the model
Variable
Mean
(£) SE
Distributional
form Source
Initial hospital episode cost (EA) 1071 34.79 Gamma HEALTH
Incremental cost of initial episode (LASH) 1686 75.32 Normal HEALTH
Postoperative complication cost (EA) 854 176.81 Gamma HEALTH
Incremental cost of postoperative
complications (LASH)
194 149.47 Normal HEALTH
Hysterectomy post EA 3408 725 Gamma NHS Reference Costs 2016–201732
(HRG MA08, elective inpatient)
Removal of cervical stump post LASH 2776 704 Gamma NHS Reference Costs 2016–201732
(HRG MA03, elective inpatient)
Laparoscopic investigation for pain
(post LASH)
2482 628 Gamma NHS Reference Costs 2016–201732
(HRG MA29, average)
Laparoscopic BSO 3408 725 Gamma NHS Reference Costs 2016–201732
(HRG MA08, elective inpatient)
Post-EA monthly health state cost (first year) 5.96 0.84 Gamma HEALTH
Post-LASH monthly health state cost
(first year)
6.04 0.92 Gamma HEALTH
Post-EA monthly health state cost (> 1 year) 3.49 0.48 Gamma HEALTH
Post-LASH monthly health state cost
(> 1 year)
3.30 0.56 Gamma HEALTH
SE, standard error.
TABLE 23 Trial- and model-based estimates of mean costs and effects, at 15 months post randomisation and
12 months post surgery, respectively
Variable EA LASH Difference
Trial-based estimates
Mean cost (£) 1282 2886 1604
Mean QALY 0.974 0.978 0.004
Model-based 12-month estimates
Mean cost (£) 1277 2890 1612
Mean QALY 0.8119 0.8140 0.0021
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projected that cumulative incidence of hysterectomy following EA was 3.3%, 6.8% and 12.8% after 1,
2 and 5 years, respectively. This compares to estimates from a large population-based English study of
5.6%, 9.6% and 13.5%, respectively, at these corresponding time points.46 The incidence was lower in
the model because the lower 12-month rate from HEALTH was applied in year 1. There were few data
against which to validate the projections for further surgery following LASH. As previously discussed under
Extrapolation of subsequent surgery following laparoscopic supracervical hysterectomy, the projected
estimates are in line with the incidence observed at 12–36 months in a Norwegian cohort,17 and reach
≈11% by 10 years post surgery when combined with the extrapolation assumptions.
Model analysis
The model-based analysis utilised second-order Monte Carlo simulation to characterise the joint uncertainty
surrounding the estimated incremental costs and effects of LASH compared with EA.62 A probability
distribution was assigned to each model input parameter, reflecting the degree of uncertainty surrounding
it owing to sampling variation. The functional form and variance of each input distribution are provided in
Tables 20–23. In general, gamma distributions were used to represent uncertainty surrounding cost inputs,
beta distributions were applied for probabilities and utility parameters and lognormal distributions were
used for HRs. The probabilistic analysis was run using 10,000 random draws from the assigned input
distributions, generating 10,000 estimates of incremental costs and effects. The point estimate of the ICER
was expressed as the mean incremental cost divided by the mean incremental effect across the 10,000
iterations. Tabulated results express the probability of each treatment option being preferred on grounds
of cost-effectiveness at willingness-to-pay (WTP) thresholds of £13,000, £20,000 and £30,000 per QALY
gained.42,63 Cost-effectiveness scatterplots and acceptability curves are provided to further summarise the
uncertainty surrounding the results. Further deterministic analysis was also conducted to assess the
sensitivity of the model results to changes in key input parameters and structural assumptions.
Key assumptions
The following points summarise some of the key assumptions applied in the base-case analysis:
l Index surgery costs associated with randomisation to EA or LASH were modelled to occur in the first
cycle of the model and are estimated by intention to treat.
l Data inputs were derived entirely from HEALTH over the first 12 cycles (months) of the model. The
15 months post-randomisation utility estimates were applied as 12 months post-surgery estimates.
l The difference in health state utility between the post-EA and post-LASH health states is at its
maximum by 12 months post surgery.
l The difference in utility between the post-EA and post-LASH health state diminished over time in the
model, in proportion with the number of post-EA hysterectomies expected to have been completed.
Thus, post-EA and post-LASH health state utility converges completely by 10 years in the model.
l Health state utility in the ‘well post total hysterectomy’ state was set equal to health state utility in the
‘well post LASH’ state of the model (i.e. this assumes that those requiring a hysterectomy following EA
ultimately achieve the same level of HRQoL as those who remain well following LASH).
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FIGURE 13 Modelled incidence of further surgery following EA and LASH.
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l Beyond 12 months, the incidence of post-EA hysterectomy was based on Scottish data reported by
Cooper et al.,5 with the modelled cumulative incidence reaching 18.6% by 10 years.
l Beyond 12 months, the incidence of further related surgery following LASH (removal of the stump
and/or ovaries or laparoscopy investigation for pain) was calibrated to Norwegian data reported by
Lieng et al.17 The combined cumulative modelled incidence reaches 4.5% by 3 years and 11% by
10 years. It was assumed that all related surgery will have been completed by this time.
Results
Base-case analysis
Table 24 presents the results of the base-case analysis. Over the modelled 10-year time horizon, intention
to treat with LASH resulted in an increased cost to the health service of £1362 per woman, for an
expected QALY gain of 0.111 per woman, compared with EA. The corresponding ICER was £12,314 per
QALY gained for LASH compared with EA. The chance of LASH being cost-effective ranged from 53% to
80% at WTP per QALY thresholds of £13,000 and £30,000, respectively. It can be noted that extending
the time horizon of the evaluation from 1 year to 10 years reduced the incremental cost of LASH by £250
(£1362 at 10 years vs. £1612 at 1 year). This is due to the incorporation of expected costs of further
surgery. The QALY gain associated with LASH resulted primarily from extrapolation of the estimated
difference in 12-month post-EA and post-LASH health state utility. Further temporary reductions in utility
associated with further surgery accounted for only a very small proportion of the incremental QALY.
Figures 14 and 15 further illustrate the uncertainty surrounding the estimated incremental costs and effects
of LASH compared with EA. LASH remained the significantly more costly strategy based on extrapolation
to 10 years, with all the estimated points being above zero on the y-axis of Figure 14. Most points (≈93%)
also lie to the right of zero on the x-axis, indicating a 93% chance that LASH will generate more QALYs
based on the simulation. The cost-effectiveness acceptability curve for LASH (see Figure 15) therefore
asymptotes to 93%, as the threshold of WTP per QALY increases towards infinity. This is analogous to
finding a p-value (one-sided) of 0.07 for an estimated difference in QALYs favouring LASH.
TABLE 24 Base-case model results
Strategy Cost (£) Δ cost (£) QALYs Δ QALYs ICER (£)
Probability cost-effective
£13,000 £20,000 £30,000
EA 2089 6.938 0.468 0.291 0.201
LASH 3452 1362 7.049 0.111 12,314 0.532 0.709 0.799
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FIGURE 14 Incremental cost-effectiveness scatterplot (LASH vs. EA).
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Scenario analyses
Further scenario analyses were conducted to assess the sensitivity of the model results to changes in key
input parameters and assumptions. These included the following:
1. Running the model over a 5-year time horizon instead of a 10-year time horizon.
2. Lowering the rate of hysterectomy following EA, by applying a HR or 0.76 reported by Bansi-Matharu
et al.46 for radiofrequency ablation compared with first-generation techniques. The cumulative
incidence of hysterectomy following EA drops to 15% by 10 years in this scenario.
3. Applying a lower rate of further surgery following LASH, by assuming that all further surgery will be
complete by 5 years at a cumulative incidence of 7%.
4. Applying the estimated 12-month difference in post-EA and post-LASH utility over the entire time
horizon of the model with no convergence.
5. Capping convergence of the post-EA and post-LASH health state utility at 50% of the
12-month difference.
6. Applying total convergence of the post-EA and post-LASH health state utility by 5 years post surgery,
but retaining a 10-year time horizon.
7. Setting long-term health state utility following total hysterectomy (or removal of the cervical stump)
0.05 units higher than post-LASH health state utility.
8. Basing model input parameters on a per-protocol analysis of HEALTH data.
9. Inclusion of repeat ablation (first-generation rollerball) in the treatment pathway following failed
second-generation ablation. Under this scenario, 2.5% of the EA cohort receive repeat ablation over
the first 3 years of the model.5
10. Inclusion of a separate pathology examination cost of £31.08 to reflect possible increased pathology
costs with LASH compared with EA.31
11. Utilisation of time-dependent transition probabilities derived directly from the KM curve reported by
Cooper et al.,5 to model the incidence of hysterectomy following EA beyond month 12 in the model.
In this scenario the HR for further surgery following LASH relative to EA is recalibrated to yield the
4.5% incidence at 36 months. This results in a cumulative incidence of 8% for further surgery by
10 years following LASH.
12. Utilisation of time-dependent transition probabilities derived directly from the KM curve reported by
Cooper et al.5 to model the incidence of hysterectomy over the entire time horizon of the model (i.e.
from month 1). In this scenario the HR for further surgery following LASH relative to EA is recalibrated
to yield the 4.5% incidence at 36 months. This results in a cumulative incidence of 8% for further
surgery by 10 years following LASH.
The results of these scenario analyses are presented in Table 25. They illustrate that the ICER was most
sensitive to changes in the extrapolation assumptions applied to the 12-month difference in post-EA and
post-LASH health state utility (scenarios 5 to 6). When no convergence was applied in the model, the
QALY gain associated with LASH increased substantially and the ICER dropped to around £5000 per
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FIGURE 15 Cost-effectiveness acceptability curve (LASH vs. EA).
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TABLE 25 Selected scenario analyses
Strategy Cost
Incremental
cost (£) QALY
Incremental
QALYs ICER (£)
Probability cost-effective
£13,000 £20,000 £30,000
Base case
EA 2089 – 6.938 – – 0.468 0.291 0.201
LASH 3452 1362 7.049 0.111 12,314 0.532 0.709 0.799
Scenario 1: 5-year time horizon
EA 1759 – 3.747 – – 0.656 0.414 0.268
LASH 3205 1446 3.834 0.087 16,628 0.344 0.586 0.732
Scenario 2: lower rate of hysterectomy following EA (see Scenario analyses)
EA 1979 – 6.936 – – 0.476 0.296 0.205
LASH 3393 1414 7.050 0.114 12,429 0.524 0.704 0.795
Scenario 3: lower rate of further related surgery following LASH (see Scenario analyses)
EA 2088 – 6.936 – – 0.427 0.269 0.184
LASH 3362 1274 7.048 0.112 11,385 0.573 0.731 0.816
Scenario 4: no convergence of 12-month post-EA and post-LASH health state utility
EA 2089 – 6.794 – – 0.191 0.138 0.110
LASH 3451 1362 7.048 0.253 5377 0.809 0.862 0.890
Scenario 5: convergence of post-EA and post-LASH health state utility capped at 50% of the 12-month difference
EA 2088 – 6.894 – – 0.319 0.203 0.149
LASH 3450 1362 7.047 0.153 8907 0.681 0.797 0.851
Scenario 6: total convergence of 12-month post-EA and post-LASH health state utility by 5 years post surgery
EA 2089 – 6.989 – – 0.819 0.552 0.359
LASH 3452 1363 7.051 0.062 21,992 0.181 0.448 0.641
Scenario 7: long-term health state utility following total hysterectomy (or removal of the cervical stump) is 0.05 higher than
it is post LASH
EA 2088 – 6.986 – – 0.597 0.410 0.300
LASH 3452 1364 7.072 0.086 15,864 0.403 0.590 0.700
Scenario 8: model parameters based on per-protocol analysis of HEALTH data
EA 2093 – 6.985 – – 0.636 0.381 0.241
LASH 3677 1584 7.084 0.099 15,927 0.364 0.619 0.759
Scenario 9: include repeat ablation (first-generation rollerball) in the treatment pathway following failed second-generation
ablation
EA 2137 – 6.934 – – 0.433 0.273 0.187
LASH 3451 1315 7.048 0.114 11,544 0.567 0.727 0.813
Scenario 10: include the cost of additional pathology testing for LASH
EA 2088 – 6.938 – – 0.488 0.300 0.202
LASH 3480 1392 7.049 0.111 12,589 0.512 0.700 0.798
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additional QALY gained over EA (scenario 4). When complete convergence of the health state utility values
was modelled to occur by 5 years, the QALY gain associated with LASH was approximately halved and the
ICER increased substantially (scenario 6). The ICER also increased substantially when the model inputs were
informed by a per-protocol analysis of HEALTH (scenario 8). This was primarily due to the cost increment
being greater in this restricted population who received their allocated treatment as their index operation.
Discussion
The modelling exercise reported in this chapter indicates that intention to treat with LASH has the higher
probability of being cost-effective in the longer term across a range of plausible values of WTP per QALY
gained. The key sources of uncertainty in the model relate to the extrapolation of the observed difference
in health state utility between the post-EA and post-LASH health states, and the impact that the incidence
of further surgery will have on this parameter. The ICER for LASH ranged from as low as £5377, when the
observed 15 months post-randomisation (12 months post surgery) utility difference was maintained over
the entire time horizon of the model, to £21,992 when it was assumed to diminish to zero by 5 years post
surgery. The further collection of patient-reported outcome data and the need for subsequent surgery at
3–5 years would help to reduce this uncertainty.
A strength of the modelling is its basis on randomised data from a large multicentre and pragmatic RCT.
HEALTH utilised a detailed approach to costing the initial surgical episode and captured subsequent
complications out to 15 months post randomisation (≈12 months post surgery). However, the censoring of
patients for longer-term post-surgery health state utility is a limitation based on the trial design. Had a larger
percentage of the cohort reached a minimum of 12 months post surgery by 15 months post randomisation,
we may have observed a more marked difference in health state utility between the randomisation groups.
A further limitation relating to the duration of HEALTH was the need to rely on external non-randomised data
to inform the expected longer-term incidence of further surgery by treatment allocation group. Although
good data were available on the incidence of hysterectomy following EA, limited published data were
available to inform the incidence of subsequent surgery post LASH. Therefore, conservative assumptions
(favouring EA) were applied in the base-case analysis, with further surgery following LASH modelled to
reach ≈11% by 10 years. This is substantially higher than the long-term incidence of further gynaecological
surgery following total hysterectomy, reported to be 4% at a median duration of 11 years, based on Scottish
population data.5
TABLE 25 Selected scenario analyses (continued )
Strategy Cost
Incremental
cost (£) QALY
Incremental
QALYs ICER (£)
Probability cost-effective
£13,000 £20,000 £30,000
Scenario 11: use extracted KM data from Cooper et al.5 (1–10 years) to estimate transition probabilities for hysterectomy
post EA (beyond year 1)a
EA 2159 – 6.961 – – 0.533 0.327 0.217
LASH 3386 1227 7.050 0.089 13,774 0.467 0.673 0.783
Scenario 12: use extracted KM data from Cooper et al.5 (0–10 years) to estimate transition probabilities for hysterectomy
post EA (entire time horizon)a
EA £2364 – 6.963 – – 0.454 0.278 0.191
LASH 3386 1022 7.048 0.085 11,991 0.546 0.722 0.809
a Model recalibrated to retain cumulative incidence of further surgery post LASH of 4.5% by 36 months.
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As indicated above, the 15-month post-randomisation follow-up also necessitated the application of
assumptions to extrapolate observed differences in health state utility over time. Again, conservative
assumptions were applied, in that the observed 15-month (post-randomisation) difference in health state
utility between the post-EA and post-LASH health states was modelled to diminish to zero by 10 years.
This may underestimate the QALY gain for LASH compared with EA if the observed difference in utility at
15 months were to diverge further before converging, and/or converge less quickly over time. Nevertheless,
the QALY gain for LASH compared with EA remains uncertain as it accrued primarily during the extrapolation
phase of the model. A further uncertainty relates to the fact that the difference in health state utility observed
at 15 months post randomisation (≈12 months post surgery) was not statistically significant. This uncertainty
was propagated through the model and was reflected in the probabilistic model output. Furthermore,
the direction of the effect observed for the EQ-5D-3L score at 12 months was consistent with the observed
significant differences in the primary clinical outcomes.
Currently, no published studies have assessed the cost-effectiveness of LASH compared with EA, but several
studies have assessed the cost-effectiveness of total hysterectomy compared with EA from a UK NHS
perspective. These have generally found that hysterectomy is likely to be cost-effective.9,10,43 These previous
studies utilised a similar model structure to the one described in this chapter, but made less conservative
assumptions regarding the extrapolation of the estimated difference in post-EA and post-hysterectomy utility.
Thus, the above-mentioned studies reported a larger QALY gain for total hysterectomy compared with EA
than we report here for LASH compared with EA. Nevertheless, when applying a cost-effectiveness threshold
ratio of £20,000 per QALY gained, our results indicate a relatively high probability that LASH offers a
cost-effective alternative to EA for women with HMB. It may also prove a more acceptable alternative to
total hysterectomy in terms of risks of AEs. If applying the more recently suggested cost-effectiveness
threshold of £13,000 per QALY,63 there is greater uncertainty surrounding the cost-effectiveness of LASH.
It will therefore be important to assess the longer-term risks of subsequent surgery following LASH and
to formalise comparisons with total hysterectomy through indirect treatment comparisons and decision
modelling. The first of these issues will be addressed through extended follow-up of the HEALTH cohort.
In conclusion, the cost-effectiveness analysis based on HEALTH participant data indicates that LASH cannot
be considered cost-effective by 15 months post randomisation (≈12 months post surgery). However, based
on extrapolation over a more relevant time horizon, there is a relatively high probability that LASH offers a
cost-effective alternative to EA at thresholds of WTP per QALY gained typically applied in the UK NHS
(£20,000–30,000). Longer-term follow-up of HEALTH participants will be beneficial for reducing the
current decision uncertainty.
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Chapter 7 Discussion
Aim and overview
Heavy menstrual bleeding is a common condition that affects many women of reproductive age and
significantly impairs their QoL. For those for whom medical treatment is ineffective, NICE recommends
either EA or hysterectomy.43 In comparison with EA, total hysterectomy is a more definitive procedure but
is associated with higher surgical morbidity and slower postoperative recovery.8 Two small randomised
trials have suggested that a less invasive form of hysterectomy, LASH, is superior to EA but with similar
morbidity and recovery.12,13 Our large, pragmatic, randomised trial was designed to determine whether or
not LASH was more effective than EA without incurring additional risks or recovery time.
Our primary clinical outcomes were satisfaction and condition-specific QoL (MMAS). Additional secondary
clinical outcomes were collected along with economic end points.
Summary of findings
Primary outcomes
This large multicentre RCT showed that LASH is superior to EA in terms of the primary clinical outcomes of
satisfaction and MMAS score. The levels of improvement achieved from both LASH and EA demonstrate a
clear clinical benefit of both techniques, although the clinical outcomes following LASH are significantly
better and are comparable with outcomes obtained following total hysterectomy.8 The results of the
health economic analyses indicate that LASH cannot be considered cost-effective compared with EA at
15 months post randomisation, but it has a 70–80% chance of being considered cost-effective at accepted
cost-effectiveness thresholds (£/QALY) based on extrapolation over a 10-year time horizon.
Secondary outcomes
Both operations were associated with high rates of acceptability, but more women favoured LASH. There
was a similar reduction in cyclical pain with both procedures, favouring EA at 6 weeks post surgery but
LASH at 6 months post surgery and 15 months post randomisation. There was no change or difference in
urinary symptoms following either procedure. Most generic QoL scores favoured the EA group at 6 weeks
post surgery and LASH at 15 months post randomisation. Women who had EA were discharged more
quickly and returned to work and social activities much sooner than those who had LASH. This resulted in
EA imposing lower production costs on society in the short term (£990 vs. £2586).
Although the shorter recovery times following EA are to be expected, it was anticipated that the
resumption of social activities and return to work following LASH would occur earlier than our data
suggest. Despite making women allocated to LASH aware that there were no restrictions postoperatively,
their expectations of recovery may have been coloured by more traditional views on hysterectomy and its
required convalescence, as expressed by relatives, nurses and GPs. Patients are advised and know that they
are entitled to up to 12 weeks off work following a hysterectomy and this information needs to be revised
and based on the underlying condition, the route of procedure and other mitigating factors. It would be
worth exploring this by asking patients about the factors influencing their recovery and return to activities.
Theatre time associated with EA was almost half of that for LASH. Although surgical morbidity and
postoperative complications were comparable in both groups, women who had undergone EA needed less
pain relief after surgery and were discharged much sooner than those treated with LASH. Improvements in
immediate postoperative recovery and discharge times could probably be attained with the introduction of
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an enhanced recovery programme. Fourteen women in the EA group were readmitted for hysterectomy
(12 for total hysterectomy and two for LASH) within 15 months of randomisation.
The results of our predetermined subgroup analyses showed that the presence of fibroids was associated
with poorer outcomes following EA than following LASH. The opportunity to make a definitive diagnosis
of fibroids was greater in the LASH arm, in which visual inspection of the pelvis and uterus by laparoscopy
in addition to an initial screening ultrasound allowed small fibroids not identified at baseline scan to be
detected. It is likely, however, that the actual numbers with fibroids up to 3 cm were similar in both arms
owing to randomisation.
Strengths and limitations of the trial
To our knowledge, this was the first large randomised trial comparing LASH with EA and the first study to
undertake a cost-effectiveness analysis. The pragmatic nature of the trial and inclusion of centres across
the UK has generated results that are robust, reliable and generalisable.
The main weakness of our trial was a higher loss to follow-up than anticipated. As soon as we became
aware of this problem, we implemented a number of strategies, including cash incentives (an unconditional
£25 gift voucher issued with the first reminder) and telephone follow-up from the trial office, which enabled
us to increase our response rates from 74% to 85% for the primary outcome questionnaire.
As a surgical trial recruiting within NHS hospitals with variable waiting lists, we were unable to enforce a
standard time between randomisation and surgery. In view of the NHS waiting list target of 12 weeks for
routine operations, we chose to collect primary outcome data at 15 months post randomisation, believing
that this would give us a 12-month duration of follow-up. Although this was appropriate for most women,
a minority (10%) faced delays in receiving treatment. This occurred as a result of patient unavailability
through either illness or preference, theatre staff shortages in some centres and seasonal pressures on
elective hospital admission. However, these were balanced across the groups, although those allocated to
LASH did have to wait slightly longer for their procedures than those allocated to EA.
A strength of the economic modelling based on randomised data from a large trial was that it enabled a
detailed approach to costing of the initial surgical episode and the capture of subsequent events, including
complications. However, the censoring of patients for subsequent surgery and longer-term post-surgery
health state utility is a limitation, as is the need to rely on external non-randomised data to inform the
longer-term risk of further surgery. Although data on the incidence of hysterectomy following EA are
relatively robust, this is not currently the case for the chance of subsequent surgery post LASH.
The 15-month time horizon post randomisation also required us to make assumptions about differences in
health state utility over time. Again, conservative estimates were applied, in that the observed 15-month
(post-randomisation) difference in health state utility between the post-EA and post-LASH health states
was modelled to diminish to zero by 10 years, which may underestimate the QALY gain for LASH
compared with EA if the observed difference in utility at 15 months were to diverge further before
converging, and/or converge less quickly. Future longer-term follow-up of the HEALTH cohort would help
to reduce the current uncertainties in the economic model. As is most commonly practised in the UK NHS,
EA procedures in HEALTH were carried out in theatre as admitted patient care, the majority (95%) under
general anaesthetic. Scope may exist for cost-effectiveness to move in favour of EA if it were to prove
widely acceptable to deliver in an ambulatory outpatient setting in the NHS.
To our knowledge, no published studies assess the cost-effectiveness of LASH compared with EA, but
several studies9,10,43 have assessed the cost-effectiveness of total hysterectomy compared with EA. These
have generally found that hysterectomy is likely to be cost-effective from a UK NHS perspective.9,10,43
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Interpretation in the context of available literature
At 15 months post randomisation (approximately 12 months post surgery), our results show high levels
of satisfaction in both groups, which are similar to those reported in an individual participant data
meta-analysis of total hysterectomy compared with EA.8 The key difference between the two is that total
hysterectomy, but not LASH, guarantees amenorrhoea. In our trial, both types of surgery resulted in
high rates of patient satisfaction, but women had 2.5 times higher odds of being in a more favourable
satisfaction category following LASH without any appreciable increase in surgical or postoperative risk.
Both LASH and EA resulted in significant improvements in MMAS scores from baseline that are higher
than those reported in a previous trial evaluating medical treatment for HMB.64 Women randomised to
LASH had almost twice the odds of being in a more favourable MMAS score category, and a higher
proportion of women (69% vs. 54%) reported the maximum score of 100.
The amenorrhoea rate of 60% achieved in the EA arm of our trial is higher than reported in previous
randomised trials, in which rates of around 40% are commonly described.65 However, those women
allocated to LASH reported an amenorrhoea rate of 80%, which is lower than the 90–95% rates quoted
by a Cochrane review16 but consistent with results reported by Lieng et al.17
Women who underwent EA spent half as much time in theatre as those who underwent LASH, required
significantly less postoperative analgesia and were discharged after a median of 3 hours post procedure
(compared with 22 hours following LASH). Surgical morbidity and postoperative complications were
comparable in both groups.
Fourteen women in the EA arm were readmitted for hysterectomy within 15 months after randomisation.
Long-term hysterectomy rates of almost 20% following EA are described in population studies.5,49 Rates
for further surgery after LASH in the longer run are less well known as follow-up of only 3 years has been
reported and rates are quoted as 7% at this point.17 An English population-based study showed that 10%
of women aged > 45 years have further surgery 5 years following EA, compared with about one-third of
women aged < 35 years.46 We found no such association with age in this trial. There were poorer outcomes
following EA in women with fibroids, although more fibroids were diagnosed in the LASH arm because of
laparoscopy. There was no association with cavity length, which is at odds with a meta-analysis of trials on
second-generation EA, which found that a uterine cavity length of > 8 cm had an adverse impact on patient
satisfaction.8
A Cochrane review of total versus subtotal hysterectomy suggests a cyclical bleeding rate of 5–10%
following LASH,16 whereas a higher rate of 23% was reported by Lieng et al.17 Despite a standardised
procedure of cervical canal cautery after removal of the body of the uterus, the observed rate of cyclical
bleeding in the LASH group was 19%. This is in some way explained by the fact that, of 330 women
allocated to the LASH group, 21 women had no treatment and 11 women had EA. Even so, it seems that
our rates of post-LASH cyclical bleeding lie between those quoted by the Cochrane database16 and the
longer-term rates quoted by Lieng et al.17
The potential risk of malignancy is always an important consideration in planning conservative surgical
treatments for HMB. In EA, in which the uterus, tubes and ovaries are conserved, an endometrial biopsy
is undertaken before surgery to exclude endometrial atypia. As the cervix is retained in both techniques,
ongoing cervical screening is required in all women. The risk of cervical stump carcinoma in women with
a previously normal Pap smear is no more than 0.3%66 and is not considered to be a justification for
total over subtotal hysterectomy in countries with cervical screening programmes,16 especially where
immunisation against human papillomavirus (HPV) virus is the norm.
At the time when this trial was launched, concerns were raised by the US Food and Drug Administration
about the potential risk of disseminating cells from undiagnosed uterine malignancy associated with the use
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of morcellators during laparoscopic hysterectomy in women with fibroids.67 This prompted us to modify our
eligibility criteria to exclude women with fibroids measuring > 3 cm, as the risk of malignancy is associated
with fibroid size. The results from our trial are reassuring, as specimens from the 308 women who
underwent hysterectomy have not shown any evidence of histological atypia or malignancy. The initial
estimate of risk of 1 in 350 for unexpected/unknown malignancy within a presumed fibroid by the Food and
Drug Administration has been revised, and a recent review puts this risk figure closer to 1 in 2000.68 Updated
estimates of leiomyosarcoma (LMS) rates at hysterectomy have been published, and show that women aged
> 50 years with larger presumed fibroids are at particular risk. These are exclusion criteria for participation in
HEALTH.69 Although we have been reassured by the absence of any histological abnormalities in this trial,
continued vigilance is required, and morcellation avoided and total hysterectomy performed if there are
concerns of possible sarcomatous change within a fibroid based on morphological appearance or rapid
growth. Dissemination of morcellated material can be avoided by using containment bags, although these
have not been formally assessed. An alternative is to remove unmorcellated specimens in a bag through a
culdotomy, but this may be associated with different morbidities and also needs to be assessed. It must be
remembered that if a woman with unknown LMS has conservative treatment of her HMB, such as EA, she
continues with an unknown and untreated LMS. It is worth noting that the routine removal of fallopian
tubes during LASH could halve the subsequent risk of epithelial ovarian cancer,70 without any increase in
surgical risk.
Conclusions
Laparoscopic supracervical hysterectomy is superior to EA in terms of clinical effectiveness. EA is quicker,
cheaper and associated with an earlier discharge and shorter recovery than LASH. It is less costly in the
short term, but its higher failure rate means that LASH is more likely to be considered more cost-effective
than EA by 10 years post procedure.
DISCUSSION
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Patient data
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patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Additional information for baseline
results
TABLE 26 Participating centres
Centre recruiting LASH (N= 330), n EA (N= 330), n Total (N)
Aberdeen 77 75 152
Birmingham 39 37 76
Glasgow 23 22 45
South Tees 22 20 42
Chester 16 17 33
Forth Valley 15 16 31
Hull 14 15 29
Poole 14 14 28
North Tees 12 12 24
Cornwall 11 10 21
Northampton 9 9 18
Kilmarnock 8 9 17
Basildon 8 8 16
Winchester 7 7 14
Newcastle 6 6 12
Basingstoke 6 5 11
Sunderland 5 6 11
Edinburgh 4 5 9
Southampton 4 5 9
Preston 4 4 8
Whipps Cross 4 4 8
Surrey 3 4 7
Durham 3 4 7
Fife 4 3 7
Wirral 3 4 7
Kent 2 3 5
Plymouth 2 2 4
Worcester 2 2 4
Stockport 1 2 3
Sheffield 1 0 1
Worthing 1 0 1
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TABLE 27 Approached participants
Participant status n (%)
Screened 2552 (100.0)
l Randomised 664 (26.0)
l Not included 1888 (74.0)
Ineligible 1201 (47.1)
Patient declined 589 (23.1)
Clinical preference 98 (3.8)
TABLE 28 Reasons for non-inclusion
Reason n (%)
Ineligible 1201 (100.0)
Fibroids > 3cm 361 (30.1)
Preference to continue with medical management 244 (20.3)
Aged ≥ 50 years 239 (19.9)
Previous EA 145 (12.1)
Plans to conceive 128 (10.7)
Contraindications for laparoscopic surgery 44 (3.7)
Uterine cavity > 11cm 12 (1.0)
Unable to understand or complete study documentation 12 (1.0)
Abnormal cytology 10 (0.8)
Endometrial atypia 6 (0.5)
Eligible but patient declined randomisation/participation 589 (100.0)
Preference: EA 151 (25.6)
Preference: hysterectomy 126 (21.4)
No reason given 98 (16.6)
Preference: medical management 89 (15.1)
Patient did not want to be randomised 54 (9.2)
Unable to make contact with patient 25 (4.2)
Preference: unknown 18 (3.1)
Patient did not want to participate in research 10 (1.7)
Preference: no treatment 8 (1.4)
Personal reason 8 (1.4)
Other 2 (0.3)
Eligible but not recruited due to clinical preference/decision 98 (100)
Clinical decision 39 (39.8)
Planned hysterectomy 25 (25.5)
Planned EA 18 (18.4)
Other treatment planned 16 (16.3)
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TABLE 29 Additional participant-reported outcomes at baseline
Outcome
LASH (N= 330),
n (%)
EA (N= 330),
n (%)
Pain at intercourse?
No 106 (35.5) 120 (39.2)
Rarely 90 (30.1) 69 (22.5)
Often 81 (27.1) 87 (28.4)
Always 22 (7.4) 30 (9.8)
Not applicable 26 20
Severity of pain at intercourse
Mild 78 (41.5) 81 (42.0)
Moderate 76 (40.4) 85 (44.0)
Severe 34 (18.1) 27 (14.0)
Do you have problems with your bladder?
No 135 (41.8) 147 (45.2)
Yes, I need to dash to the toilet (urgency), but don’t leak 43 (13.3) 58 (17.8)
Yes, I need to dash to the toilet (urgency), but often don’t make it and leak 26 (8.0) 24 (7.4)
Yes, I regularly leak when I cough, sneeze or exercise 69 (21.4) 64 (19.7)
Yes, both. I have urgency and I also leak when I cough, sneeze or exercise 50 (15.5) 32 (9.8)
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Appendix 2 Additional information for
clinical results
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FIGURE 16 Days from randomisation to operation by randomised group: (a) LASH; and (b) EA.
TABLE 30 Results for satisfaction at 15 months post randomisation (LASH vs. EA) by analysis approach
Analysis approach Effect size (95% CI) p-value
OLR (primary analysis, adjusted) OR 2.53 (1.83 to 3.28) < 0.001
OLR (unadjusted) OR 2.55 (1.79 to 3.63) < 0.001
Binary logistic regression (totally satisfied vs. other, adjusted) OR 2.40 (1.77 to 3.26) < 0.001
RD 0.19 (0.13 to 0.25)
Binary logistic regression (totally/generally satisfied vs. other, adjusted) OR 2.78 (1.50 to 5.13) 0.001
RD 0.13 (0.07 to 0.20)
Binary logistic regression (satisfied vs. dissatisfied, adjusted) OR 4.89 (1.91 to 12.45) 0.001
RD 0.10 (0.05 to 0.15)
OLR (multiple imputation, adjusted) OR 2.15 (1.53 to 3.02) < 0.001
OLR (by actual treatment received, adjusted) OR 2.60 (1.91 to 3.55) < 0.001
OLR (including only those operated on by consultant, adjusted) OR 2.52 (1.74 to 3.66) < 0.001
RD, risk difference.
Notes
Adjusted: adjusted for age category and centre (random effect).
ORs > 1 favour LASH.
The primary analysis approach is highlighted in bold.
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TABLE 31 Menorrhagia Multi-Attribute Quality-of-Life Scale items by randomised group at baseline, 6 months post
surgery and 15 months post randomisation
Outcome
Item
response
Baseline 6 months post surgery
15 months post
randomisation
LASH
(n= 330),
n (%)
EA
(n= 330),
n (%)
LASH
(n= 309),
n (%)
EA
(n= 307),
n (%)
LASH
(n= 330),
n (%)
EA
(n= 330),
n (%)
Practical difficulties 1 4 (1.2) 5 (1.5) 222 (93.7) 194 (84.0) 247 (91.1) 226 (81.9)
2 70 (21.5) 65 (19.9) 5 (2.1) 14 (6.1) 11 (4.1) 30 (10.9)
3 109 (33.5) 97 (29.7) 3 (1.3) 14 (6.1) 6 (2.2) 9 (3.3)
4 142 (43.7) 160 (48.9) 7 (3.0) 9 (3.9) 7 (2.6) 11 (4.0)
NK 2 1 16 13 9 9
Social life 1 12 (3.7) 12 (3.7) 215 (90.3) 186 (80.2) 249 (92.2) 215 (77.1)
2 93 (28.6) 95 (29.1) 13 (5.5) 30 (12.9) 13 (4.8) 37 (13.3)
3 141 (43.4) 144 (44.0) 7 (2.9) 8 (3.4) 5 (1.9) 22 (7.9)
4 79 (24.3) 76 (23.2) 3 (1.3) 8 (3.4) 3 (1.1) 5 (1.8)
NK 2 1 16 12 10 6
Psychological health 1 13 (4.0) 24 (7.3) 187 (78.9) 166 (71.6) 207 (76.4) 192 (69.6)
2 128 (39.4) 124 (37.9) 37 (15.6) 48 (20.7) 48 (17.7) 50 (18.1)
3 120 (36.9) 123 (37.6) 9 (3.8) 12 (5.2) 10 (3.7) 26 (9.4)
4 64 (19.7) 56 (17.1) 4 (1.7) 6 (2.6) 6 (2.2) 8 (2.9)
NK 2 1 17 12 9 9
Physical health and
well-being
1 6 (1.8) 9 (2.8) 176 (73.9) 155 (66.8) 210 (77.8) 176 (64.0)
2 36 (11.1) 51 (15.6) 34 (14.3) 39 (16.8) 36 (13.3) 44 (16.0)
3 190 (58.5) 175 (53.7) 23 (9.7) 32 (13.8) 19 (7.0) 49 (17.8)
4 93 (28.6) 91 (27.9) 5 (2.1) 6 (2.6) 5 (1.9) 6 (2.2)
NK 2 2 16 12 10 10
Work/daily routine 1 17 (5.2) 13 (4.0) 207 (87.7) 175 (76.1) 233 (86.0) 210 (75.8)
2 83 (25.5) 91 (28.2) 21 (8.9) 36 (15.7) 27 (10.0) 42 (15.2)
3 146 (44.9) 134 (41.5) 4 (1.7) 12 (5.2) 7 (2.6) 20 (7.2)
4 79 (24.3) 85 (26.3) 4 (1.7) 7 (3.0) 4 (1.5) 5 (1.8)
NK 2 5 18 14 9 8
Family life/
relationships
1 17 (5.2) 30 (9.2) 190 (80.2) 158 (67.8) 221 (81.5) 200 (72.2)
2 106 (32.4) 111 (34.0) 40 (16.9) 55 (23.6) 38 (14.0) 54 (19.5)
3 131 (40.1) 121 (37.1) 7 (3.0) 16 (6.9) 7 (2.6) 20 (7.2)
4 73 (22.3) 64 (19.6) 0 4 (1.7) 5 (1.8) 3 (1.1)
NK 0 2 17 11 9 8
NK, not known.
Note
For each item, 1 represents the best outcome and 4 the worst; response category labels vary by item.
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TABLE 32 Results for MMAS total score at 15 months post randomisation (LASH vs. EA)
Analysis approach (MMAS split) Effect size (95% CI) p-value
OLR (primary analysis, adjusted) OR 1.87 (1.31 to 2.67) 0.001
OLR (unadjusted) OR 1.90 (1.35 to 2.68) < 0.001
Binary logistic regression (0–49.9 vs. 50–100, adjusted) OR 1.84 (1.04 to 3.25) 0.04
RD 0.04 (0.00 to 0.08)
Binary logistic regression (0–74.9 satisfied vs. 75–100, adjusted) OR 2.10 (1.35 to 3.27) 0.001
RD 0.10 (0.04 to 0.16)
Binary logistic regression (0–99.9 vs. 100, adjusted) OR 1.79 (1.18 to 2.70) 0.006
RD 0.13 (0.04 to 0.29)
OLR (multiple imputation, adjusted) OR 1.68 (1.16 to 2.45) 0.007
OLR (by actual treatment received, adjusted) OR 1.96 (1.40 to 2.77) 0.001
OLR (including only those operated on by consultant, adjusted) OR 2.19 (1.33 to 3.62) 0.002
Linear regression analysis treating MMAS as continuous (adjusted) MD 5.59 (1.93 to 9.25) 0.004
MD, mean difference; RD, risk difference.
Notes
Adjusted: adjusted for age category, centre (random effect) and baseline MMAS (continuous).
ORs > 1, RDs < 1 and MDs > 0 favour LASH.
The primary analysis approach is highlighted in bold.
TABLE 33 Subgroup analyses
Category Studied category
Satisfaction at 15 months post
randomisation
MMAS at 15 months post
randomisation
Adjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Cavity length ≥ 8 cm 0.55 (0.25 to 1.22) 0.14 0.85 (0.52 to 3.28) 0.57
Menstrual pain
at baseline
Severe/crippling pain 1.44 (0.72 to 2.89) 0.31 1.15 (0.61 to 2.20) 0.66
Age (years) ≥ 40 1.59 (0.77 to 3.29) 0.21 1.35 (0.68 to 2.68) 0.39
Fibroids Present 7.27 (2.32 to 41.8) 0.002 1.26 (0.39 to 4.10) 0.70
Notes
The table shows interaction terms (ORs and their 95% CIs) from two OLR models including interactions between the
treatment group and four binary variables. ORs represent the additional effect of being in both the LASH group and in the
studied category. Models are also adjusted for centre and baseline scores (if applicable).
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Satisfaction
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FIGURE 17 Odds ratios (95% CI) from OLR models by subgroup. For the two co-primary outcomes (satisfaction and
MMAS at 15 months post randomisation) the horizontal lines show ORs and 95% CIs from eight OLR models,
including particular subgroups of participants and adjusting for age and baseline score (if appropriate). The size of
the square is proportional to the number of women in each subgroup. The result for fibroids for the satisfaction
outcome (OR 9.85, 95% CI 3.30 to 29.34) has been truncated because of space considerations.
TABLE 34 Patient diary (1–14 days post surgery)
Outcome LASH (N= 309) EA (N= 307)
Level of pain today (0 = no pain, 10 = worst imaginable), mean (SD) [n]
Day 1 6.08 (2.35) [265] 5.13 (2.60) [257]
Day 2 5.66 (2.32) [265] 4.35 (2.61) [254]
Day 3 4.89 (2.34) [264] 3.78 (2.67) [251]
Day 4 4.33 (2.36) [263] 3.29 (2.62) [250]
Day 5 3.81 (2.34) [264] 2.97 (2.55) [251]
Day 6 3.44 (2.30) [265] 2.47 (2.41) [250]
Day 7 3.19 (2.37) [262] 2.09 (2.34) [248]
Day 8 2.89 (2.23) [259] 1.92 (2.39) [249]
Day 9 2.63 (2.22) [256] 1.72 (2.31) [245]
Day 10 2.32 (2.20) [254] 1.59 (2.26) [244]
Day 11 2.18 (2.08) [257] 1.52 (2.22) [240]
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TABLE 34 Patient diary (1–14 days post surgery) (continued )
Outcome LASH (N= 309) EA (N= 307)
Day 12 1.99 (1.98) [257] 1.31 (2.07) [245]
Day 13 1.88 (1.94) [255] 1.28 (2.12) [243]
Day 14 1.69 (1.94) [256] 1.19 (2.05) [243]
Used pads for vaginal bleeding or discharge?, n (%)
Day 1 182 (68.2) 238 (91.9)
Day 2 134 (50.2) 227 (87.6)
Day 3 80 (30.0) 206 (79.8)
Day 4 54 (20.2) 197 (77.0)
Day 5 43 (16.2) 200 (78.1)
Day 6 29 (10.9) 205 (79.5)
Day 7 36 (13.5) 200 (77.8)
Day 8 33 (12.5) 193 (75.1)
Day 9 34 (12.8) 190 (73.9)
Day 10 34 (12.9) 184 (71.9)
Day 11 33 (12.5) 181 (71.0)
Day 12 29 (10.9) 178 (69.0)
Day 13 34 (12.8) 177 (68.9)
Day 14 34 (12.7) 177 (69.1)
Took paracetamol?, n (%)
Day 1 223 (94.5) 166 (86.5)
Day 2 213 (94.7) 147 (84.0)
Day 3 195 (91.6) 128 (81.5)
Day 4 180 (89.1) 107 (74.8)
Day 5 164 (89.6) 104 (73.8)
Day 6 145 (84.8) 77 (70.6)
Day 7 138 (83.6) 69 (65.7)
Day 8 127 (80.4) 54 (57.4)
Day 9 112 (78.3) 48 (54.5)
Day 10 103 (74.6) 42 (53.8)
Day 11 92 (72.4) 40 (51.3)
Day 12 86 (68.8) 30 (44.8)
Day 13 77 (67.0) 38 (49.4)
Day 14 67 (62.0) 40 (50.6)
Took other painkillers?, n (%)
Day 1 256 (95.9) 234 (90.7)
Day 2 253 (95.1) 208 (81.3)
Day 3 235 (88.7) 174 (69.3)
continued
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TABLE 34 Patient diary (1–14 days post surgery) (continued )
Outcome LASH (N= 309) EA (N= 307)
Day 4 220 (84.0) 147 (59.3)
Day 5 195 (75.3) 138 (56.3)
Day 6 180 (67.9) 109 (44.1)
Day 7 164 (64.3) 97 (39.6)
Day 8 159 (61.2) 84 (34.1)
Day 9 139 (54.1) 82 (34.0)
Day 10 127 (49.2) 68 (27.9)
Day 11 119 (46.5) 63 (26.4)
Day 12 111 (43.0) 51 (20.7)
Day 13 102 (39.2) 56 (23.3)
Day 14 88 (34.0) 61 (25.2)
TABLE 35 Menstrual outcomes at baseline, 6 months post surgery and 15 months post randomisation
Outcome
Baseline
6 months after
surgery
15 months after
randomisation
LASH
(N= 330)
EA
(N= 330)
LASH
(N= 309)
EA
(N= 307)
LASH
(N= 330)
EA
(N= 330)
Are you still having periods?, n (%)
Yes nc nc 39 (15.4) 111 (45.7) 52 (18.8) 117 (42.1)
No nc nc 214 (84.6) 132 (54.3) 225 (81.2) 161 (57.9)
Description of period, n (%)
Light 2 (0.6) 0 27 (73.0) 56 (49.6) 35 (76.1) 56 (54.4)
Moderate 6 (1.8) 7 (2.1) 7 (18.9) 29 (25.7) 5 (10.9) 27 (26.2)
Heavy with clots 58 (17.7) 61 (18.7) 3 (8.1) 19 (16.8) 3 (6.5) 17 (16.5)
Very heavy with clots and
flooding
261 (79.8) 259 (79.2) 0 9 (8.0) 3 (6.5) 3 (2.9)
On average for how many days is the bleeding heavy?, n (%)
Not heavy 3 (0.9) 2 (0.6) 25 (67.6) 54 (47.8) 26 (57.8) 56 (54.9)
1–3 days 50 (15.3) 51 (15.6) 9 (24.3) 32 (28.3) 9 (20.0) 28 (27.5)
4–6 days 118 (36.1) 125 (38.2) 2 (5.4) 23 (20.4) 8 (17.8) 13 (12.7)
≥ 7 days 156 (47.7) 149 (45.6) 1 (2.7) 4 (3.5) 2 (4.4) 5 (4.9)
At any time in the last 3 months have you needed to use more than one form of sanitary protection at a time?, n (%)
No 27 (8.3) 25 (7.7) 15 (39.5) 30 (27.0) 19 (40.4) 25 (23.8)
Tampon and pad 117 (35.9) 118 (36.3) 15 (39.5) 29 (26.1) 14 (29.8) 32 (30.5)
Two pads 88 (27.0) 84 (25.8) 6 (15.8) 35 (31.5) 9 (19.1) 25 (23.8)
Tampon and two pads 48 (14.7) 56 (17.2) 2 (5.3) 17 (15.3) 5 (10.6) 23 (21.9)
More than this (e.g. bath
towel)
46 (14.1) 42 (12.9) 0 0 0 0
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TABLE 35 Menstrual outcomes at baseline, 6 months post surgery and 15 months post randomisation (continued )
Outcome
Baseline
6 months after
surgery
15 months after
randomisation
LASH
(N= 330)
EA
(N= 330)
LASH
(N= 309)
EA
(N= 307)
LASH
(N= 330)
EA
(N= 330)
Are your periods usually painful?, n (%)
No 19 (5.8) 18 (5.5) 42 (97.7) 89 (70.2) 41 (85.4) 88 (82.2)
Mild pain 33 (10.1) 38 (11.7) 1 (2.3) 20 (17.5) 2 (4.2) 11 (10.3)
Moderate pain 104 (31.9) 110 (33.7) 0 11 (9.6) 5 (10.4) 6 (5.6)
Severe/crippling pain 170 (52.1) 160 (49.1) 0 3 (2.6) 0 2 (1.9)
Bleeding score [0 = none
(baseline only), 1 = mild, 5 = worst
imaginable], median (IQR) [n]
3.67 (3.1–4.2)
[322]
3.5 (3.1–4.1)
[322]
1 (1–1.7)
[34]
1.75 (1–2.6)
[107]
1.25 (1–2.25)
[37]
1.67 (1–2.35)
[92]
Are you having cyclical (period like) pain?, n (%)
Yes nc nc 68 (28.8) 108 (54.3) 71 (31.7) 118 (60.2)
No nc nc 168 (71.2) 91 (45.7) 153 (68.3) 78 (39.8)
Cyclical pain score (1 = mild,
5 = worst imaginable), median
(IQR) [n]
nc nc 1.5 (1–2.3)
[58]
2 (1.4–2.8)
[107]
1.33 (1–2.3)
[62]
2 (1.33–3)
[113]
Pain at intercourse?, n (%)
No 106 (35.5) 120 (39.2) 153 (71.5) 141 (65.6) 151 (70.9) 124 (60.8)
Rarely 90 (30.1) 69 (22.5) 40 (18.7) 38 (17.7) 42 (19.7) 44 (21.6)
Often 81 (27.1) 87 (28.4) 17 (7.9) 29 (13.5) 18 (8.5) 27 (13.2)
Always 22 (7.4) 30 (9.8) 4 (1.9) 7 (3.3) 2 (0.9) 9 (4.4)
Not applicable 26 20 29 20 21 20
Severity of pain at intercourse, n (%)
Mild 78 (41.5) 81 (42.0) 44 (63.8) 42 (51.9) 39 (65.0) 46 (59.7)
Moderate 76 (40.4) 85 (44.0) 22 (31.9) 33 (40.7) 18 (30.0) 26 (33.8)
Severe 34 (18.1) 27 (14.0) 3 (4.3) 6 (7.4) 3 (5.0) 5 (6.5)
Do you have problems with your bladder?, n (%)
No 135 (41.8) 147 (45.2) 125 (50.4) 123 (51.3) 116 (50.0) 110 (49.3)
Yes, I need to dash to the
toilet (urgency), but don’t leak
43 (13.3) 58 (17.8) 29 (11.7) 30 (12.5) 21 (9.1) 21 (9.4)
Yes, I need to dash to the
toilet (urgency), but often
don’t make it and leak
26 (8.0) 24 (7.4) 24 (9.7) 24 (10.0) 18 (7.8) 22 (9.9)
Yes, I regularly leak when I
cough, sneeze or exercise
69 (21.4) 64 (19.7) 46 (18.6) 50 (20.8) 45 (19.4) 48 (21.5)
Yes, both. I have urgency and
I also leak when I cough,
sneeze or exercise
50 (15.5) 32 (9.8) 24 (9.7) 13 (5.4) 32 (13.8) 22 (9.9)
nc, not collected.
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TABLE 36 Menstrual outcomes at 15 months post randomisation by actual treatment received (per-protocol analysis)
Outcome LASH (N= 297), n (%) EA (N= 303), n (%)
Are you still having periods?
Yes 41 (16.1) 106 (40.3)
No 213 (83.9) 157 (59.7)
Description of period
Light 33 (80.5) 58 (58.6)
Moderate 4 (9.8) 24 (24.2)
Heavy with clots 2 (4.9) 14 (14.1)
Very heavy with clots and flooding 2 (4.9) 3 (3.0)
On average for how many days is the bleeding heavy?
Not heavy 25 (64.1) 55 (56.1)
1–3 days 8 (20.5) 26 (26.5)
4–6 days 4 (10.3) 12 (12.2)
≥ 7 days 2 (5.1) 5 (5.1)
At any time in the last 3 months have you needed to use more than one form of sanitary protection at a time?
No 17 (41.5) 26 (26.0)
Tampon and pad 14 (34.1) 31 (31.0)
Two pads 6 (14.6) 23 (23.0)
Tampon and two pads 4 (9.8) 20 (20.0)
More than this (e.g. bath towel) 0 0
Are your periods usually painful?
No 38 (90.5) 85 (82.5)
Mild pain 2 (4.8) 11 (10.7)
Moderate pain 2 (4.8) 5 (4.9)
Severe/crippling pain 0 2 (1.9)
TABLE 37 Quality-of-life outcomes reported using categories used in the OLR models
Outcome LASH (N= 330), n (%)a EA (N= 330), n (%)b OR (95% CI) p-value
MMAS total score (baseline)
0–50 274 (84.8) 256 (79.8)
51–75 42 (13.0) 59 (18.4)
76–99 7 (2.2) 6 (1.9)
100 0 0
MMAS total score (6 months) 1.48 (1.02 to 2.14)c 0.04
0–50 9 (3.9) 19 (8.5)
51–75 20 (8.7) 32 (14.3)
76–99 46 (20.0) 38 (17.0)
100 155 (67.4) 135 (60.3)
MMAS total score (15 months) 1.87 (1.31 to 2.67)c 0.001
0–50 15 (5.7) 29 (10.8)
51–75 17 (6.5) 34 (12.7)
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TABLE 37 Quality-of-life outcomes reported using categories used in the OLR models (continued )
Outcome LASH (N= 330), n (%)a EA (N= 330), n (%)b OR (95% CI) p-value
76–99 50 (19.1) 59 (22.0)
100 180 (68.7) 146 (54.5)
EQ-5D-3L utility score (baseline)
–0.59 to 0.49 56 (17.6) 63 (19.6)
0.5–0.99 176 (55.2) 170 (52.8)
1 87 (27.3) 89 (27.6)
EQ-5D-3L utility score (6 weeks) 0.66 (0.48 to 0.90)d 0.009
–0.59 to 0.49 14 (5.6) 23 (9.3)
0.5–0.99 129 (51.4) 88 (35.8)
1 108 (43.0) 135 (54.9)
EQ-5D-3L utility score (6 months) 1.15 (0.84 to 1.57) 0.38
–0.59 to 0.49 27 (10.8) 20 (8.4)
0.5–0.99 87 (34.7) 102 (43.0)
1 137 (54.6) 115 (48.5)
EQ-5D-3L utility score (15 months) 1.21 (0.89 to 1.64) 0.23
–0.59 to 0.49 23 (8.2) 33 (11.7)
0.5–0.99 115 (40.9) 115 (40.9)
1 143 (50.9) 133 (47.3)
EQ-5D-3L VAS (baseline)
0–50 101 (31.9) 79 (24.6)
51–75 96 (30.3) 105 (32.7)
76–100 120 (37.9) 137 (42.7)
EQ-5D-3L VAS (6 weeks) 1.12 (0.80 to 1.58) 0.51
0–50 26 (10.5) 35 (14.3)
51–75 54 (21.8) 51 (20.8)
76–100 168 (67.7) 159 (64.9)
EQ-5D-3L VAS (6 months) 1.53 (1.08 to 2.17)c 0.02
0–50 26 (10.6) 29 (12.3)
51–75 47 (19.1) 66 (28.1)
76–100 173 (70.3) 140 (59.6)
EQ-5D-3L VAS (15 months) 1.50 (1.12 to 1.99)c 0.006
0–50 29 (10.4) 46 (16.3)
51–75 51 (18.3) 57 (20.2)
76–100 199 (71.3) 179 (63.5)
a Maximum n = 330 for baseline, 15 months; maximum n = 309 for 6 weeks, 6 months.
b Maximum n = 330 for baseline, 15 months; maximum n = 307 for 6 weeks, 6 months.
c Favours LASH (p < 0.05).
d Favours EA (p < 0.05).
Notes
MMAS total score: 0 represents worst possible health and 100 represents best possible health.
EQ-5D-3L utility score: –0.59 represents worst possible QoL and 1 represents best possible QoL.
EQ-5D-3L VAS: 0 represents worst imaginable health state and 100 represents best possible health state.
SF-12 PCS and MCS: 0 represents worst possible QoL and 100 represents best possible QoL.
Analyses used OLR, adjusting for age group, centre and baseline score (if applicable).
Co-primary outcomes are highlighted in bold.
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TABLE 38 Summary of adjusted and unadjusted effect sizes (LASH vs. EA)
Outcome
Analysis
method
(effect size)
Adjusted effect size
(95% CI) p-value
Unadjusted effect
size (95% CI) p-value
AE
Any SAE Log Reg
(OR, RD)
1.30 (0.56 to 3.02),
0.01 (–0.02 to 0.04)
0.54 1.28 (0.57 to 2.87),
0.01 (–0.02 to 0.04)
0.54
Further treatment for HMB Log Reg
(OR, RD)
0.11 (0.04 to 0.28),a
–0.05 (–0.07 to –0.02)
< 0.001 0.11 (0.02 to 0.46),
–0.05 (–0.07 to –0.02)
0.003
Pain
Pain (0–10) (patient diary,
1–14 days)
RM (MD) 0.92 (0.59 to 1.24)b < 0.001 0.91 (0.58 to 1.23)b < 0.001
Level of pain (0–10) (6 weeks) OLR (OR) 1.43 (1.05 to 1.96)b 0.03 1.40 (0.96 to 2.05) 0.08
Time-to-event outcome
Time to return to paid work
(6 weeks)
Cox Reg
(HR)
0.23 (0.18 to 0.30)b < 0.001 0.24 (0.18 to 0.30)b < 0.001
Time to return to unpaid
work (6 weeks)
Cox Reg
(HR)
0.64 (0.57 to 0.73)b < 0.001 0.65 (0.54 to 0.78)b < 0.001
Time to return to sporting or
social activities (6 weeks)
Cox Reg
(HR)
0.48 (0.42 to 0.56)b < 0.001 0.49 (0.40 to 0.59)b < 0.001
Menstrual outcome
Are you still having periods?
(6 months)
Log Reg
(OR, RD)
0.22 (0.15 to 0.32),a
–0.30 (–0.37 to –0.22)
< 0.001 0.22 (0.14 to 0.33),a
–0.30 (–0.38 to –0.23)
< 0.001
Are you still having periods?
(15 months PR)
Log Reg
(OR, RD)
0.32 (0.21 to 0.48),a
–0.23 (–0.31 to –0.15)
< 0.001 0.32 (0.22 to 0.47),a
–0.23 (–0.31 to –0.16)
< 0.001
QoL outcome
MMAS (6 months) OLR (OR) 1.48 (1.02 to 2.14)a 0.04 1.49 (1.03 to 2.17)a 0.04
MMAS (15 months post
randomisation)
OLR (OR) 1.87 (1.31 to 2.67)a 0.001 1.90 (1.35 to 2.68)a < 0.001
EQ-5D-3L utility score
(6 weeks)
OLR (OR) 0.66 (0.48 to 0.90)b 0.009 0.71 (0.50 to 1.00) 0.05
EQ-5D-3L utility score
(6 months)
OLR (OR) 1.15 (0.84 to 1.57) 0.38 1.18 (0.83 to 1.66) 0.35
EQ-5D-3L utility score
(15 months post
randomisation)
OLR (OR) 1.21 (0.89 to 1.64) 0.23 1.20 (0.88 to 1.65) 0.25
EQ-5D-3L VAS (6 weeks) OLR (OR) 1.12 (0.80 to 1.58) 0.51 1.18 (0.82 to 1.70) 0.39
EQ-5D-3L VAS (6 months) OLR (OR) 1.53 (1.08 to 2.17)a 0.02 1.54 (1.06 to 2.23)a 0.02
EQ-5D-3L VAS (15 months
post randomisation)
OLR (OR) 1.50 (1.12 to 1.99)a 0.006 1.47 (1.04 to 2.08)a 0.03
SF-12 PCS (6 weeks) Lin Reg (MD) –4.97 (–6.31 to –3.63)b < 0.001 –4.58 (–6.34 to –2.81)b < 0.001
SF-12 PCS (6 months) Lin Reg (MD) 0.83 (–0.70 to 2.35) 0.28 0.83 (–0.87 to 2.53) 0.34
SF-12 PCS (15 months post
randomisation)
Lin Reg (MD) 1.08 (–0.65 to 2.81) 0.21 1.16 (–0.53 to 2.85) 0.18
SF-12 MCS (6 weeks) Lin Reg (MD) 1.33 (–0.78 to 3.44) 0.21 1.10 (–0.94 to 3.15) 0.29
SF-12 MCS (6 months) Lin Reg (MD) 3.36 (1.69 to 5.03)a < 0.001 2.75 (0.52 to 4.98)a 0.02
SF-12 MCS (15 months post
randomisation)
Lin Reg (MD) 2.47 (1.07 to 3.87)a 0.001 1.83 (–0.27 to 3.93) 0.09
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TABLE 38 Summary of adjusted and unadjusted effect sizes (LASH vs. EA) (continued )
Outcome
Analysis
method
(effect size)
Adjusted effect size
(95% CI) p-value
Unadjusted effect
size (95% CI) p-value
Satisfaction with treatment
Acceptability of treatment
(6 weeks)
OLR (OR) 4.73 (2.86 to 7.81)a < 0.001 4.74 (3.10 to 7.27)a < 0.001
Satisfaction with treatment
(6 months)
OLR (OR) 2.91 (2.04 to 4.16)a < 0.001 2.96 (2.04 to 4.30)a < 0.001
Satisfaction with
treatment (15 months post
randomisation)
OLR (OR) 2.53 (1.83 to 3.48)a < 0.001 2.55 (1.79 to 3.63)a < 0.001
Recommend treatment to
friend (6 months)
Log Reg
(OR, RD)
4.49 (2.44 to 8.27),a
0.11 (0.07 to 0.14)
< 0.001 4.58 (2.15 to 9.75),a
0.11 (0.06 to 0.16)
< 0.001
Recommend treatment to
friend (15 months post
randomisation)
Log Reg
(OR, RD)
4.52 (2.14 to 9.53),a
0.09 (0.04 to 0.14)
< 0.001 4.54 (2.06 to 10.01),a
0.09 (0.05 to 0.14)
< 0.001
Cox Reg, Cox proportional hazards regression; Lin Reg, linear regression; Log Reg, logistic regression; MD, mean difference;
RD, risk difference; RM, repeated measures.
a Favours LASH (p < 0.05).
b Favours EA (p < 0.05).
Note
Co-primary outcomes are indicated in bold font.
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Appendix 3 Additional information for the
economic evaluation (within-trial analysis)
Within-trial economic evaluation: further details on the statistical
analysis
Model selection
A number of regression model specifications were explored on the study raw data for total cost and total
QALYs. For total cost, a GLM with a gamma family and identity link was defined initially. A modified Park
test71 was conducted (Table 39), showing a Gaussian family as a better model specification. This family
can be linked using identity, logarithmic or power functions and therefore alternative models were fitted
using these links. Based on the p-values for the Pearson’s correlation test, the Pregibon link test and the
modified Hosmer–Lemeshow test71 makes it impossible to unambiguously select one link function.
Therefore, a final model specifying a Gaussian family and identity link was chosen for the base-case
analysis for total costs. Alternative models fitting Gaussian family and log or power links were run showing
trivial differences in the estimation of cost differences (i.e. < £1 difference in the treatment dummy
coefficient between identity, log and power 2 link functions).
A similar approach was followed for selecting the model for total QALYs. However, it was not possible to
identify a family distribution for the raw QALY data and a simple transformation was conducted (i.e.
maximum possible total QALYs at 15 months follow-up (1.25) minus observed QALYs). Table 40 reports
the results for the modified Park test on the transformed QALY data, supporting a Poisson family model
specification. A number of link functions were fitted (see Table 40 for selected test results), and a model
defining a Poisson family and identity link was finally selected for the QALY analysis.
TABLE 39 Model selection test results: total costs
Fitted model: link= identity; family= gamma
Coefficient 0.172825
Family, chi-squared and p-value in descending order of likelihood
Family Chi-squared p-value
Gaussian 0.3319 0.5645
Poisson 7.6031 0.0058
Gamma 37.0985 0.0000
Inverse Gaussian or Wald 88.8181 0.0000
Results of tests for link; p-values
GLM, Gaussian family Identity link Log-link Power 2 link
Pearson’s correlation test 1.0000 0.9989 0.9952
Pregibon link test 0.6039 0.9376 0.5032
Modified Hosmer–Lemeshow 0.5487 0.5804 0.4929
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Missing data
Table 41 reports the proportion of missing data on costs. Relying on complete data allowed us to calculate
total costs for 57% of the study sample. However, total cost results and total cost differences between study
groups were driven by the cost of the index interventions. It was possible to estimate index intervention costs
for 97% (n = 639) of individuals. Complete data analysis would result in many of these observations being
discarded (see Table 41); this issue was crucial to decide relying on multiple imputed data for the base-case
analysis. In addition, the proportion of missing data differs slightly between treatment groups, dismissing the
notion that data could be missing completely at random and supporting the view that data are missing at
random. This missing mechanism could be explained by, for example, the treatment allocation.
Table 42 reports the proportion of missing data for QoL. Between 2% (baseline) and 27% (6 months post
intervention) of observations were missing for EQ-5D-3L score data. Therefore, total QALY calculations
were possible for 64% of the study sample. Again, the proportion of missing data differs between study
groups, supporting the notion that data are missing at random.
Imputation model
Multiple imputation was implemented as part of the within-trial analysis, using chained equations and
predictive mean matching for continuous variables with imputed values drawn from the five closest
observations (kth nearest neighbour = 5). The method was implemented in Stata and starts with the
variable with fewer missing observations. Predictive mean matching imputes an observed value from
another individual whose predicted value is close to the predicted value of the individual with the missing
observation. All other variables being imputed and those included in the imputation model are used in
the prediction models. This process generated 20 complete data sets, with plausible fitted values assigned
for missing cost [i.e. cost of anaesthetic room, operation room, recovery room, subsequent hospital stay,
operation, 6- and 15-month outpatient visits, GP visits (practice, home and telephone calls) and medications]
and utility elements (i.e. EQ-5D-3L and SF-12 scores at baseline, 6 weeks and 6 months post surgery and
15 months post randomisation). The imputation model included all variables incorporated in the analysis
model (centre number, age, treatment dummy), plus randomisation date and one of the co-primary clinical
outcome measures (i.e. patient satisfaction as a binary variable: totally satisfied/not totally satisfied) included
as auxiliary variables. Rubin’s rules were used to pool estimates across the multiple imputation data sets.
TABLE 40 Model selection test results: total QALYs
Fitted model: link= identity; family=Gaussian
Coefficient 0.86363
Family, chi-squared and p-value in descending order of likelihood
Family Chi-squared p-value
Poisson 0.7180 0.3968
Gaussian 28.80 0.0000
Gamma 49.86 0.0000
Inverse Gaussian or Wald 176.21 0.0000
Results of tests for link; p-values
GLM, Poisson family Identity link Log-link Power 0.5 link
Pearson’s correlation test 0.6656 0.1427 0.0723
Pregibon link test 0.4768 0.0000 0.0003
Modified Hosmer–Lemeshow 0.0000 0.0000 0.0239
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
Regression model results: base case
Tables 43 and 44 report regression results for total costs and total QALYs for the base-case analysis based
on the imputed data. The methods of recycled predictions71 was used to obtain the within-trial economic
evaluation results reported in Chapter 5.
TABLE 42 Missing data proportions by treatment allocation: EQ-5D-3L and QALYs
Variable
LASH EA
Number of
missing
observations
Proportion (%)
of missing data
(over 330 possible
observations)
Number of
missing
observations
Proportion (%)
of missing data
(over 330 possible
observations)
Baseline EQ-5D-3L score 11 3.33 8 2.42
6-week post-surgery EQ-5D-3L score 78 25.08a 82 26.37a
6-month post-surgery EQ-5D-3L score 75 24.12a 90 28.94a
15-month post-randomisation EQ-5D-3L
score
49 14.85 49 14.85
QALYs 103 31.21 117 35.45
a Percentages calculated over 311 possible observations, as 19 participants in each arm did not have surgery.
TABLE 41 Missing data proportions by treatment allocation: costs
Variable
LASH EA
Number of
missing
observations
Proportion (%)
of missing data
(over 330 possible
observations)
Number of
missing
observations
Proportion (%)
of missing data
(over 330 possible
observations)
Index operation 6 1.82 15 4.55
Readmissions 0 0.00 0 0.00
6-month data
Outpatient visits 94 28.48 99 30.00
GP visits 96 29.09 102 30.91
GP home visits 96 29.09 102 30.91
GP telephone consultations 96 29.09 102 30.91
Medications 96 29.09 102 30.91
15-month data
Outpatient visits 101 30.61 112 33.94
GP visits 99 30.00 115 34.85
GP home visits 99 30.00 115 34.85
GP telephone consultations 99 30.00 115 34.85
Medications 99 30.00 115 34.85
Total costs 131 30.00 155 46.97
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Subgroup analyses
Subgroup analyses are shown in Table 45.
Productivity costs
Productivity costs are shown in Table 46.
TABLE 43 Regression results: total cost base case (multiple imputed data)
GLMs; Gaussian family, identity link
Variable Coefficient Standard errora
Treatment dummy (1 = LASH) 1604*** 63.7
Baseline EQ-5D-3L score –9 142.6
Age dummy (1 = ≥ 40 years) –32 98.8
Constant 1312*** 118.7
Observations 660
***p < 0.01.
a Robust standard errors.
TABLE 44 Regression results: total QALYs (transformeda) base case (multiple imputed data)
GLM, Poisson family, identity link
Variable Coefficient Standard errorb
Treatment dummy (1 = LASH) –0.004 0.015
Baseline EQ-5D-3L score –0.669*** 0.042
Age dummy (1 = ≥ 40 years) –0.007 0.015
Constant 0.752*** 0.039
Observations 660
***p < 0.01.
a QALY transformed = 1.25 – observed QALYs (1.25 being maximum possible QALYs at 15 months).
b Robust standard errors.
TABLE 45 Subgroup analyses: p-values for interaction term with treatment effect variable – multiple imputed data
Variable Cost (£) QALY
Uterine cavity length ≥ 8 cm 0.19 0.25
Severe dysmenorrhoea at baseline 0.56 0.29
Fibroids present 0.57 0.21
Age ≥ 40 years 0.92 0.68
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TABLE 46 Time to return to paid or unpaid work and productivity costs: 6 months post surgery and 15 months post
randomisation
Variable Number of observations LASH EA
6 months post surgery
Time lost from usual activities (days within last 4 weeks)
From paid work: n (%); mean [SD] 33 15 (6.3); 6.1 [8.1] 18 (7.7); 7.2 [7.9]
From unpaid work: n (%); mean [SD] 64 25 (11.5); 10.1 [8.4] 39 (18.3); 5.7 [4.4]
From leisure/social activities: n (%); mean [SD] 70 29 (14.5); 7.9 [8.5] 41 (21.5); 6.4 [5.8]
Productivity costs (£)
Cost of time from paid work, mean (SD) 470 26 (171) 40 (210)
Cost of time from unpaid work, mean (SD) 423 96 (544) 113 (512)
15 months post randomisation
Time lost from usual activities (days within last 4 weeks)
From paid work: n (%); mean [SD] 43 16 (6.9); 8.1 [11] 27 (12.2); 4.4 [4.2]
From unpaid work: n (%); mean [SD] 67 25 (11.8); 8.9 [8.6] 42 (20.7); 6.9 [7.3]
From leisure/social activities: n (%); mean [SD] 72 27 (13.4); 7.7 [7.5] 45 (23.8); 5.4 [5.3]
Productivity costs (£)
Cost of time from paid work, mean (SD) 452 39 (260) 54 (234)
Cost of time from unpaid work, mean (SD) 401 81 (460) 144 (539)
DOI: 10.3310/hta23530 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 53
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99

Appendix 4 Literature searches for trials, cohort
studies or case series reporting the incidence of
further related surgery following endometrial ablation
or laparoscopic supracervical hysterectomy
As HEALTH reported at 15 months post randomisation, too early to observe all further associatedgynaecological surgery following treatment with EA or LASH, focused literature searches of MEDLINE
were conducted to identify relevant studies to inform the model.
First, a search was conducted during the model development phase for RCTs of LASH. The search was
broad in that it did not specify the indication or comparators of interest (Box 1).
This search identified nine reviews and 84 primary studies of potential relevance. The abstracts were
reviewed to identify any trials comparing LASH with EA for HMB. Only two trials were identified meeting
these criteria. Zupi et al.13 compared hysteroscopic endometrial resection with LASH for abnormal uterine
bleeding, and the primary results were published in 2003. A further long-term follow-up paper, including
reoperations, was published in 2010.48 The latter paper was considered potentially useful for informing
the economic model and is discussed in the main body of the report in Extrapolation of subsequent
hysterectomy following endometrial ablation. Sesti et al.12 compared thermal balloon ablation with LASH
for the surgical treatment of HMB, but reported only on short-term (30-day) complications resulting in
readmission to hospital. Therefore, this study was not considered useful for informing the model.
BOX 1 Search strategy for trials comparing EA and LASH
1. exp clinical trial/ (850,485)
2. randomized controlled trial.pt. (414,266)
3. controlled clinical trial.pt. (91,931)
4. randomi?ed.ab. (404,360)
5. placebo.ab. (169,219)
6. drug therapy.fs. (1,848,006)
7. randomly.ab. (242,942)
8. trial.ab. (351,099)
9. groups.ab. (1,513,597)
10. 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 (3,886,527)
11. exp animals/not humans/ (4,132,479)
12. 51 not 52 (3,369,623)
13. (laparoscop* and supracervical).tw. (240)
14. (laparoscop* and supra-cervical).tw. (5)
15. (hysterectomy and laparoscop* and subtotal).tw. (110)
16. (hysterectomy and laparoscop* and sub-total).tw. (2)
17. 54 or 55 or 56 or 57 (334)
18. 53 and 58 (93)
19. limit 59 to ‘review articles’ (9)
20. 59 not 60 (84)
Date searched: October 2015.
No limits applied to date range searched.
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In addition to the trials of ablation compared with LASH, the above search identified a retrospective study53
that reported on comparative reoperation rates following total laparoscopic hysterectomy (n = 567) and
laparoscopically assisted supracervical hysterectomy (n = 300). A further study72 was also identified that
reported on long-term outcomes following laparoscopic (n = 315) and abdominal (n = 134) supracervical
hysterectomies performed at a university hospital in Oslo, Norway. These studies were considered further
to inform the economic model.
Given the limited comparative evidence on the incidence of further related surgery following LASH and EA,
a broader search was developed to identify cohort studies or case series reporting on the longer-term
follow-up of these procedures. The search strategy is provided in Table 47. The results were restricted to
published articles in the English language from 2010 onwards, to capture follow-up of reasonably
contemporary cohorts.
The 379 identified abstracts were reviewed to identify studies reporting long-term rates of related
gynaecological surgery following EA or LASH. When selecting studies for use in informing the rate of
hysterectomy following EA, the focus was on identifying large population-based cohort studies relevant to
the UK NHS. With respect to further surgery following LASH, the focus was on informing the rate of surgery
considered to be directly related to the initial procedure or continued menstrual bleeding, subsequent
removal of the cervical stump, laparoscopy to investigate subsequent pain and salpingo-oophorectomy.
Given the paucity of published data on further relevant surgery following LASH, a less restrictive approach
was applied, focusing on larger cohort studies (n > 150) reporting longer-term follow-up (> 1 year). This
process yielded three large population-based cohort studies5,46,49 reporting the incidence of further surgery
following EA and three smaller cohort studies reporting on rates of subsequent surgery following LASH.54–56
The two non-randomised comparative studies identified above53,72 were added to this pool, as were three
additional studies identified through the reference lists of other included studies,50–52 providing a total of
eight observational studies of potential use for informing rates of post-LASH surgery in the model.
The reported incidence of trachelectomy (removal of the cervical stump) following supracervical
hysterectomy has ranged from 0.9% to 23%.50,51 The highest reported incidence of 23% comes from an
older UK series performed by a single surgeon (Okaro et al50). In this series, 16 out of 70 patients who
received LASH between 1992 and 1995 were reported to require subsequent trachelectomy, with mean
time to treatment of 14 months. It has been noted that 82.3% of women who required removal of the
cervical stump in the Okara study had been previously treated for endometriosis (Jenkins et al.58), and
endometriosis has subsequently been identified as a significant risk factor for trachelectomy following
hysterectomy (Tsafrir et al.51). This high rate does not appear applicable to the population enrolled in
HEALTH, as it suggests that the incidence of trachelectomy should already be > 10% by 12 months post
LASH. Only one person is known to have required a trachelectomy following LASH by 15 months post
randomisation in HEALTH.
The most recent study by Tsafrir et al.51 reported that only 17 (0.9%) out of 1892 women who underwent
supracervical hysterectomy between 2002 and 2014 at a single US medical centre subsequently underwent
removal of the cervical stump. However, the duration of follow-up to which this incidence relates was not
clearly reported.
From 192 laparoscopic subtotal hysterectomies carried out at three teaching hospitals in the Netherlands
between 1998 and 2007 for benign and malignant indications, van Evert et al.52 reported that four
patients (2%) required further surgery to remove the cervix. The corresponding duration of follow-up was
not clearly reported but the minimum was 6 months.
The study by Boosz et al.53 turned out to include only short-term follow-up data and reported that 3.7% of
300 women receiving LASH at a university hospital in Germany (between January 2002 and December 2009)
had a subsequent operation within 6 months of the initial surgery. It was reported that 2.7% required
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removal of the cervical stump.53 This 6-month rate is significantly higher than the observed rate in HEALTH at
15 months post randomisation and is not useful for informing longer-term extrapolation.
Graziano et al.54 reported on mainly perioperative and early postoperative complications occurring in
365 women undergoing LASH, but also reported one later vaginal trachelectomy and operative
laparoscopies (n = 4) performed beyond 6 months.54 However, the precise follow-up time for these
further procedures was not reported.
TABLE 47 Ovid MEDLINE®: literature search results on cohorts or case series reporting follow-up of laparoscopic
supracervical or subtotal hysterectomy, or EA
# Search Result Type
1 Menorrhagia/ 4050 Advanced
2 Menorrhagia.tw. 2730 Advanced
3 (heavy and menstrua*).tw. 1091 Advanced
4 abnormal uterine bleeding.tw. 1568 Advanced
5 1 or 2 or 3 or 4 7008 Advanced
6 (laparoscop* and supracervical).tw. 276 Advanced
7 (laparoscop* and supra-cervical).tw. 5 Advanced
8 (hysterectomy and laparoscop* and subtotal).tw. 126 Advanced
9 (hysterectomy and laparoscop* and sub-total).tw. 5 Advanced
10 Endometrial Ablation Techniques/ 337 Advanced
11 endometrial ablation.tw. 1037 Advanced
12 thermal balloon.tw. 182 Advanced
13 radio frequency.tw. 5267 Advanced
14 Novasure.tw. 49 Advanced
15 thermachoice.tw. 43 Advanced
16 cavaterm.tw. 17 Advanced
17 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 6822 Advanced
18 Hysterectomy/ 27,214 Advanced
19 Hysterectomy.tw. 28,028 Advanced
20 6 or 7 or 8 or 9 390 Advanced
21 (18 or 19) and 20 387 Advanced
22 17 or 21 6822 Advanced
23 exp Cohort Studies/ 1,774,326
24 exp case-control studies/ 937,492 Advanced
25 case series.ti,ab,kw. 49,673 Advanced
26 treatment outcome/or treatment failure/ 885,911 Advanced
27 23 or 24 or 25 or 26 2,514,214
28 22 and 27 1305 Advanced
29 (surgery or surgical).ti,ab. or su.fs. 2,469,340
30 28 and 29 1029 Advanced
31 limit 30 to (english language and humans and yr = ‘2010 -Current’) 379 Advanced
Date searched: September 2018.
Date range searched: 1946 to August Week 4 2018.
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Schuster et al.55 reported that 5 out of 277 (1.8%) women undergoing LASH in a single Canadian centre
had a repeat operative procedure for pain or bleeding. However, again, the duration of follow-up was
unclear.
Wallwiener et al.56 provided an analysis of a prospective cohort of women who underwent LASH (n = 1658)
or total laparoscopic hysterectomy (n = 294) at a single centre in Germany and reported that 20 (1.2%)
patients had a postoperative complication requiring surgical intervention [with adhesions being the most
common reason (n = 9)].56 This was over mean follow-up of 2.5 years.
Finally, Lieng et al.17 reported that 7% (22/315) of women in a Norwegian cohort had further gynaecological
surgery up to 36 months following LASH. The main surgical interventions were laparoscopic adhesiolysis
(1.9%) and laparoscopic extirpation of the cervical stump (2.3%). It was also noted that one woman (0.3%)
underwent subsequent BSO. The other reported procedures included scar correction (1%), umbilical hernia
repair (0.3%), tension-free vaginal tape procedures (0.6%), laparotomy for postoperative peritonitis (0.3%)
and laparoscopic drainage of postoperative abscess (0.3%). These other surgical procedures were not
included in the long-term rate of further surgery post LASH in the economic model. Some reflect short-term
postoperative complications that are already informed in the model using HEALTH data, and the others are
of very low incidence and of uncertain association with LASH.
MEDLINE search
for cohort studies
(n = 379)
Population-based
cohort studies
reporting rates
of further
surgery post EA
(n = 3)
Cohort potentially
reporting on
long-term rate
of further related
surgery post LASH
(n = 23)
Directly applicable
to a UK
NHS setting
(n = 2)
Total number of
studies considered
for informing
post-LASH
gynaecological
surgery rate
(n = 9:
observational
studies, n = 8;
 trial, n = 1)
Additional studies
identified from
the trials search
reporting
rates for LASH
(n = 2)
Additional studies
identified through
reference lists
(n = 3)
FIGURE 18 Identification of studies.
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Appendix 5 Extrapolation of hysterectomy post
endometrial ablation
As the primary analysis of HEALTH took place at 15 months post randomisation, further modelling wasconducted to extrapolate cost-effectiveness over a longer time horizon. Ten years was selected based
on existing modelling studies and the availability of long-term follow-up data for a population-based
cohort of similarly aged women who received primary EA on the UK NHS.
The cohort study by Cooper et al.5 provided a published KM curve of time to subsequent hysterectomy
based on 14,078 women identified as having received primary EA for HMB between 1989 and 2006 in
Scotland. The data indicated that > 50% of hysterectomies were performed in the first year post ablation,
but the percentage went on increasing steadily out to and beyond 10 years post ablation. The historical
Scottish data also indicated that ≈10% of patients had a hysterectomy by 12 months following ablation, a
substantially greater proportion than the estimated 3% by 12 months in HEALTH. Therefore, for consistency
with the trial-based evaluation at 15 months post randomisation, we used the HEALTH data to inform the
hysterectomy rate in the first 12 cycles (12 months) of the economic model. We then used the data reported
by Cooper et al.5 (beyond year 1) to guide extrapolation of the expected rate of further hysterectomies in
the longer term. This was achieved by fitting a mathematical function to the observed KM data reported by
Cooper et al.5 and then referencing it for the estimation of cycle-specific transition probabilities from month
13 onwards in the economic model.
In order to achieve this, a sample of data points were extracted from the published KM curve using
WebPlotDizitizer software [URL: https://automeris.io/WebPlotDigitizer/ (accessed 22 May 2019)]. An attempt
was made to reconstruct the individual patient data behind the published KM curve using the spreadsheet
developed by Hoyle and Henley.73 This was challenging due to the large sample informing the KM plot,
resolution of the published figure and lack of details on numbers at risk over time. Nevertheless, a
reconstructed data set was approximated based on 15 extracted points. Alternative parametric survival functions
were then fitted to the reconstructed KM data, including an exponential, Weibull, logistic, log-normal and
log-logistic function. Of these alternative distributions, the Weibull provided the best statistical fit based
on the Akaike information criterion and Bayesian information criterion (Table 48). However, this Weibull
function did not provide a good visual fit to the extracted data points, resulting in underprediction of the
event (hysterectomy) in the short term and overprediction in the longer term [Figure 19, S(t)_Weibull A].
Therefore, we utilised an alternative regression-based method to fit a Weibull function to KM data, ignoring
extracted points in the first year. This involved regressing log(–log(S)) on log(t), where S represents the
extracted survivor proportions and t represents the corresponding survival times. The constant term from
this model gives the log of the rate parameter (lambda) for a fitted Weibull distribution, and the parameter
TABLE 48 Akaike information criterion for alternative functional forms of time to hysterectomy following EA
Model Intercept Log(scale parameter) AIC BIC
Exponential 3.353 0.0190 25,850.18 25,857.59
Weibull 4.378 0.564 24,560.75 24,575.56
Logistic 16.256 1.820 30,952.16 30,966.97
Log-normal 3.459 0.847 24,648.1 24,662.91
Log-logistic 3.382 0.244 24,948.85 24,963.65
AIC, Akaike information criterion; BIC, Bayesian information criterion.
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estimate for log(t) provides the shape parameter (gamma). This fitted curve provided a better visual fit
against the extracted KM data beyond year 1, the time period requiring extrapolation in the economic
model (see Figure 19). Although the fitted curve is initially slightly shallower than the observed KM curve,
this may not be inappropriate for extrapolation of HEALTH, in which the 1-year KM data illustrates a
slower rate of progression to hysterectomy than expected based on the historical cohort (see Figure 19).
The slight over prediction of hysterectomy beyond 10 years is of limited concern because the time horizon
of the model is curtailed at 10 years. Therefore, this fitted Weibull curve was used to derive time-dependent
monthly probabilities of hysterectomy beyond year 1 in the base case. The time-dependent monthly transition
probabilities were calculated using the following equation:
1− exp(λ(t0γ – t1γ)), (1)
in which λ (lambda) is the rate parameter of the Weibull distribution, γ (gamma) is the shape parameter
(indicating a diminishing hazard over time when < 1), t0 is the time at the beginning of the interval of
interest and t1 is the time at the end of the interval of interest. The parameter estimates for lambda and
gamma are provided in Table 19.
Given the uncertainty surrounding time to hysterectomy following EA, and its importance in the model
with respect to extrapolation of QALYs, further sensitivity analysis was undertaken using cycle-specific
transition probabilities derived directly from the published KM curve reported by Cooper et al.5 For this
analysis, further data points were extracted from the published KM curve at approximately 6-month
intervals (Figure 20). A transition probability for each extracted 6-month interval was then estimated as
1 – (S(t1)/S(t0)). These were further transformed into constant monthly transition probabilities corresponding
to each extracted 6-month interval for application in the model, using the following equations:
r = −ln(1 –p) /t, (2)
p = 1− exp(−rt), (3)
where r is a constant rate (expressed per unit of time at risk), t is the time period to which the initial
probability relates (6 months) and p is the transition probability. which is rescaled to the time period of
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20
Pr
o
b
ab
ili
ty
 o
f 
b
ei
n
g
 h
ys
te
re
ct
o
m
y 
fr
ee
 (
%
)
Time (years)
S(t)_Weibull (base case)
Extracted data points
S(t)_Weibull A
FIGURE 19 Extracted data points and fitted Weibull curves for hysterectomy following EA. Survivor function (S(t)).
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interest (1 month). In the first sensitivity analysis, the HEALTH KM data were used up to 12 months in the
model, with the transition probabilities derived from year 1 onwards (see Figure 20) applied thereafter.
In an alternative specification, transition probabilities derived from Figure 20 were applied over the full
duration of the model. This latter scenario assessed the impact of assuming a higher probability of
hysterectomy in year 1 and a long-term probability of 25% by 10 years, as indicated in the population
based KM curve reported by Cooper et al.5
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FIGURE 20 Extracted 6-monthly data points for hysterectomy following EA. Survivor function (S(t)).
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